Text

Offsite Dose Calculation Manual, Revision 24
	ML11129A079
Person / Time
Site:	Big Rock Point, Rensselaer Polytechnic Institute File:Consumers Energy icon.png
Issue date:	07/07/2010
From:	; Entergy Nuclear Operations
To:	; Office of Nuclear Reactor Regulation
References
	PNP 2011-038
	Download: ML11129A079 (89)
	v • d • e

ENCLOSURE 1 PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL, REVISION 24 80 Pages Follow

ODCM Revision 24 Issued Date 7/7/10 PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL TITLE: OFFSITE DOSE CALCULATION MANUAL Process Applicability Exclusion L JBBurnett / 7/6/10 Procedure Sponsor Date JILFontaine 1/25/10 Technical Reviewer Date JBBurnett 6/3/10 User Reviewer Date TPKirwin 6/24/10 General Manager Plant Operations Date

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 Table of Contents G A SEO US EFFLU ENTS ............................................................................................... 1 A. ALARM/TRIP SETPOINT METHOD ........................................................... I

1. Allowable Concentration ............................... 2

2. Monitor Response ......................................... 3 B. DOSE RATE CALCULATION ................................................................... 4 C. GASEOUS RADWASTE TREATMENT SYSTEM OPERATION ............. 19

1. System Description ..................................... 19

2. Determination of Satisfactory Operation ....... 19 D. RELEASE RATE FOR OFFSITE EC ...................................................... 20 E. PARTICULATE AND IODINE SAMPLING ............................................. 20 F. NOBLE GAS SAMPLING ....................................................................... 21 G. TRITIUM SAM PLING ................................................................................ 21 H. FIGURE - GASEOUS EFFLUENTS FLOW PATHS ................. 22 LIQ UID EFFLUENTS .............................................................................................. 23 A. CONCENTRATION .................................................................................. 23

1. Requirements ........................ 23

2. Prerelease Analysis ..................................... 23

3. Effluent Concentration (EC) - Sum of the Ratios ........................................................... 24 B. INSTRUMENT SETPOINTS ..................................................................... 25

1. Setpoint Determination ............................... 25

2. Composite Samplers ................................... 25

3. Post-Release Analysis ................................ 26 C. D O S E ...................................................................................................... 26

1. RETS Requirement ..................................... 26

2. Release Analysis ......................................... 26 D. OPERABILITY OF LIQUID RADWASTE EQUIPMENT .......................... 30 E. RELEASE RATE FOR OFFSITE EC (50 MREM/YR) .............................. 30 F. FIG UR ES ................................................................................................ 31

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 Table of Contents III. URANIUM FUEL CYCLE DOSE .............................................................................. 33 A. SPECIFICATIO N...................................................................................... 33 B. ASSUM PTIO NS ...................................................................................... 33 C. DOSE CALCULATION ........................................................................... 34 IV. REVISIONS TO THE OFFSITE DOSE CALCULATION MANUAL ........................ 34 A. REQ UIREM ENTS .................................................................................... 34 , "Offsite Dose Calculation Manual Change Reviews" , "Palisades Gaseous And Liquid Source Terms, Curies/Year , "Basic Radionuclide Data" , "Dose Factors for Submersion in Noble Gases" , "Stable Element Transfer Data" , "Inhalation Dose Commitment Factors , "External Dose Factors 2

for Standing on Contaminated Ground (DFGi)

(mrem/hr per pCi/m )"' , "Bioaccumulation Factors (pCi/gm per pCi/ml) , "Ingestion Dose Commitment Factors"

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24

1. GASEOUS EFFLUENTS A. ALARM/TRIP SETPOINT METHOD Appendix A,Section III.B.1 requires that the dose rate due to radioactive materials released in gaseous effluents from the site to areas at and beyond the SITE BOUNDARY shall be limited to the following:

For noble gases: Less than or equal to 500 mrems/yr to the total body and less than or equal to 3000 mrems/yr to the skin, and For iodine-1 31, for iodine-1 33, for tritium, and for all radionuclides in particulate form with half lives greater than 8 days: Less than or equal to 1500 mrems/yr to any organ.

Appendix A,Section III.A.1 requires gaseous effluent monitors to have alarm/trip setpoints to ensure that offsite concentrations, when averaged over 1 hour1.157407e-5 days 2.777778e-4 hours 1.653439e-6 weeks 3.805e-7 months , will not be greater than Appendix A,Section III.B.1. This section of the ODCM describes the methodology that will be used to determine these setpoints.

The methodology for determining alarm/trip setpoints is divided into two major parts.

The first consists of calculating an allowable concentration for the nuclide mixture to be released. The second consists of determining monitor response to this mixture in order to establish the physical settings on the monitors.

1

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24

1. Allowable Concentration The total EC-fraction (Rk) for each release point will be calculated by the relationship defined by Note 4 of Appendix B, 10 CFR 20:

Rk = X/Q x F x 7i Ci/ECi 5 10.0 (1.1) I where:

C ]* = Actual or measured concentration, at ambient temperature and pressure of nuclide i (ýtCi/cc)

ECi= The EC of nuclide i from 10 CFR 20, Appendix B, Table 2 F*(k) = The total EC-fraction for release point k UQ = Most conservative sector site boundary dispersion (sec/m 3 )

(listed in site procedure CH 6.41, Land Use Census)

F = Release flow rate (83,000 cfm = 39.2 m 3/sec) for stack monitor considerations; variable for other monitors 2

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 NOTE: If a batch release is made while a continuous release or another batch release is in progress, the sum of all values of Rk must be less than 10.0.

2. Monitor Response Normal radioactivity releases consist mainly of well-decayed fission gases.

Therefore, monitor response calibrations are performed to fission gas typical of normal releases (mainly Xe-133). Response of monitors used to define fission product release rates under accident conditions may vary from that of Xe-1 33, however. Monitor response for the two categories of monitor is determined as follows:

a. Normal Release (aged fission gasses)

Total gas concentration (jiCi/cc) at the monitor is calculated. The detector response to isotopic activities (cpm/gCi/cc) is applied to determine cpm expected. The setting for monitor alarms is established at some factor (b) greater than 1 but less than 1/Rk (Equation 1.1) times the measured concentration (c):

s=bxc (1.2)

b. Accident Releases Monitors are preset to alarm at or before precalculated offsite dose rates would be achieved under hypothetical accident conditions.

These setpoints are established in accordance with Emergency Plan requirements for defining Emergency Action Levels and associated actions. Emergency Implementing Procedures contain monitor-specific curves or calibration constants for conversion between cpm and pCi/cc (or R/hr and pCi/cc), depending on monitor type, for fission product mixtures as a function of mixture decay time.

When these monitors are utilized for other than accident conditions, either an appropriately decayed "accident" conversion curve may be used, or a decayed fission gas calibration factor may be applied. In these cases, setpoints are established as in 1.A above.

Setpoints of accident monitors (if set to monitor normal releases) are reset to the accident alarm settings at the end of normal release.

Setpoints of other release monitors are maintained at the level used at the latest release (well below the level which would allow 10 times EC to be exceeded at the site boundary), or are reset to approximately three times background in order to detect leakage or inadvertent releases of low level gases.

3

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 B. DOSE RATE CALCULATION

1. Dose rates are calculated for (1) noble gases and (2) iodines and particulates.

Dose rates as defined in this section are based on 10 CFR 50 Appendix I limits of mrem per quarter and millirem per year. All dose pathways of major importance in the Palisades environs are considered.

a. Equations and assumptions for calculating doses from noble gases are as follows:

1) Assumptions a) Doses to be calculated are the maximum offsite point in air, total body and skin.

b) Exposure pathway is submersion within a cloud of noble gases.

c) Noble gas radionuclide mix is based on the historically observed source term given in Attachment 2, plus additional nuclides.

d) Basic radionuclide data are given in Attachment 3.

e) All releases are treated as ground-level.

f) Meteorological data expressed as joint-frequency distribution of wind speed, wind direction, and atmospheric stability for the period resulting in X/Q's and D/Q's shown in site procedure CH 6.41, Land Use Census.

g) Raw meteorological data consists of wind speed and direction measurements at 10m and temperature measurements at 10m and 60m.

h) Dose is to be evaluated at the offsite exposure points where maximum concentrations are expected to exist (overland sector site boundaries), and nearest residents.

i) Potential maximum population (resident) exposure points are identified in site procedure CH 6.41, Land Use Census.

4

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 j) A semi-infinite cloud model is used.

k) Radioactive decay is considered for the plume.

I) Building wake effects on effluent dispersion are considered.

m) A sector-average dispersion equation is used.

n) The wind speed classes that are used are as follows:

Wind Speed Class Number Range (m/s) Midpoint (m/s) 1 0.0-0.4 0.2 2 0.4-1.5 0.95 3 1.5-3.0 2.25 4 3.0-5.0 4.0 5 5.0-7.5 6.25 6 7.5-10.0 8.75 7 > 10.0 --

o) The stability classes that will be used are the standard A through G classifications. The stability classes 1-7 will correspond to A=1, B=2, ..., G=7.

p) Terrain effects are not considered.

5

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24

2) Equations To calculate the dose for any one of the exposure points, the following equations are used.

For determining the air concentration of any radionuclide:

9 7 (2 1/ kQ Xi=" Y I ,zkuj (2 x/n) exp i (1.3) j=1 k=1 x uj where:

Xi = Air concentration of radionuclide i, pCi/m 3 .

fjk = Joint relative frequency of occurrence of winds in wind speed class j, stability class k, blowing toward this exposure point, expressed as a fraction.

Qi = Average release rate of radionuclide i, ýtCi/s.

p = Fraction of radionuclide remaining in plume.

Zzk = Vertical dispersion coefficient for stability class k (m).

uj = Midpoint value of wind speed class interval j, m/s..

x = Downwind distance, m.

n = Number of sectors, 16.

i = Radioactive decay coefficient of radionuclide i, s1.

27rx/n = Sector width at point of interest, m.

6

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 For determining the total body dose rate:

DTB Xi DFBi (1.4) where:

DTB = Total body dose rate, mrem/y.

Xi = Air concentration of radionuclide I, gCi/m 3 .

DFB1 = Total body dose factor due to gamma radiation, mrem/y per gCi/m 3 (Attachment 4).

For determining the skin dose rate:

Ds = . Xi (DFSi+1.11DFYi) (1.5) where:

D = Skin dose rate, mrem/y.

3 Xi = Air concentration of radionuclide i, gCi/m DFSj = Skin dose factor due to beta radiation, mrem/y per pCi/m 3 (Attachment 4).

1.11 = The average ratio of tissue to air energy absorption coefficients, mrem/mrad.

DFYi = Gamma-to-air dose factor for radionuclide i, mrad/y per ýtCi/m 3 (Attachment 4).

For determining dose rate to a point in air:

Da= Xi (DFYior DFB) (1.6) where:

Da Air dose rate, mrad/yr.

DFBi = Air dose factor for beta radiation (Attachment 4).

7

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24

b. Equations and assumptions for calculating doses from radioiodines and particulates are as follows:

1) Assumptions a) Dose is to be calculated for the critical organ, thyroid, and the critical age groups (adult, teen, child, infant), infant (milk) and child (green, leafy vegetables).

b) Exposure pathways from iodines and particulates are milk ingestion, ground contamination, green leafy vegetables from home gardens, and inhalation.

c) The radioiodine and particulate mix is based on the historically observed source term given in Attachment 2.

d) Basic radionuclide data are given in Attachment 3.

e) All releases are treated as ground-level.

f) Mean annual average X/Q's are given in site procedure CH 6.41, Land Use Census.

g) Raw meteorological data for ground-level releases consist of wind speed and direction measurements at 10m and temperature measurements at 10m and 60m.

h) Dose is to be evaluated at the potential offsite exposure points where maximum doses to man are expected to exist.

i) Real cow, goat and garden locations are considered.

j) Potential maximum exposure points (site procedure CH 6.41, Land Use Census) considered are the nearest cow, goat, and home garden locations in each sector.

k) Terrain effects and open terrain recirculation factors are not considered.

I) Building wake effects on effluent dispersion are considered.

8

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 m) Plume depletion and radioactive decay are considered for air-concentration calculations.

n) Radioactive decay is considered for ground-concentration calculations.

o) Deposition is calculated based on the curves given in Figure 1.2.

p) Milk cows and goats obtain 100% of their food from pasture grass May through October of each year. Use default values of 0.58 for cows and 0.67 for goats for fraction of year on pasture.

2) Equations To calculate the dose for any one of the potential maximum-exposure points, the following equations in Section 1.2.2 are used.

a) Inhalation Equation for calculating air concentration, Xi is the same as in the Noble Gas Section (Equation 1.3).

For determining the organ dose rate:

Di=1X106 Xi DFiBR (1.7) where:

D - Organ dose rate due to inhalation, mrem/y.

Xi = Air concentration of radionuclide i, jiCi/m3 .

DFI = Inhalation dose factor, mrem/pCi (Attachment 6).

BR = Breathing rate 1400 m 3/y infant; 3700 m 3/y child; or 8000 m 3/y teen and adult.

lx106 = pCi/pCi conversion factor.

9

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 b) Ground Contamination For determining the ground concentration of any nuclide; 7

Gi=3.15x10 7 T fk Q 1DR [1-exp-(Aitb) (1.8) k =1 (2; x/n),(l[

where:

G* = Ground concentration of radionuclide i, 2

gCi/m .

k = Stability class.

fk = Joint relative frequency of occurrence of winds in stability class k blowing toward this exposure point, expressed as a fraction.

Qi = Average release rate of radionuclide i, pCi/s.

DR = Relative deposition rate, m-1 (Fig 1.2).

x = Downwind distance, m.

n = Number of sectors, 16.

2nx/n = Sector width at point of interest, m.

i = Radioactive decay coefficient of radionuclide i, y-1.

tb = Time for buildup of radionuclides on the ground, 15 y.

3.15x 10 = s/y conversion factor.

10

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 Figure 1.2 Corrected 3 uary 1977 10- .

Lu Lu I-14 10-7 0.1 1.0 10.0 100.0 200.0 PLUME TRAVEL DISTANCE (KILOMETERS)

Figure 7. Relative Deposition for Ground Levewl Relem (All Atmospheric Stability Clas*s) 11

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 For determining the total body or organ dose rate from ground contamination:

DG = (8,760)(1 X 106)(0.7) Gi DFGi (1.9) where:

DG = Dose rate due to ground contamination, mrem/y.

Gi = Ground concentration of radionuclide i,

ý,Ci/m 2 .

DFGi = Dose factor for standing on contaminated ground, mrem/h per pCi/m 2 (Attachment 7).

8,760 = Occupation time, h/y.

lx1 06 = pCi/ýtCi conversion factor.

0.7 = Shielding factor accounting for a distance of 1.0 meter above ordinary ground, dimensionless.

c) Milk and Vegetation Ingestion For determining the concentration of any nuclide (except C-14 and H-3) in and on vegetation:

7 fkQiDR r-1-exp(-AEite)I 1-exp -(Ai th)))

k = 1 (21rx/n) Yv ABEi PA (i 01) Ij (1.10) where:

CVI = Concentration of radionuclide i in and on vegetation, pCi/kg.

k = Stability class.

fk = Frequency of this stability class and wind direction combination, expressed as a fraction.

12

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 Q0 = Average release rate of radionuclide i, pCi/s.

DR = Relative deposition rate, m- 1 (Figure 1.2).

x - Downwind distance, m.

n = Number of sectors, 16.

2ktx/n = Sector width at point of interest, m.

r = Fraction of deposited activity retained on vegetation (1.0 for iodines, 0.2 for particulates).

XEi = Effective removal rate constant, XEi = Xi + Xw, where Xj is the radioactive decay coefficient, h-1, and Xw is a measure of physical loss by weathering (Xw = 0.0021 h-).

te = Period over which deposition occurs, 720 h.

Yv = Agricultural yield, 0.7 kg/m 2 .

Biv = Transfer factor from soil to vegetation of radionuclide i (Attachment 5).

i = Radioactive decay coefficient of radionuclide i, h-1.

tb = Time for buildup of radionuclides on the ground, 1.31x10 5 h (15Y).

p = Effective surface density of soil, 240 kg/m 2 .

3,600 = s/h conversion factor.

th = Holdup time between harvest and consumption of food (2,160 hours0.00185 days 0.0444 hours 2.645503e-4 weeks 6.088e-5 months for stored food).

13

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 For determining the concentration of C-14 in vegetation:

CV14 =1X10 3X 14 (0.1.1/0.16) (1.11) where:

CV14 " Concentration of C-14 in vegetation, 1iCi/kg.

X14 = Air concentration of C-14, [tCi/m 3 .

0.11 = Fraction of total Plant mass that is natural carbon.

0.16 = Concentration of natural carbon in the atmosphere, g/m 3 .

lx103 = g/kg conversion factor.

For determining the concentration of H-3 in vegetation:

CVT = X103 XT (0.75)(0.5/H) (1.12) where:

CVT = Concentration of H-3 in vegetation, [tCi/m 3 .

XT = Air concentration of H-3, gCi/m 3 .

0.75 = Fraction of total Plant mass that is water.

0.5 = Ratio of tritium concentration in Plant water to tritium concentration in atmospheric water.

H = Absolute humidity of the atmosphere, g/m 3 .

lx103 = g/kg conversion factor.

14

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 For determining the concentration of any nuclide in cow's or goat's milk:

CMi = CVi FMi Qf exp (-Xi tf) (1.13) where:

CM1 = Concentration of radionuclide i (including C-14 and H-3) in milk, RiCi/Il.

CV1 = Concentration of radionuclide i in and on vegetation, RCi/kg.

FMi Transfer factor from feed to milk for radionuclide i, d/I (Attachment 5).

Qf Amount of feed consumed by the milk animal per day, kg/d (cow, 50 kg/d or goat 6 kg/d).

Xi = Radioactive decay coefficient of radionuclide i, d-1.

tf Transport time of activity from feed to milk to receptor, 2 days.

15

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 1

For determining the organ dose rate from ingestion of green leafy vegetables and milk:

D=lxl0o6 CMiDFiUM (1.14) where:

D = Organ dose rate due to ingestion, mrem/y.

CM = Concentration of radionuclide i in vegetables or milk, ýtCi/kg (or liters).

DFi = Ingestion dose factor, mrem/pCi (Attachment 9).

UM = Ingestion rate for milk, 330 I/y; for vegetables 26 kg/yr (child), no ingestion by infant.

lx106 = pCi/pCi conversion factor.

d) Meat Ingestion (Beef)

To calculate the concentration of a nuclide in animal flesh:

Cfi = Ffi CVi Qfi exp (Xits) (1.15) where:

Cfi = Concentration of nuclide i in the animal flesh, pCi/kg.

Ffi = Fraction of animal's daily intake which appears in each kg of flesh, days/kg (Attachment 5).

CV = Concentration of radionuclide i in the animal's feed (Equation 1.10).

16

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 Qf = Amount of feed consumed by the cow per day, 50 kg/d.

ts = Average time from slaughter to consumption, 20 days.

To determine the organ dose from ingestion of beef:

D = Cfi Dfi Uf (1.16) where:

Dfi - Ingestion dose factor for age group, mrem/pCi (Attachment 9) for nuclide i.

Uf = Ingestion rate of meat for age group, kg/y (child-41, teen-65, adult-1 10).

e) Organ Dose Rates For determining the total body and organ dose rate from iodines and particulates:

D = DI +DG + DM + Dv + DF (1.17) where:

D = Total organ dose rate, mrem/y.

D, = Dose rate due to inhalation, mrem/y.

DG = Dose rate due to ground contamination, mrem/y.

DM = Dose rate due to milk ingestion, mrem/y.

Dv = Dose rate due to vegetable ingestion, mrem/y.

DF = Dose rate due to beef ingestion, mrem/y.

17

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24

3) The maximum organ dose rate, maximum total body dose rate, and maximum skin dose rate calculated in the previous section (Sec 1.B) are used to calculate design basis quantities as described in Section I.B.1.3.

c. Land Use Census Appendix A, Sections J.3.b and J.3.c describe the requirements for an annual land use census. Changes will be effective on January 1 of the year following the year of the survey.

d. Gaseous Releases From the Steam Generator Blowdown Vent and Atmosphere Release Valves Releases from the steam generator blowdown vent and atmospheric relief valves are difficult to quantify as there are no sampling capabilities on these steam release systems. However, neither system is a normal release path. The steam generator blowdown vent is normally routed to the main condenser and recirculated. Radioactive releases will be calculated by analyzing steam generator blowdown liquid and assuming that 100 percent of Noble Gases, 10 percent of the lodines and 1 percent of the Particulates will.be released to the environment in the steam phase. Volumes will be released to the environment in the steam phase. Volumes will be calculated using water balances or alternate means as available.

18

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 C. GASEOUS RADWASTE TREATMENT SYSTEM OPERATION The gaseous radwaste treatment system (GRTS) described below shall be maintained and operated to keep releases ALARA.

1. System Description A flow diagram for the GRTS is given in Figure 1-1. The system consists of three waste-gas compressor packages, six gas decay tanks, and the associated piping, valves, and instrumentation. Gaseous wastes are received from the following: degassing of the reactor coolant and purging of the volume control tank prior to a cold shutdown and displacing of cover gases caused by liquid accumulation in the tanks connected to the vent header.

Design of the system precludes hydrogen explosion by means of ignition source elimination (diaphragm valves, low flow diaphragm compressors and system electrical grounding), and minimization of leakage outside the system.

Explosive mixtures of hydrogen and oxygen have been demonstrated compatible with the system by operational experience.

2. Determination of Satisfactory Operation Doses will be calculated for batch and continuous releases as described in Section I.B. These calculations will be used to ensure that the GRTS is operating as designed. Because the Plant was designed to collect and hold for decay a vast majority of the high level gases generated within the primary system, and because the operating history of the Plant has demonstrated the system's consistent performance well below Appendix I limits, no additional operability requirements are specified.

19

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 D. RELEASE RATE FOR OFFSITE EC 10 CFR 20.1302 requires radioactive effluent releases to unrestricted areas be in concentrations less than the limits specified in Appendix B, Table 2 when averaged over a period not to exceed one year. (Note: there are no unrestricted areas anywhere within the site boundary as defined by Figure 1-1.) Concentrations at this level if inhaled or ingested continuously for one year will result in a dose of 50 mrem whole body except for submersion dose isotopes (gaseous tritium and noble gasses) which will results in a dose of 100 mrem whole body. 10 CFR 50.36a requires that the release of radioactive materials be kept as low as reasonably achievable.

However, the section further states that the licensee is permitted the flexibility of operation, to assure a dependable source of power even under unusual operating conditions, to release quantities of material higher than a small percentage of 10 CFR 20.1302 limits but still within those limits. Appendix I to 10 CFR 50 provides the numerical guidelines on limiting conditions for operations to meet the as low as reasonably achievable requirement.

The GASPAR code has been run to determine the dose due to external radiation and inhalation. The source term used is listed in Attachment 2. The meteorology data is given in site procedure CH 6.41, Land Use Census. Dose using annual average meteorology, to the most limiting organ of the person assume to be residing at the site boundary with highest X/Q, is 2.15E-02 mrem (for one year). The release rate which would result in a dose rate equivalent to 50 mrem/year (using the more conservative total body limit) is the curies/year given in Attachment 2 multiplied by 50/2.15E-02 or 0.11 Ci/sec.

E. PARTICULATE AND IODINE SAMPLING Particulate and iodine samples are obtained from the continuous sample stream pulled from the Plant stack. Samples typically are obtained to represent an integrated release from a gas batch (waste gas decay tank or Containment purge, for example), or a series of samples are obtained to follow the course of a release.

In any event, sample intervals are weekly, at a minimum.

Because HEPA filters are present between most source inputs to the stack and the sample point, releases of particulates normally are significantly less than pre-release calculations indicate. This provides for conservatism in establishing setpoints and in estimation of pre-release dose calculations. However, for the sake of maintaining accurate release totals, monitor results (for gases) and sample results (for particulates and iodines) utilized rather than the pre-release estimates, for cumulative records.

20

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 Gamma analytical results for particulate and halogen filters are combined for determination of total activity of particulates and halogens released. Sampling and analysis will be performed per Appendix A, Table B-1 requirements.

F. NOBLE GAS SAMPLING Noble gases will be sampled from Waste Gas Decay Tanks prior to release and the Containment prior to purging. Analysis of these samples will be used for accountability of noble gases. Off gas will be sampled at least weekly and used to calculate monthly noble gas releases. Non-routine releases will be quantified from the stack noble gas monitor (RE 2326) which has a LLD of 1E-06 lCi/cc. Sampling and analysis will be performed per Appendix A, Table B-1 requirements.

G. TRITIUM SAMPLING Tritium has a low dose consequence to the public because of low production rates.

The major contributors to tritium effluents are evaporation from the fuel pool and reactor cavity (when flooded). Because of the low dose impact, gaseous tritium sampling will not be required. Tritium effluents will be estimated using conservative evaporation rate calculations from the fuel pool and reactor cavity.

21

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 H. FIGURE - GASEOUS EFFLUENTS FLOW PATHS is JIM LL(J LL0 Ct, 0-22

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 LIQUID EFFLUENTS A. CONCENTRATION

1. Requirements Appendix A, Section 111.G requires that the concentration of radioactive material released at any time from the site to unrestricted areas shall be limited to ten times the Effluent Concentration (EC) specified in 10 CFR 20, Appendix B, Table 2, Column 2 for nuclides other than dissolved or entrained noble gases. For dissolved or entrained noble gases, the concentration shall be limited to 2E-04 gCi/ml total activity. To ensure compliance, the following approach will be used for each release.

2. Prerelease Analysis Most tanks will be recirculated through two volume changes prior to sampling for release to the environment to ensure that a representative sample is obtained. The appropriate recirculation time for those tanks'too large to provide two volume changes will be the time that the suspended particulate concentration reaches steady state. Either a one-time test, or prior sampling data, may be used to determine appropriate recirculation time.

Prior to release, a grab sample will be analyzed for each release, and the concentration of each radionuclide determined.

n C = Ci (2.1) i=1 where:

C = Total concentration in the liquid effluent at the release point, rtCi/ml.

Ci Concentration of a single radionuclide i, [tCi/ml.

23

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24

3. Effluent Concentration (EC) - Sum of the Ratios The EC-Fraction (Ri) for each release point will be calculated by the relationship defined by Note 4 of Appendix B, 10 CFR 20:

Rj = _<10.0 (2.2)

'EQ where:

Ci = Effluent concentration of radionuclide i, RiCi/ml.

ECi = The EC of radionuclide i, 10 CFR 20, Appendix B, Table 2, Column 2 - iiCi/ml.

Rj = The Total EC-Fraction for the release point.

The sum of the ratios at the discharge to the lake must be _<10 due to the releases from any or all concurrent releases. The following relationship will assure this criterion is met:

f1(R1-1) + f2(R2 -1) + f 3 (R3 -1) < F (2.3) where:

fl,f 2 ,f3 = The effluent flow rate (gallons/minute) for the respective releases, determined by Plant personnel.

R,R2,R3 = The Total EC-Fractions for the respective releases as determined by Equation 2.2.

F = Minimum required dilution flow rate. Normally, a conservatively high dilution flow rate is used, that is, flow rate used = (bi)(F) where bi is a conservative factor greater than 1.0.

24

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 B. INSTRUMENT SETPOINTS

1. Setpoint Determination Appendix A,Section III.F requires alarm setpoints for each liquid effluent monitor will be established using Plant instructions to ensure the requirements of Appendix A,Section III.G are not exceeded. Concentration, flow rate, dilution, principal gamma emitter, geometry, and detector efficiency are combined to give an equivalent setpoint in counts per minute (cpm). The identification number for each liquid effluent radiation detector is contained in Figure 2-2.

The respective alarm/trip setpoints at each release point will be set such that the sum of the ratios at each point, as calculated by Equation 2.2, will not be exceeded. The value of R is directly related to the total concentration calculated by Equation 2.1. An increase in the concentration would indicate an increase in the value of R. A large increase would cause the limits specified in Section 2.1.1 to be exceeded. The minimum alarm/trip setpoint value is equal to the release concentration, but for ease of operation it may be desired that the setpoint (S) be set above the effluent concentration (C) by the same factor (b) utilized in setting dilution flow. That is:

S = bxC (2.4)

Liquid effluent flow paths and release points are indicated in Figure 2.1.

2. Composite Samplers Effluent pathways, Turbine Sump and Service Water, are equipped with continuous compositors to meet the requirements of Appendix A, Table D-1.

These compositors are adjustable and normally set in a time mode and collect three to six samples hourly, 24 hours2.777778e-4 days 0.00667 hours 3.968254e-5 weeks 9.132e-6 months a day with a total collection of approximately one gallon per day. A representative sample is collected daily from the compositor and saved for the weekly and monthly analysis requirements of Appendix A, Table D-1. In the event that a compositor is not operational, effluent releases via this pathway may continue provided that grab samples are collected and analyzed for gross beta or gamma radioactivity at least once per 24 hours2.777778e-4 days 0.00667 hours 3.968254e-5 weeks 9.132e-6 months per Appendix A, Table C-1, Action 3.

25

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24

3. Post-Release Analysis A post-release analysis will be done using actual release data to ensure that the limits specified in Section 1 were not exceeded.

A composite list on concentrations (CQ), by isotope, will be used with the actual liquid radwaste (f) and dilution (F) flow rates (or volumes) during the release. The data will be substituted into Equation 2.3 to demonstrate compliance with the limits in Section 1. This data and setpoints will be recorded in auditable records by Plant personnel.

C. DOSE

1. RETS Requirement Appendix A,Section III.H.1 requires that the quantity of radionuclides released by limited such that the dose or dose commitment to an individual from radioactive materials in liquid effluents release to unrestricted areas from the reactor (see Figure 2-1) will not exceed:

a. During any calendar quarter, 1.5 mrem to the total body and 5 mrem to any organ, and

b. During any calendar year, 3 mrem to the total body and 10 mrem to any organ.

To ensure compliance, quantities of activity of each radionuclide released will be summed for each release and accumulated for each quarter as follows in Section 2.

2. Release Analysis Dose calculations shall be performed for each batch release, and weekly for continuous'releases unless documentation exists to demonstrate an activity below which dose limits of Section I1.C.1 will not be exceeded.

a. Water Ingestion The dose to an individual from ingestion of radioactivity from any source as described by the following equation:

i Di Y_ (DCF)ijXli (2.5) 26

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 where:

Dj Dose for the jth organ from radionuclides releases, mrem.

j The organ of interest.

(DCF)ij Ingestion dose commitment factor for the jth organ from the ith radionuclide mrem/pCi, see Attachment 9.

I = Activity ingested of the ith radionuclide, pCi.

li is described by:

- (Ai)(V)( 3 6 5 )(1E0 6) (2.6)

(1000)(d) where:

365 = Days per year.

Ai = Annual activity released of ith radionuclide, ltCi.

V = Average rate of water consumption (2000 ml/d - adult, 1400 ml/d - teen and child, 900 ml/d - infant, ICRP 23, p 358).

d = Dilution water flow for year, ml.

1000 = Dispersion factor from discharge to nearest drinking water supply.

1E06 = Conversion gCi to pCi.

The dose equation then becomes:

i (3.65E05)(V) Z (DCF)ijx Aimrem (2.7) i=1 27

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24

b. Fish Inqestion The dose to an individual from the consumption of fish is described by Equation 2.10. In this case, the activity ingested of the ith radionuclide (1i)is described by:

SAiBiF(1E09) = pCi (2.8) 15dI where:

Ai = Annual released of ith radionuclide, gCi.

Bi = Fish concentration factor of ith radionuclide P Ci/gm

,uCi/mi (see Attachment 8).

F = Amount of fish eaten per year (21 kg adult, 16 kg teen, 6.9 kg child, none infant).

15 = Dispersion factor from discharge to fish exposure point.

d = Dilution water flow for year, ml.

1E09 = Conversion of giCi and Kgm to gross.

Substitution of Equation 2.8 into Equation 2.5 gives:

(6.7E07)F Ai x Bi x DCFi mrem (2.9) d D

28

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24

c. Annual Analysis A complete analysis utilizing the NRC computer code LADTAP with the total source release will be done annually in conjunction with the annual environmental report. This analysis will provide estimates of dose to the total body and various organs in addition to the dose limiting organs considered in the method of Section 2. The following approach is utilized on LADTAP. The dose to the jth organ from m radionuclides, Dj, is described by:

m Dj= Dijrmrem (2.10) i=1 m

= Y (DCF)ij x Ijmrem (2.11) i=1 where:

Dj = Dose to the jth organ from the ith radionuclide, mrem.

j= The organ of interest (bone, GI tract, thyroid, liver, kidney, lung, or total body).

(DCF)j = Adult ingestion dose commitment factor for the jth organ from the ith radionuclide, mrem/pCi (see Attachment 9).

I = Activity ingested of the ith radionuclide, gCi.

li for water ingestion is described by:

= Aii-Vr 1 ci (2.12) vd and for fish ingestion li is described by:

h, AiBiFr PCi (2.13) vd 29

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 where:

Ai = Activity release of jth radionuclide during the year, [tCi.

V = Average rate of water consumption (2000 ml/d).

F Number of days during the year (365 d).

v Dispersion factor from point of discharge to point of exposure.

d Dilution water volume (ml).

Bi = Fish concentration factor of the ith radionuclide, uCi/gm Attachment 8, pCi/ml F = Amount of fish eaten per day (57.5 gm/d).

D. OPERABILITY OF LIQUID RADWASTE EQUIPMENT The Palisades liquid radwaste system is designed to reduce the radioactive materials in liquid wastes prior to their discharge (by shipment for disposal) so that radioactivity in liquid effluent releases to unrestricted areas (see Figure 2-1) will not exceed the limits of Appendix A, III.H.1.

E. RELEASE RATE FOR OFFSITE EC (50 MREM/YR) 10 CFR 20.1302 requires radioactive effluent releases to unrestricted areas be less than the limits specified in Appendix B, Table 2 when averaged over a period not to exceed one year. Concentrations at this Effluent Concentration (EC) level, if ingested for one year, will result in a dose of 50 millirem to the total body. In addition, 10 CFR 50.36a requires that the release of radioactive materials be kept as low as is reasonably achievable. Appendix I to 10 CFR 50 provides the numerical guidelines on limiting conditions for operations to meet the as low as is reasonably achievable requirement.

The LADTAP code has been run to determine the dose due to drinking water at Plant discharge concentration (1,000 x nearest drinking water intake concentration).

The nominal average source term used is given in Attachment 2. Dose to the most limiting organ of the person hypothetically drinking this water is 3.88E-03 mrem.

This is only 0.13% of the more conservative 50 mrem/yr total body value.

30

z 0~

z 0

4 I.

w 04I

-J 4)

V 0 z ME.

C,,

w 0 C.)

4 -I.

C,,

4 0~ 0 U)

I - 9\ . SITE ENVIRONMENT

/i 28&07 TLD STATIONS "I PALISADES NUCLEAR PLANT U- i ,SITF BOUNDARY FIGuRE 2-1 LL:

PALISADES RADWASTE EFFLUENTS - LIQUID 471,EAN WASTE S*S r LKM STEAM GEN B IWDOWN PRIMARY TN TANK SYSTEEM lI 7T ]

STORAGE RE 0707 zTREATI[) A T;ANK I STANKS; 121 TRIP & FLOW CONTROL 0

SERVICE r -I r_ .

CLLI C_

.0 ) STEM WATERA 0 0) MISCEI ANEOUS WAST SYSTEM LAKE U LAUN Y .,.. UTILITY 1323 S

SYSTIEM WATER ;

0STORAGE a0 TANK

- j: 9UILn[N DRAINS BLDG BASIN DAN C)WASTE TANK T.M..E21 01

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 Ill. URANIUM FUEL CYCLE DOSE A. SPECIFICATION In accordance with Appendix A, Section 1I1.1.1, if either liquid or gaseous quarterly releases exceed the quantity which would cause offsite doses more than twice the limit of Appendix A, Sections 111.0.1, III.D.1, or III.H.1, then the cumulative dose contributions from combined release plus direct radiation sources (from the reactor unit and radwaste storage tanks) shall be calculated. The dose is to be determined for the member of the public protected to be the most highly exposed to these combined sources.

B. ASSUMPTIONS

1. The full time resident determined to be maximally exposed individual (excluding infant) is assumed also to be a fisherman. This individual is assumed to drink water and ingest local fish at the rates specified in Sections 11.C.2.1 and 11.0.2.2.

2. Amount of shore line fishing (at accessible shoreline adjacent to site security fence) is conservatively assumed as 48 hours5.555556e-4 days 0.0133 hours 7.936508e-5 weeks 1.8264e-5 months per quarter (average of approximately 1/2 hour per day each day of the quarter) for the second and third quarters of the year, 36 hours4.166667e-4 days 0.01 hours 5.952381e-5 weeks 1.3698e-5 months for the fourth quarter and 16 hours1.851852e-4 days 0.00444 hours 2.645503e-5 weeks 6.088e-6 months for the first quarter.

33

PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 24 C. DOSE CALCULATION Maximum doses to the total body and internal organs of an individual shall be determined by use of LADTAP and GASPAR computer codes, and doses to like organs and total body summed. Added to this sum will be a mean dose rate, calculated or measured for the shoreline due to Plant present curing the quarter in question, times the assumed fishing time.

D40 = DG + DL + (RT)(T) (2.15) where:

D40 = 40 CFR 190 dose (mrem).

DG = Limiting dose to an individual from gaseous source term (mrem).

DL = Limiting dose to an individual from liquid source term (mrem).

RT = Mean dose rate calculated to be applicable to Lake Michigan shoreline adjacent to Plant site (mrem/hr).

T = Assumed shoreline fishing time for the quarter in questions (hours).

IV. REVISIONS TO THE OFFSITE DOSE CALCULATION MANUAL A. REQUIREMENTS

1. For all revisions to the Offsite Dose Calculation Manual, complete Attachment 1.

2. All revisions to the Offsite Dose Calculation Manual are required to be reviewed by the Onsite Safety Review Committee.

34

Proc No ODCM Aftachment 1 Revision 24 Page 1 of 3 OFFSITE DOSE CALCULATION MANUAL CHANGE REVIEWS

1. Description and Evaluation:

Provide a brief description of each change and provide sufficient information to support the change, with appropriate analyses or evaluations justifying the change if needed.

2. Determination:

Answer the following questions:

a. Does the proposed chanqe maintain the level of radioactive effluent control required by 10 CFR 20.1302? (Compliance with dose limits for individual members of the public, where annual average concentrations of radioactive material released in gaseous and liquid effluents at the boundary of the unrestricted area do not exceed the values specified in Table 2 of Appendix B Part 20.)

FI]I Yes I1 No

b. Does the proposed chanqe maintain the level of radioactive effluent control required by 40 CFR 190? (Total dose uranium fuel cycle - less than or equal to 25 mrem total body or any organ, or less than or equal to 75 mrem thyroid.)

-- Yes

--I No

Proc No ODCM Attachment 1 Revision 24 Page 2 of 3 OFFSITE DOSE CALCULATIONMANUAL CHANGE REVIEWS

c. Does the proposed change maintain the level of radioactive effluent control required by 10 CFR 50.36a? (Technical Specifications on effluents from nuclear power reactors, where the Offsite Dose Calculation Manual is the document where the effluent controls are specified, and all the requirements of this regulation are demonstrated.)

IM Yes LI No

d. Does the proposed change maintain the level of radioactive effluent control required by 10 CFR 50, Appendix I? (Numerical guides for design objectives and limiting conditions for operation to meet the criterion "as low as reasonably achievable," for radioactive material in light-water-cooled nuclear power reactor effluents, lists the annual dose commitments to unrestricted areas for liquid and gaseous effluents.)

FII Yes

] No Does the proposed change adversely impact the accuracy or reliability of e.

effluent calculations?

r-l Yes IN No

Proc No ODCM Attachment 1 Revision 24 Page 3 of 3 OFFSITE DOSE CALCULATION MANUAL CHANGE REVIEWS

f. Does the proposed change adversely impact the accuracy or reliability of dose calculations?

FI Yes

[-I No Does the proposed change adversely impact the accuracy or reliability of g.

setpoint calculations?

--I Yes LI No 3.

Conclusion:

Changes to the ODCM were made in accordance to the provisions of Technical Specification 5.5.1, Section c.

Prepared By: /

Date Reviewed By:

Date r

Proc No ODCM Attachment 2 Revision 24 Page 1 of I PALISADES GASEOUS AND LIQUID SOURCE TERMS, CURIESIYEAR (1)

Nuclide Gaseous(2) Liquid(2)

H-3 5.5 159 Kr-85 4.1 NA Kr-85m 0.12 NA Kr-87 8.4E-02 NA Kr-88 2.1E-01 NA Ar-41 3.1 E-02 NA Xe-131m 2.2 NA Xe-133 1493 NA Xe-1 33m 0.43 NA Xe-1 35 1.11 NA Xe-1 35m 0.3 NA 1-131 0.025 3.21 E-03 1-132 2.91 E-03 NA 1-133 6.5E-03 4.7E-05 1-134 4.8E-04 NA 1-135 1.84E-02 NA Na-24 1.5E-06 NA Cr-51 2.5E-04 3.9E-03 Mn-54 4.1 E-04 7.8E-03 Co-57 2.1 E-06 3.2E-05 Co-58 8.6E-04 2.9E-02 Fe-59 6.6E-06 4.1 E-04 Co-60 1. 1 E-03 1.24E-02 Se-75 3.7E-06 NA Nb-95 2.4E-05 4.53E-04 Zr-95 4.7E-06 1.79E-04 Mo-99 1.5E-07 NA Ru-103 0.3E-07 0.1 E-05 Sb-127 NA 3.5E-05 Cs-134 4.5E-05 0.7 Cs-136 NA 1.8E-06 Cs-137 2.6E-04 1.36E-02 Ba-140 2.8E-07 NA La-140 7.5E-07 1.1E-04 Unidentified beta 3.9E-04 3.3E-03 (i) Data derived from taking the effluents released during July-December 1978 through January-June 1982 and dividing by 4.

(2) Nuclide values listed as NA have not been observed at detectable levels in these waste streams.

Proc No ODCM Affachment 3 Revision 24 Page 1 of 2 BASIC RADIONUCLIDE DATA NUCLIDE HALF-LIFE LAMBDA BETA1 GAMMA1 (dady) (1/s) (MEV/DIS) (MEV/DIS) 1 Tritium 4.49E 03 1.79E-09 5.68E-03 0.0 2 c-14 2.09E 06 3.84E-1 2 4.95E-02 0.0 3 N-13 6.94E-03 1.16E-03 4.91E-01 1.02E 00 4 0-19 3.36E-04 2.39E-02 1.02E 00 1.05E 00 5 F-18 7.62E-02 1.05E-04 2.50E-01 1.02E 00 6 NA-24 6.33E-01 1.27E-05 5.55E-01 4.12E 00 7 P-32 1.43E 01 5.61 E-07 6.95E-01 0.0 8 AR-41 7.63E-02 1.05E-04 4.64E-01 1.28E 00 9 CR-51 2.78E 01 2.89E-07 3.86E-03 3.28E-02 10 MN-54 3.03E 02 2.65E-08 3.80E-03 8.36E-01 11 MN-56 1.07E-01 7.50E-05 8.29E-01 1.69E 00 12 FE-59 4.50E 01 1.78E-07 1.18E-01 1.19E 00 13 CO-58 7.13E 01 1.12E-07 3.41 E-02 9.78E-01 14 CO-60 1.92E 03 4.18E-09 9.68E-02 2.50E 00 15 ZN-69m 5.75E-01 1.39E-05 2.21 E-02 4.16E-01 16 ZN-69 3.96E-02 2.03E-04 3.19E-01 0.0 17 BR-84 2.21 E-02 3.63E-04 1.28E 00 1.77E 00 18 BR-85 2.08E-03 3.86E-03 1.04E 00 6.60E-02 19 KR-85m 1.83E-01 4.38E-05 2.53E-01 1.59E-01 20 KR-85 3.93E 03 2.04E-09 2.51 E-01 2.21E-03 21 KR-87 5.28E-02 1.52E-04 1.32E 00 7.93E-01 22 KR-88 1.17E-01 6.86E-05 3.61E-01 1.96E 00 23 KR-89 2.21 E-03 3.63E-03 1.36E 00 1.83E 00 24 RB-88 1.24E-02 6.47E-04 2.06E 00 6.26E-01 25 RB-89 1.07E-02 7.50E-04 1.01 E 00 2.05E-00 26 SR-89 5.20E 01 1.54E-07 5.83E-01 8.45E-05 27 SR-90 1.03E 04 7.79E-1 0 1.96E-01 0.0 28 SR-91 4.03E-01 1.99E-05 6.50E-01 6.95E-01 29 SR-92 1.13E-01 7.1OE-05 1.95E-01 1.34E 00 30 SR-93 5.56E-03 1.44E-03 9.20E-01 2.24E 00 31 Y-90 2.67E 00 3.OOE-06 9.36E-01 0.0 32 Y-91m 3.47E-02 2.31 E-04 2.73E-02 5.30E-01 33 Y-91 5.88E 01 1.36E-07 6.06E-01 3.61 E-03 34 Y-92 1.47E-01 5.46E-05 1.44E 00 2.50E-01 35 Y-93 4.29E-01 1.87E-05 1.17E 00 8.94E-02 36 ZR-95 6.50E 01 1.23E-07 1.16E-01 7.35E-01 37 NB-95m 3.75E 00 2.14E-06 1.81E-01 6.06E-02 38 NB-95 3.50E 01 2.29E-07 4.44E-02 7.64E-01 39 MO-99 2.79E 00 2.87E-06 3.96E-01 1.50E-01 40 TC-99m 2.50E-01 3.21 E-05 1.56E-02 1.26E-01

Proc No ODCM Attachment 3 Revision 24 Page 2 of 2 BASIC RADIONUCLIDE DATA NUCLIDE HALF-LIFE LAMBDA BETA1 GAMMA 1 (days) (i/s) (MEV/DIS) (MEV/DIS) 41 TC-99 7.74E 07 1.04E-13 8.46E-02 0.0 42 TC- 104 1.25E-02 6.42E-04 1.60E 00 1 .95E 00 43 RU-106 3.67E 02 2.19E-08 1.01E-02 0.0 44 TE-132 3.24E 00 2.48E-06 1.OOE-01 2.33E-01 45 1-129 6.21E 09 1.29E-15 5.43E-02 2.46E-02 46 1-131 8.05E 00 9.96E-07 1.94E-01 3.81E-01 47 1-132 9.58E-02 8.37E-05 4.89E-01 2.24E 00 48 1-133 8.75E-01 9.17E-06 4.08E-01 6.02E-01 49 1-134 3.61 E-02 2.22E-04 6.16E-01 2.59E 00 5O 1-135 2.79E-01 2.87E-05 3.68E-01 1.55E 00 51 XE-131m 1.18E 01 6.80E-07 1.43E-01 2.01 E-02 52 XE-133m 2.26E 00 3.55E-06 1.90E-01 4.15E-02 53 XE-133 5.27E 00 1.52E-06 1.35E-01 4.60E-02 54 XE-135m 1.08E-02 7.43E-04 9.58E-02 4.32E-01 55 XE-135 3.83E-01 2.09E-05 3.17E-01 2.47E-01 56 XE-137 2.71E 03 2.96E-03 1.77E 00 1.88E-01 57 XE-138 9.84E-03 8.15E-04 6.65E-01 1.10E 00 58 CS-134 7.48E 02 1.07E-08 1.63E-01 1.55E 00 59 GS-135 1.10E 09 7.29E-1 5 5.63E-02 0.0 60 CS-136 1.30E 01 6.17E-07 1.37E-01 2.15E 00 61 CS-137 1.10E 04 7.29E-1 0 1.71E-01 5.97E-01 62 CS-1 38 2.24E-02 3.58E-04 1.20E 00 2.30E 00 63 BA-139 5.76E-02 1.39E-04 8.96E-01 3.53E-02 64 BA-140 1.28E 01 6.27E-07 3.15E-01 1.71E-01 65 LA-140 1.68E 00 4.77E-06 5.33E-01 2.31E 00 66 CE-144 2.84E 02 2.82E-08 9.13E-02 1.93E-02 67 PR-143 1.36E 01 5.90E-07 3.14E-01 0.0 68 PR-144 1.20E-02 6.68E-04 1.21E 00 3.18E 00 Average energy per disintegration values were obtained from ICRP Publication No 38, Radionuclide Transformations: Ener-gy and Intensity of Emissions 1983 and NUREG/CR-1413 (ORNL/NUREG-70), a Radionuclide Decay Data Base - Index and Summary Table, DC Kocher, May 1980.

Proc No ODCM Attachment 4 Revision 24 Page 1 of 1 DOSE FACTORS FOR SUBMERSION IN NOBLE GASES*

Gamma body Gamma2 air Beta skin Beta air 2

dose 1 dose dose1 dose Kr-85m 1.17E3 1.23E3 1.46E3 1.97E3 Kr-85 1.61 El 1.72E1 1.34E3 1.95E3 Kr-87 5.92E3 6.17E3 9.73E3 1.03E4 Kr-88 1.47E4 1.52E4 2.37E3 2.93E3 Kr-89 1.66E4 1.73E4 1.01 E4 1.06E4 Xe-131m 9.15E1 1.56E2 4.76E2 1.11E3 Xe-133m 2.51 E2 3.27E2 9.94E2 1.48E3 Xe-133 2.94E2 3.53E2 3.06E2 1.05E3 Xe-135m 3.12E3 3.36E3 7.11E2 7.39E3 Xe-135 1.81 E3 1.92E3 1.86E3 2.46E3 Xe-137 1.42E3 1.51E3 1.22E4 1.27E4 Xe-138 8.83E3 9.21E3 4.13E3 4.75E3 Ar-41 8.84E3 9.30E3 2.69E3 3.28E3

1. mrem/y per ýiCi/m 3 3

2. mrad/y per pCi/m

Dose factors for exposure to a semi-infinite cloud of noble gases. Values were obtained from USNRC Regulatory Guide 1.109, Revision 1 (October 1977).

Proc No ODCM Attachment 5 Revision 24 Page 1 of I STABLE ELEMENT TRANSFER DATA Fm - MILK (COW) Fm - MILK (GOAT) Ff- MEAT aiv ELEMENT (DAYS/L) (DAYS/L) (DAYS/KG) (VEG/SOIL)

H 1.OE-02 1.7E-01 1.2E-02 4.8E-00 C 1.2E-02 1.OE-01 3.1 E-02 5.5E-00 Na 4.OE-02 4.OE-02 3.0E-02 5.2E-02 P 2.5E-02 2.5E-01 4.6E-02 1.1 E-00 Cr 2.2E-03 2.2E-03 2.4E-03 2.5E-04 Mn 2.5E-04 2.5E-04 8.OE-04 2.9E-02 Fe 1.2E-03 1.3E-04 4.OE-02 6.6E-04 Co 1.OE-03 1.OE-03 1.3E-02 9.4E-03 Ni 6.7E-03 6.7E-03 5.3E-02 1.9E-02 Cu 1.4E-02 1.3E-02 8.OE-03 1.2E-01 Zn 3.9E-02 3.9E-02 3.OE-02 4.OE-01 Rb 3.OE-02 3.OE-02 3.1 E-02 1.3E-01 Sr 8.OE-04 1.4E-02 6.OE-04 1.7E-02 Y 1.OE-05 1.OE-05 4.6E-03 2.6E-03 Zr 5.OE-06 5.OE-06 3.4E-02 1.7E-04 Nb 2.5E-03 2.5E-03 2.8E-01 9.4E-03 Mo 7.5E-03 7.5E-03 8.OE-03 1.2E-01 Tc 2.5E-02 2.5E-02 4.OE-01 2.5E-01 Ru 1.OE-06 1.OE-06 4.OE-01 5.OE-02 Rh 1.0E-02 1.OE-02 1.5E-03 1.3E+01 Ag 5.OE-02 5.OE-02 1.7E-02 1.5E-01 Te 1.OE-03 1.OE-03 7.7E-02 1.3E-00 6.OE-03 6.OE-02 2.9E-03 2.OE-02 Cs 1.2E-02 3.OE-01 4.OE-03 1.OE-02 Ba 4.OE-04 4.OE-04 3.2E-03 5.OE-03 La 5.OE-06 5.OE-06 2.OE-04 2.5E-03 Ce 1.OE-04 1.OE-04 1.2E-03 2.5E-03 Pr 5.OE-06 5.OE-06 4.7E-03 2.5E-03 Nd 5.OE-06 5.OE-06 3.3E-03 2.4E-03 W 5.OE-04 5.OE-04 1.3E-03 1.8E-02 Np 5.OE-06 5.OE-06 2.OE-04 2.5E-03

Proc No ODCM Attachment 6 Revision 24 Page 1 of 16 INHALATION DOSE COMMITMENT FACTORS INFANT INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3* 0. 4.62E-07 4.62E-07 4.62E-07 4.62E-07 4.62E-07 4.62E-07 BE10 9.49E-04 1.25E-04 2.65E-05 0. 0. 1.49E-03 1.73E-05 C14 1.89E-05 3.79E-06 3.79E-06 3.79E-06 3.79E-06 3.79E-06 3.79E-06 N13 4.39E-08 4.39E-08 4.39E-08 4.39E-08 4.39E-08 4.39E-08 4.39E-08 F18 3.92E-06 0. 3.33E-07 0. 0. 0. 6.10E-07 NA22 7.37E-05 7.37E-05 7.37E-05 7.37E-05 7.37E-05 7.37E-05 7.37E-05 NA24 7.54E-06 7.54E-06 7.54E-06 7.54E-06 7.54E-06 7.54E-06 7.54E-06 P32 1.45E-03 8.03E-05 5.53E-05 0. 0. 0. 1.15E-05 AR39 0. 0. 0. 0. 0. 1.OOE-08 0.

AR41 0. 0. 0. 0. 0. 3.14E-08 0.

CA41 7.48E-05 0. 8.16E-06. 0. 0. 6.94E-02 2.96E-07 SC46 3.75E-04 5.41E-04 1.69E-04 0. 3'.56E-04 0. 2.19E-05 CR51 0. 0. 6.39E-08 4.11E-08 9.45E-09 9.17E-06 2.55E-07 MN54 0. 1.81E-05 3.56E-06 0. 3.56E-06 7.14E-04 5.04E-06 MN56 0. 1.1OE-09 1.58E-10 0. 7.86E-10 8.95E-06 5.12E-05 FE55 1.41E-05 8.39E-06 2.38E-06 0. 0. 6.21E-05 7.82E-07 FE59 9.69E-06 1.68E-05 6.77E-06 0. 0. 7.25E-04 1.77E-05 C057 0. 4.65E-07 4.58E-07 0. 0. 2.71 E-04 3.47E-06 C058 0. 8.71 E-07 1.30E-06 0. 0. 5.55E-04 7.95E-06 C060 0. 5.73E-06 8.41 E-06 0. 0. 3.22E-03 2.28E-05 N159 1.81 E-05 5.44E-06 3.1OE-06 0. 0. 5.48E-05 6.34E-07 N163 2.42E-04 1.46E-05 8.29E-06 0. 0. 1.49E-04 1.73E-06 N165 1.71E-09 2.03E-10 8.79E-11 0. 0. 5.80E-06 3.58E-05 CU64 0. 1.34E-09 5.53E-10 0. 2.84E-09 6.64E-06 1.07E-05 ZN65 1.38E-05 4.47E-05 2.22E-05 0. 2.32E-05 4.62E-04, 3.67E-05 ZN69M+D 8.98E-09 1.84E-08 1.67E-09 0. 7.45E-09 1.91 E-05 2.92E-05 ZN69 3.85E-11 6.91E-11 5.13E-12 0. 2.87E-11 1.05E-06 9.44E-06 SE79 0. 2.25E-06 4.20E-07 0. 2.47E-06 2.99E-04 3.46E-06 BR82 0. 0. 9.49E-06 0. 0. 0. 0.

BR83+D 0. 0. 2.72E-07 0. 0. 0. 0.

BR84 0. 0. 2.86E-07 0. 0. 0. 0.

BR85 0. 0. 1.46E-08 0. 0. 0. 0.

KR83M 0. 0. 0. 0. 0. 2.50E-09 0.

KR85M 0. 0. 0. 0. 0. 1.31E-08 0.

KR85 0. 0. 0. 0. 0. 1.16E-08 0.

KR87 0. 0. 0. 0. 0. 6.59E-08 0.

KR88+D 0. 0. 0. 0. 0. 1.38E-07 0.

KR89 0. 0. 0. 0. 0. 8.67E-08 0.

RB86 0. 1.36E-04 6.30E-05 0. 0. 0. 2.17E-06 RB87 0. 7.11E-05 2.64E-05 0. 0. 0. 2.99E-07 RB88 0. 3.98E-07 2.05E-07 0. 0. 0. 2.42E-07 RB89+D 0. 2.29E-07 1.47E-07 0. 0. 0. 4.87E-08 SR89+D 2.84E-04 0. 8.15E-06 0. 0. 1.45E-03 4.57E-05 SR90+D 2.92E-02 0. 1.85E-03 0. 0. 8.03E-03 9.36E-05 SR91+D 6.83E-08 0. 2.47E-09 0. 0. 3.76E-05 5.24E-05 SR92+D 7.50E-09 0. 2.79E-10 0. 0. 1.70E-05 1.OOE-04 Includes a 50% increase to account for percutaneous transpiration.

Proc No ODCM Attachment 6 Revision 24 Page 2 of 16 INHALATION DOSE COMMITMENT FACTORS INFANT INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 2.35E-06 0. 6.30E-08 0. 0. 1.92E-04 7.43E-05 Y91M+D 2.91 E-1 0 0. 9.90E-12 0. 0. 1.99E-06 1.68E-06 Y91 4.20E-04 0. 1.12E-05 0. 0. 1.75E-03 5.02E-05 Y92 1.17E-08 0. 3.29E-10 0. 0. 1.75E-05 9.04E-05 Y93 1.07E-07 0. 2.91 E-09 0. 0. 5.46E-05 1.19E-04 ZR93+D 2.24E-04 9.51 E-05 6.18E-05 0. 3.19E-04 1.37E-03 1.48E-05 ZR95+D 8.24E-05 1.99E-05 1.45E-05 0. 2.22E-05 1.25E-03 1.55E-05 ZR97+D 1.07E-07 1.83E-08 8.36E-09 0. 1.85E-08 7.88E-05 1.OOE-04 NB93M 1.38E-04 3.59E-05 1.15E-05 0. 3.68E-05 2.09E-04 2.47E-06 NB95 1.12E-05 4.59E-06 2.70E-06 0. 3.37E-06 3.42E-04 9.05E-06 NB97 2.44E-10 5.21 E-1 1 1.88E-11 0. 4.07E-11 2.37E-06 1.92E-05 M093 0. 6.46E-06 2.22E-07 0. 1.54E-06 3.40E-04 3.76E-06 M099+D 0. 1.18E-07 2.31 E-08 0. 1.89E-07 9.63E-05 3.48E-05 TC99M 9.98E-13 2.06E-12 2.66E-11 0. 2.22E- 11 5.79E-07 1.45E-06 TC99 2.09E-07 2.68E-07 8.85E-08 0. 2.49E-06 6.77E-04 7.82E-06 TC101 4.65E-14 5.88E-14 5.80E-13 0. 6.99E-13 4.17E-07 6.03E-07 RU 103+D 1.44E-06 0. 4.85E-07 0. 3.03E-06 3.94E-04 1.15E-05 RU 105+D 8.74E-10 0. 2.93E-10 0. 6.42E-10 1.12E-05 3.46E-05 RU106+D 6.20E-05 0. 7.77E-06 0. 7.61 E-05 8.26E-03 1.17E-04 RH105 8.26E-09 5.41 E-09 3.63E-09 0. 1.50E-08 2.08E-05 1.37E-05 PD107 0. 4.92E-07 4.11 E-08 0. 2.75E-06 6.34E-05 7.33E-07 PD109 0. 3.92E-09 1.05E-09 0. 1.28E-08 1.68E-05 2.85E-05 AG110M+D 7.13E-06 5.16E-06 3.57E-06 0. 7.80E-06 2.62E-03 2.36E-05 AG111 3.75E-07 1.45E-07 7.75E-08 0. 3.05E-07 2.06E-04 3.02E-05 CD113M 0. 6.67E-04 2.64E-05 0. 5.80E-04 1.40E-03 1.65E-05 CD115M 0. 1.73E-04 6.19E-06 0. 9.41 E-05 1.47E-03 5.02E-05 SN123 2.09E-04 4.21 E-06 7.28E-06 4.27E-06 0. 2.22E-03 4.08E-05 SN125+D 1.01 E-05 2.51 E-07 6.OOE-07 2.47E-07 0. 6.43E-04 7.26E-05 SN126+D 8.30E-04 1.44E-05 3.52E-05 3.84E-06 0. 4-93E-03 1.65E-05 SB124 2.71 E-05 3.97E-07 8.56E-06 7.18E-08 0. 1.89E-03 4.22E-05 SB125+D 3.69E-05 3.41 E-07 7.78E-06 4.45E-08 0. 1.17E-03 1.05E-05 SB126 3.08E-06 6.01 E-08 1.11E-06 2.35E-08 0. 6.88E-04 5.33E-05 SB127 2.82E-07 5.04E-09 8.76E-08 3.60E-09 0. 1.54E-04 3.78E-05 TE125M 3.40E-06 1.42E-06 4.70E-07 1.16E-06 0. 3.19E-04 9.22E-06 TE127M+D 1.19E-05 4.93E-06 1.48E-06 3.48E-06 2.68E-05 9.37E-04 1.95E-05 TE127 1.59E-09 6.81 E-1 0 3.49E-10 1.32E-09 3.47E-09 7.39E-06 1.74E-05 TE129M+D 1.01E-05 4.35E-06 1.59E-06 3.91 E-06 2.27E-05 1.20E-03 4.93E-05 TE129 5.63E-1 1 2.48E-1 1 1.34E-11 4.82E- 11 1.25E-10 2.14E-06 1.88E-05 TE131M+D 7.62E-08 3.93E-08 2.59E-08 6.38E-08 1.89E-07 1.42E-04 8.51 E-05 TE131+D 1.24E-11 5.87E-12 3.57E-12 1.13E-11 2.85E-11 1.47E-06 5.87E-06 TE132+D 2.66E-07 1.69E-07 1.26E-07 1.99E-07 7.39E-07 2.43E-04 3.15E-05 TE133M+D 6.13E-11 3.59E-1 1 2.74E-1 1 5.52E-11 1.72E-10 3.92E-06 1.59E-05 TE134+D 3.18E-11 2.04E-1 1 1.68E-11 2.91 E-11 9.59E-1 1 2.93E-06 2.53E-06 1129 2.16E-05 1.59E-05 1.16E-05 1.04E-02 1.88E-05 0. 2.12E-07 1130 4.54E-06 9.91 E-06 3.98E-06 1.14E-03 1.09E-05 0. 1.42E-06 1131+D 2.71 E-05 3.17E-05 1.40E-05 1.06E-02 3.70E-05 0. 7.56E-07

Proc No ODCM Affachment 6 Revision 24 Page 3 of 16 INHALATION DOSE COMMITMENT FACTORS INFANT INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 1.21 E-06 2.53E-06 8.99E-07 1.21 E-04 2.82E-06 0. 1.36E-06 1133+D 9.46E-06 1.37E-05 4.OOE-06 2.54E-03 1.60E-05 0. 1.54E-06 1134 6.58E-07 1.34E-06 4.75E-07 3.18E-05 1.49E-06 0. 9.21 E-07 1135+D 2.76E-06 5.43E-06 1.98E-06 4.97E-04 6.05E-06 0. 1.31 E-06 XE131M 0. 0. 0. 0. 0. 6.77E-09 0.

XE133M 0. 0. 0. 0. 0. 8.89E-09 0.

XE133 0. 0. 0. 0. 0. 7.41 E-09 0.

XE135M 0. 0. 0. 0. 0. 8.05E-09 0.

XE135 0. 0. 0. 0. 0. 1.80E-08 0.

XE137 0. 0. 0. 0. 0. 8.30E-08 0.

XE138+D 0. 0. 0. 0. 0. 9.78E-08 0.

CS134M+D 1.32E-07 2.10E-07 1.11E-07 0. 8.50E-08 2.OOE-08 1.16E-07 CS134 2.83E-04 5.02E-04 5.32E-05 0. 1.36E-04 5.69E-05 9.53E-07 CS135 1.OOE-04 8.66E-05 4.73E-06 0. 2.58E-05 1.01 E-05 2.18E-07 CS136 3.45E-05 9.61 E-05 3.78E-05 0. 4.03E-05 8.40E-06 1.02E-06 CS137+D 3.92E-04 4.37E-04 3.25E-05 0. 1.23E-04 5.09E-05 9.53E-07 CS138 3.61 E-07 5.58E-07 2.84E-07 0. 2.93E-07 4.67E-08 6.26E-07 CS139+D 2.32E-07 3.03E-07 1.22E-07 0. 1.65E-07 2.53E-08 1.33E-08 BA139 1.06E-09 7.03E-1 3 3.07E-1 1 0. 4.23E-1 3 4.25E-06 3.64E-05 BA140+D 4.OOE-05 4.OOE-08 2.07E-06 0. 9.59E-09 1.14E-03 2.74E-05, BA141+D 1.12E-10 7.70E-14 3.55E-12 0. 4.64E-14 2.12E-06 3.39E-06 BA142+D 2.84E-1 1 2.36E-14 1.40E-12 0. 1.36E-14 1.11E-06 4.95E-07 LA140 3.61 E-07 1.43E-07 3.68E-08 0. 0. 1.20E-04 6.06E-05 LA141 4.85E-09 1.40E-09 2.45E-1 0 0. 0. 1.22E-05 5.96E-05 LA142 7.36E-1 0 2.69E-10 6.46E-1 1 0. 0. 5.87E-06 4.25E-05 CE141 1.98E-05 1.19E-05 1.42E-06 0. 3.75E-06 3.69E-04 1.54E-05 CE143+D 2.09E-07 1.38E-07 1.58E-08 0. 4.03E-08 8.30E-05 3.55E-05 CE144+D 2.28E-03 8.65E-04 1.26E-04 0. 3.84E-04 7.03E-03 1.06E-04 PR143 1.OOE-05 3.74E-06 4.99E-07 0. 1.41 E-06 3.09E-04 2.66E-05 PR144 3.42E- 11 1.32E-11 1.72E-12 0. 4.80E-12 1.15E-06 3.06E-06 ND147+D 5.67E-06 5.81 E-06 3.57E-07 0. 2.25E-06 2.30E-04 2.23E-05 PM147 3.91 E-04 3.07E-05 1.56E-05 0. 4.93E-05 4.55E-04 5.75E-06 PM148M+D 5.OOE-05 1.24E-05 9.94E-06 0. 1.45E-05 1.22E-03 3.37E-05 PM148 3.34E-06 4.82E-07 2.44E-07 0. 5.76E-07 3.20E-04 6.04E-05 PM149 3.1 OE-07 4.08E-08 1.78E-08 0. 4.96E-08 6.50E-05 3.01 E-05 PM151 7.52E-08 1.10E-08 5.55E-09 0. 1.30E-08 3.25E-05 2.58E-05 SM151 3.38E-04 6.45E-05 1.63E-05 0. 5.24E-05 2.98E-04 3.46E-06 SM153 1.53E-07 1.18E-07 9.06E-09 0. 2.47E-08 3.70E-05 1.93E-05 EU152 7.83E-04 1.77E-04 1.72E-04 0. 5.94E-04 1.48E-03 9.88E-06 EU154 2.96E-03 3.46E-04 2.45E-04 0. 1.14E-03 3.05E-03 2.84E-05 EU155 5.97E-04 5.72E-05 3.46E-05 0. 1.58E-04 5.20E-04 5.19E-05 EU156 1.56E-05 9.59E-06 1.54E-06 0. 4.48E-06 6.12E-04 4. 14E-05 TB160 1.12E-04 0. 1.40E-05 0. 3.20E-05 1.11E-03 2.14E-05 H0166M 1.45E-03 3.07E-04 2.51 E-04 0. 4.22E-04 2.05E-03 1.65E-05 W181 4.86E-08 1.46E-08 1.67E-09 0. 0. 1.33E-05 2.63E-07 W185 1.57E-06 4.83E-07 5.58E-08 0. 0. 4.48E-04 1.12E-05 Wi 87 9.26E-09 6.44E-09 2.23E-09 0. 0. 2.83E-05 2.54E-05

Proc No ODCM Attachment 6 Revision 24 Page 4 of 16 INHALATION DOSE COMMITMENT FACTORS INFANT INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI PB210+D 8.62E-02 2.02E-02 3.43E-03 0. 6.85E-02 1.76E-01 3.79E-05 B1210+D 0. 1.33E-05 1.18E-06 0. 1.03E-04 9.96E-03 3.27E-05 P0210 2.98E-03 5.63E-03 7.12E-04 0. 1.30E-02 2.40E-01 4.36E-05 RN222+D 0. 0. 0. 0. 0. 9.88E-06 0.

RA223+D 1.56E-03 2.26E-06 3.12E-04 0. 4.16E-05 2.25E-01 3.04E-04 RA224+D 1.77E-04 4.00E-07 3.54E-05 0. 7.30E-06 7.91 E-02 3.42E-04 RA225+D 2.57E-03 2.88E-06 5.13E-04 0. 5.31E-05 2.57E-01 2.87E-04 RA226+D 2.48E-01 1.46E-05 2.05E-01 0. 2.94E-04 7.83E-01 3.05E-04 RA228+D 1.60E-01 7.61E-06 1.80E-01 0. 1.53E-04 1.09E-00 5.19E-05 AC225 3.69E-03 4.72E-03 2.48E-04 0. 3.49E-04 1.96E-01 2.71 E-04 AC227+D 5.29E+00 8.76E-01 3.28E-01 0. 1.86E-01 1.62E+00 5.27E-05 TH227+D 1.82E-03 3.03E-05 5.24E-05 0. 1.13E-04 3.27E-01 3.53E-04 TH228+D 8.46E-01 1.1OE-02 2.86E-02 0. 5.61E-02 4.65E+00 3.62E-04 TH229 1.34E+01 1.82E-01 6.62E-01 0. 8.99E-01 1.22E+01 3.29E-04 TH230 3.46E+00 1.79E-01 9.65E-02 0. 8.82E-01 2.18E+00 3.87E-05 TH232+D 3.86E+00 1.53E-01 2.29E-01 0. 7.54E-01 2.09E+00 3.29E-05 TH234 1.33E-05 7.17E-07 3.84E-07 0. 2.70E-06 1.62E-03 7.40E-05 PA231+D 9.1OE+00 3.OOE-01 3.62E-01 0. 1.62E+00 3.85E-01 4.61E-05 PA233 6.84E-06 1.32E-06 1.19E-06 0. 3.68E-06 2.19E-04 9.04E-06 U232+D 2.57E-01 0. 2.13E-02 0. 2.40E-02 1.49E+00 4.36E-05 U233+D 5.44E-02 0. 3.83E-03 0. 1.09E-02 3.56E-01 4.03E-05 U234 5.22E-02 0. 3.75E-03 0. 1.07E-02 3.49E-01 3.95E-05 U235+D 5.01E-02 0. 3.52E-03 0. 1.01 E-02 3.28E-01 5.02E-05 U236 5.01E-02 0. 3.60E-03 0. 1.03E-02 3.35E-01 3.71E-05 U237 3.25E-07 0. 8.65E-08 0. 8.08E-07 9.13E-05 1.31E-05 U238+D 4.79E-02 0. 3.29E-03 0. 9.40E-03 3.06E-01 3.54E-05 NP237+D 3.03E+00 2.32E-01 1.26E-01 0. 7.69E-01 3.49E-01 5.10E-05 NP238 2.67E-06 6.73E-08 4.16E-08 0. 1.47E-07 9.19E-05 2.58E-05 NP239 2.65E-07 2.37E-08 1.34E-08 0. 4.73E-08 4.25E-05 1.78E-05 PU238 5.02E+00 6.33E-01 1.27E-01 0. 4.64E-01 9.03E-01 4.69E-05 PU239 5.50E+00 6.72E-01 1.34E-01 0. 4.95E-01 8.47E-01 4.28E-05 PU240 6.49E+00 6.71E-01 1.34E-01 0. 4.94E-01 8.47E-01 4.36E-05 PU241+D 1.55E-01 6.69E-03 3.11E-03 0. 1.15E-02 7.62E-04 8.97E-07 PU242 5.09E+00 6.47E-01 1.29E-01 0. 4.77E-01 8.15E-01 4.20E-05 PU244 5.95E+00 7.40E-01 1.48E-01 0. 5.46E-01 9.33E-01 6.26E-05 AM241 1.84E+00 8.44E-01 1.31 E-01 0. 7.94E-01 4.06E-01 4.78E-05 AM242M 1.90E+00 8.24E-01 1.35E-01 0. 8.03E-01 1.64E-01 6.01 E-05 AM243 1.82E+00 8.10E-01 1.27E-01 0. 7.72E-01 3.85E-01 5.60E-05 CM242 8.58E-02 7.44E-02 5.70E-03 0. 1.69E-02 2.97E-01 5.10E-05 CM243 1.73E+00 7.94E-01 1.06E-01 0. 3.91E-01 4.24E-01 5.02E-05 CM244 1.43E+00 7.04E-01 8.89E-02 0. 3.21E-01 4.08E-01 4.86E-05 CM245 2.26E+00 8.80E-01 1.36E-01 0. 5.23E-01 3.92E-01 4.53E-05 CM246 2.24E+00 8.79E-01 1.36E-01 0. 5.23E-01 3.99E-01 4.45E-05 CM247+D 2.18E+00 8.64E-01 1.33E-01 0. 5.15E-01 3.92E-01 5.85E-05 CM248 1.82E+01 7.12E+00 1.10E+00 0. 4.24E+00 3.23E+00 9.43E704 CF252 4.26E+00 0. 1.01E-01 0. 0. 1.37E+00 1.85E-04

Proc No ODCM Attachment 6 Revision 24 Page 5 of 16 INHALATION DOSE COMMITMENT FACTORS CHILD INHALATION DOSE COMMITMENT FACTORS (MREMI50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3* 0. 3.04E-07 3.04E-07 3.04E-07 3.04E-07 3.04E-07 3.04E-07 BE10 8.43E-04 9.83E-05 2.12E-05 0. 0. 7.41 E-04 1.72E-05 C14 9.70E-06 1.82E-06 1.82E-06 1.82E-06 1.82E-06 1.82E-06 1.82E-06 N13 2.33E-08 2.33E-08 2.33E-08 2.33E-08 2.33E-08 2.33E-08 2.33E-08 F18 1.88E-06 0. 1.85E-07 0. 0. 0. 3.37E-07 NA22 4.41 E-05 4.41 E-05 4.41 E-05 4.41 E-05 4.41 E-05 4.41 E-05 4.41 E-05 NA24 4.35E-06 4.35E-06 4.35E-06 4.35E-06 4.35E-06 4.35E-06 4.35E-06 P32 7.04E-04 3.09E-05 2.67E-05 0. 0. 0. 1.14E-05 AR39 0. 0. 0. 0. 0. 4.89E-09 0.

AR41 0. 0. 0. 0. 0. 1.68E-08 0.

CA41 7.06E-05 0. 7.70E-06 0. 0. 7.21 E-02 2.94E-07 SC46 1.97E-04 2.70E-04 1.04E-04 0. 2.39E-04 0. 2.45E-05 CR51 0. 0. 4.17E-08 2.31 E-08 6.57E-09 4.59E-06 2.93E-07 MN54 0. 1.16E-05 2.57E-06 0. 2.71E-06 4.26E-04 6.19E-06 MN56 0. 4.48E-10 8.43E-1 1 0. 4.52E-10 3.55E-06 3.33E-05 FE55 1.28E-05 6.80E-06 2.1 OE-06 0. 0. 3.OOE-05 7.75E-07 FE59 5.59E-06 9.04E-06 4.51 E-06 0. 0. 3.43E-04 1.91 E-05 C057 0. 2.44E-07 2.88E-07 0. 0. 1.37E-04 3.58E-06 C058 0. 4.79E-07 8.55E-07 0. 0. 2.99E-04 9.29E-06 C060 0. 3.55E-06 6.12E-06 0. 0. 1.91 E-03 2.60E-05 N159 1.66E-05 4.67E-06 2.83E-06 0. 0. 2.73E-05 6.29E-07 N163 2.22E-04 1.25E-05 7.56E-06 0. 0. 7.43E-05 1.71 E-06 N165 8.08E-10 7.99E-11 4.44E-1 1 0. 0. 2.21 E-06 2.27E-05 CU64 0. 5.39E-10 2.90E-10 0. 1.63E-09 2.59E-06 9.92E-06 ZN65 1.15E-05 3.06E-05 1.90E-05 0. 1.93E-05 2.69E-04 4.41 E-06 ZN69M+D 4.26E-09 7.28E-09 8.59E-10 0. 4.22E-09 7.36E-06 2.71 E-05 ZN69 1.81 E-11 2.61 E-11 2.41E-12 0. 1.58E-1 1 3.84E-07 2.75E-06 SE79 0. 1.23E-06 2.60E-07 0. 1.71 E-06 1.49E-04 3.43E-06 BR82 0. 0. 5.66E-06 0. 0. 0. 0.

BR83+D 0. 0. 1.28E-07 0. 0. 0. 0.

BR84 0. 0. 1.48E-07 0. 0. 0. 0.

BR85 0. 0. 6.84E-09 0. 0. 0. 0.

KR83M 0. 0. 0. 0. 0. 1.22E-09 0.

KR85M 0. 0. 0. 0. 0. 6.58E-09 0.

KR85 0. 0. 0. 0. 0. 5.66E-09 0.

KR87 0. 0. 0. 0. 0. 3.38E-08 0.

KR88+D 0. 0. 0. 0. 0. 6.99E-08 0.

KR89 0. 0. 0. 0. 0. 4.55E-08 0.

RB86 0. 5.36E-05 3.09E-05 0. 0. 0. 2.16E-06 RB87 0. 3.16E-05 1.37E-05 0. 0. 0. 2.96E-07 RB88 0. 1.52E-07 9.90E-08 0. 0. 0. 4.66E-09 RB89+D 0. 9.33E-08 7.83E-08 0. 0. 0. 5.11E-10 SR89+D 1.62E-04 0. 4.66E-06 0. 0. 5.83E-04 4.52E-05 SR90+D 2.73E-02 0. 1.74E-03 0. 0. 3.99E-03 9.28E-05 SR91+D 3.28E-08 0. 1.24E-09 0. 0. 1.44E-05 4.70E-05 SR92+D 3.54E-09 0. 1.42E-10 0. 0. 6.49E-06 6.55E-05

Includes a 50% increase to account for percutaneous transpiration.

Proc No ODCM Attachment 6 Revision 24 Page 6 of 16 INHALATION DOSE COMMITMENT FACTORS CHILD INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 1.11E-06 0. 2.99E-08 0. 0. 7.07E-05 7.24E-05 Y91M+D 1.37E-10 0. 4.98E-12 0. 0. 7.60E-07 4.64E-07 Y91 2.47E-04 0. 6.59E-06 0. 0. 7.1OE-04 4.97E-05 Y92 5.50E-09 0. 1.57E-10 0. 0. 6.46E-06 6.46E-05 Y93 5.04E-08 0. 1.38E-09 0. 0. 2.01E-05 1.05E-04 ZR93+D 2.07E-04 7.80E-05 5.55E-05 0. 3.OOE-04 7.1 OE-04 1.47E-05 ZR95+D 5.13E-05 1.13E-05 1.OOE-05 0. 1.61 E-05 6.03E-04 1.65E-05 ZR97+D 5.07E-08 7.34E-09 4.32E-09 0. 1.05E-08 3.06E-05 9.49E-05 NB93M 1.27E-04 3.17E-05 1.04E-05 0. 3.44E-05 1.04E-04 2.45E-06 NB95 6.35E-06 2.48E-06 1.77E-06 0. 2.33E-06 1.66E-04 1.OOE-05 NB97 1.16E-10 2.08E-1 1 9.74E-12 0. 2.31E-11 9.23E-07 7.52E-06 M093 0. 3.76E-06 1.35E-07 0. 1.06E-06 1.70E-04 3.78E-06 M099+D 0. 4.66E-08 1.15E-08 0. 1.06E-07 3.66E-05 3.42E-05 TC99M 4.81 E-13 9.41 E-1 3 1.56E-11 0. 1.37E-11 2.57E-07 1.30E-06 TC99 1.34E-07 1.49E-07 5.35E-08 0. 1.75E-06 3.37E-04 7.75E-06 TC101 2.19E-14 2.30E-14 2.91E-13 0. 3.92E-13 1.58E-07 4.41E-09 RU 103+D 7.55E-07 0. 2.90E-07 0. 1.90E-06 1.79E-04 1.21 E-05 RU 105+D 4.13E-10 0. 1.50E-10 0. 3.63E-10 4.30E-06 2.69E-05 RU 106+D 3.68E-05 0. 4.57E-06 0. 4.97E-05 3.87E-03 1.16E-04 RH105 3.91 E-09 2.10E-09 1.79E-09 0. 8.39E-09 7.82E-06 1.33E-05 PD107 0. 2.65E-07 2.51 E-08 0. 1.97E-06 3.16E-05 7.26E-07 PD109 0. 1.48E-09 4.95E-10 0. 7.06E-09 6.16E-06 2.59E-05 AG110M+D 4.56E-06 3.08E-06 2.47E-06 0. 5.74E-06 1.48E-03 2.71 E-05 AG111 1.81 E-07 5.68E-08 3.75E-08 0. 1.71E-07 7.73E-05 2.98E-05 CD113M 0. 4.93E-04 2.12E-05 0. 5.13E-04 6.94E-04 1.63E-05 CD115M 0. 7.88E-05 3.39E-06 0. 5.93E-05 5.86E-04 4.97E-05 SN123 1.29E-04 2.14E-06 4.19E-06 2.27E-06 0. 9.59E-04 4.05E-05 SN125+D 4.95E-06 9.94E-08 2.95E-07 1.03E-07 0. 2.43E-04 7.17E-05 SN126+D 6.23E-04 1.04E-05 2.36E-05 2.84E-06 0. 3.02E-03 1.63E-05 SB124 1.55E-05 2.OOE-07 5.41 E-06 3.41 E-08 0. 8.76E-04 4.43E-05 SB125+D 2.66E-05 2.05E-07 5.59E-06 2.46E-08 0. 6.27E-04 1.09E-05 SB126 1 .72E-06 2.62E-08 6.16E-07 1.OOE-08 0. 2.86E-04 5.67E-05 SB127 1.36E-07 2.09E-09 4.70E-08 1.51 E-09 0. 6.17E-05 3.82E-05 TE125M 1.82E-06 6.29E-07 2.47E-07 5.20E-07 0. 1.29E-04 9.13E-06 TE127M+D 6.72E-06 2.31 E-06 8.16E-07 1.64E-06 1.72E-05 4.OOE-04 1.93E-05 TE127 7.49E-1 0 2.57E-10 1.65E-10 5.30E-10 1.91 E-09 2.71 E-06 1.52E-05 TE129M+D 5.19E-06 1.85E-06 8.22E-07 1.71 E-06 1.36E-05 4.76E-04 4.91 E-05 TE129 2.64E-1 1 9.45E-12 6.44E-12 1.93E- 11 6.94E-1 1 7.93E-07 6.89E-06 TE131M+D 3.63E-08 1.60E-08 1.37E-08 2.64E-08 1.08E-07 5.56E-05 8.32E-05 TE131+D 5.87E-12 2.28E-12 1.78E-12 4.59E-12 1.59E- 11 5.55E-07 3.60E-07 TE132+D 1.30E-07 7.36E-08 7.12E-08 8.58E-08 4.79E-07 1.02E-04 3.72E-05 TE133M+D 2.93E-1 1 1.51 E-11 1.50E- 11 2.32E-1 1 1.01E-10 1.60E-06 4.77E-06 TE134+D 1.53E-1 1 8.81E-12 9.40E-12 1.24E-1 1 5.71 E-11 1.23E-06 4.87E-07 1129 1.05E-05 6.40E-06 5.71 E-06 4.28E-03 1.08E-05 0. 2.15E-07 1130' 2.21 E-06 4.43E-06 2.28E-06 4.99E-04 6.61 E-06 0. 1.38E-06 1131+D 1.30E-05 1.30E-05 7.37E-06 4.39E-03 2.13E-05 0. 7.68E-07

Proc No ODCM Attachment 6 Revision 24 Page 7 of 16 INHALATION DOSE COMMITMENT FACTORS CHILD INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 5.72E-07 1.10E-06 5.07E-07 5.23E-05 1.69E-06 0. 8.65E-07 H133+D 4.48E-06 5.49E-06 2.08E-06 1.04E-03 9.13E-06 0. 1.48E-06 1134 3.17E-07 5.84E-07 2.69E-07 1.37E-05 8.92E-07 0. 2.58E-07 1135+D 1.33E-06 2.36E-06 1.12E-06 2.14E-04 3.62E-06 0. 1.20E-06 XE131M 0. 0. 0. 0. 0. 3.30E-09 0.

XE133M 0. 0. 0. 0. 0. 4.36E-09 0.

XE133 0. 0. 0. 0. 0. 3.66E-09 0.

XE135M 0. 0. 0. 0. 0. 4.48E-09 0.

XE135 0. 0. 0. 0. 0. 9.09E-09 0.

XE137 0. 0. 0. 0. 0. 4.07E-08 0.

XE138+D 0. 0. 0. 0. 0. 5.17E-08 0.

CS134M+D 6.33E-08 8.92E-08 6.12E-08 0. 4.94E-08 8.35E-09 7.92E-08 CS134 1.76E-04 2.74E-04 6.07E-05 0. 8.93E-05 3.27E-05 1.04E-06 CS135 6.23E-05 4.13E-05 4.45E-06 0. 1.53E-05 5.22E-06 2.17E-07 CS136 1.76E-05 4.62E-05 3.14E-05 0. 2.58E-05 3.93E-06 1.13E-06 CS137+D 2.45E-04 2.23E-04 3.47E-05 0. 7.63E-05 2.81 E-05 9.78E-07 CS138 1.71E-07 2.27E-07 1.50E-07 0. 1.68E-07 1.84E-08 7.29E-08 CS139+D 1.09E-07 1.15E-07 5.80E-08 0. 9.08E-08 9.36E-09 7.23E-12 BA139 4.98E-10 2.66E-13 1.45E-11 0. 2.33E-13 1.56E-06 1.56E-05 BA140+D 2.00E-05 1.75E-08 1.17E-06 0. 5.71 E-09 4.71 E-04 2.75E-05 BA141+D 5.29E-11 2.95E-14 1.72E-12 0. 2.56E-14 7.89E-07 7.44E-08 BA142+D 1.35E-11 9.73E-15 7.54E-13 0. 7.87E-1 5 4.44E-07 7.41 E-1 0 LA140 1.74E-07 6.08E-08 2.04E-08 0. 0. 4.94E-05 6.1 OE-05 LA141 2.28E-09 5.31E-10 1.15E-10 0. 0. 4.48E-06 4.37E-05 LA142 3.50E-10 1.11E-10 3.49E-1 1 0. 0. 2.35E-06 2.05E-05 CE141 1.06E-05 5.28E-06 7.83E-07 0. 2.31 E-06 1.47E-04 1.53E-05 CE143+D 9.89E-08 5.37E-08 7.77E-09 0. 2.26E-08 3.12E-05 3.44E-05 CE144+D 1.83E-03 5.72E-04 9.77E-05 0. 3.17E-04 3.23E-03 1.05E-04 PR143 4.99E-06 1.50E-06 2.47E-07 0. 8.11E-07 1.17E-04 2.63E-05 PR144 1.61 E-11 4.99E-12 8.10E-13 0. 2.64E-12 4.23E-07 5.32E-08 ND147+D 2.92E-06 2.36E-06 1.84E-07 0. 1.30E-06 8.87E-05 2.22E-05 PM147 3.52E-04 2.52E-05 1.36E-05 0. 4.45E-05 2.20E-04 5.70E-06 PM148M+D 3.31 E-05 6.55E-06 6.55E-06 0. 9.74E-06 5.72E-04 3.58E-05 PM148 1.61 E-06 1.94E-07 1.25E-07 0. 3.30E-07 1.24E-04 6.01 E-05 PM149 1.47E-07 1.56E-08 8.45E-09 0. 2.75E-08 2.40E-05 2.92E-05 PM151 3.57E-08 4.33E-09 2.82E-09 0. 7.35E-09 1.24E-05 2.50E-05 SM151 3.14E-04 4.75E-05 1.49E-05 0. 4.89E-05 1.48E-04 3.43E-06 SM153 7.24E-08 4.51 E-08 4.35E-09 0. 1.37E-08 1.37E-05 1.87E-05 EU152 7.42E-04 1.37E-04 1.61 E-04 0. 5.73E-04 9.OOE-04 1.14E-05 EU154 2.74E-03 2.49E-04 2.27E-04 0. 1.09E-03 1.66E-03 2.98E-05 EU155 5.60E-04 4.05E-05 3.18E-05 0. 1. 51 E-04 2.79E-04 5.39E-05 EU 156 7.89E-06 4.23E-06 8.75E-07 0. 2.72E-06 2.54E-04 4.24E-05 TB160 7.79E-05 0. 9.67E-06 0. 2.32E-05 5.34E-04 2.28E-05 H0166M 1.34E-03 2.81 E-04 2.37E-04 0. 4.01 E-04 1.13E-03 1.63E-05 WI 81 2.66E-08 6.52E-09 8.99E-1 0 0. 0. 5.71E-06 2.61 E-07 WI 85 8.31 E-07 2.08E-07 2.91 E-08 0. 0. 1.86E-04 1.11E-05 Wi 87 4.41 E-09 2.61 E-09 1.17E-09 0. 0. 1.11E-05 2.46E-05

Proc No ODCM Attachment 6 Revision 24 Page 8 of 16 INHALATION DOSE COMMITMENT FACTORS CHILD INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI PB21O+D 8.03E-02 1.85E-02 3.18E-03 0. 6.31E-02 8.74E-02 3.75E-05 B1210+D 0. 5.11E-06 5.65E-07 0. 5.76E-05 3.70E-03 3.21E-05 P0210 1.70E-03 2.76E-03 4.09E-04 0. 8.85E-03 1.05E-01 4.32E-05 RN222+D 0. 0. 0. 0. 0. 4.82E-06 0.

RA223+D 7.69E-04 8.89E-07 1.54E-04 0. 2.36E-05 8.48E-02 3.00E-04 RA224+D 8.44E-05 1.53E-07 1.69E-05 0. 4.06E-06 2.92E-02 3.34E-04 RA225+1D 1.28E-03 1.14E-06 2.56E-04 0. 3.02E-05 9.74E-02 2.84E-04 RA226+D 2.34E-01 7.66E-06 1.92E-01 0. 2.03E-04 3.90E-01 3.02E-04 RA228+1D 1.49E-01 3.94E-06 1.68E-01 0. 1.04E-04 5.37E-01 5.14E-05 AC225 1.81E-03 1.87E-03 1.21E-04 0. 1199E-04 7.37E-02 2.67E-04 AC227+D 4.96E+00 8.05E-01 3.07E-01 0. 1.77E-01 8.04E-01 5.22E-05 TH227+D 9.24E-04 1.26E-05 2.67E-05 0. 6.67E-05 1.26E-01 3.49E-04 TH228+D 8.06E-01 1.04E-02 2.72E-02 0. 5.41E-02 3.34E+00 3.59E-04 TH229 1.28E+01 1.76E-01 6.31E-01 0. 8.68E-01 1.04E+01 3.27E-04 TH230 3.30E+00 1.73E-01 9.20E-02 0. 8.52E-01 1.85E+00 3.84E-05 TH232+D 3.68E+00 1.47E-01 1.28E-01 0. 7.28E-01 1.77E+00 3.27E-05 TH234 6.94E-06 3.07E-07 2.OOE-07 0. 1.62E-06 6.31 E-04 7.32E-05 PA231 +D 8.62E+00 2.86E-01 3.43E-01 0. 1.56E+00 1.92E-01 4.57E-05 PA233 4.14E-06 6.48E-07 7.25E-07 0. 2.38E-06 9.77E-05 8.95E-06 U232+D 2.19E-01 0. 1.56E-02 0. 1.67E-02 7.42E-01 4.33E-05 U233+D 4.64E-02' 0. 2.82E-03 0. 7.62E-03 1.77E-01 4.OOE-05 U234 4.46E-02 0. 2.76E-03 0. 7.47E-03 1.74E-01 3.92E-05 U235+D 4.27E-02 0. 2.59E-03 0. 7.01E-03 1.63E-01 4.98E-05 U236 4.27E-02 0. 2.65E-03 0. 7.16E-03 1.67E-01 3.67E-05 U237 1.57E-07 0. 4.17E-08 0. 4.53E-07 3.40E-05 1.29E-05 U238+D 4.09E-02 0. 2.42E-03 0. 6.55E-03 1.53E-01 3.51E-05 NP237+D 2.88E+00 2.21E-01 1.19E-01 0. 7.41E-01 1.74E-01 5.06E-05 NP238 1.26E-06 2.56E-08 1.97E-08 0. 8.16E-08 3.39E-05 2.50E-05 NP239 1.26E-07 9.04E-09 6.35E-09 0. 2.63E-08 1.57E-05 1.73E-05 PU238 4.77E+00 6.05E-01 1.21E-01 0. 4.47E-01 6.08E-01 4.65E-05 PU239 5.24E+00 6.44E-01 1.28E-01 0. 4.78E-01 5.72E-01 4.24E-05 PU240 5.23E+00 6.43E-01 1.27E-01 0. 4.77E-01 5.71E-01 4.33E-05 PU241+D 1.46E-01 6.33E-03 2.93E-03 0. 1.10E-02 5.06E-04 8.90E-07 PU242 4.85E+00- 6.20E-01 1.23E-01 0. 4.60E-01 5.50E-01 4.16E-05 PU244 5.67E+00 7.1OE-01 1.41E-01 0. 5.27E-01 6.30E-01 6.20E-05 AM241 1.74E+00 7.85E-01 1.24E-01 0. 7.63E-01 2.02E-01 4.73E-05 AM242M 1.79E+00 7.65E-01 1.27E-01 0. 7.71E-01 8.14E-02 5.96E-05 AM243 1.72E+00 7.53E-01 1.20E-01 0. 7.42E-01 1.92E-01 5.55E-05 CM242 6.33E-02 4.84E-02 4.20E-03 0. 1.34E-02 1.31 E-01 5.06E-05 CM243 1.61E+00 7.33E-01 9.95E-02 0. 3.74E-01 2.10E-01 4.98E-05 CM244 1.33E+00 6.48E-01 8.31 E-02 0. 3.06E-01 2.02E-01 4.82E-05 CM245 2.14E+00 8.16E-01 1.28E-01 0. 5.03E-01 1.95E-01 4.49E-05 CM246 2.13E+00 8.15E-01 1.28E-01 0. 5.03E-01 1.99E-01 4.41E-05 CM247+D 2.07E+00 8.02E-01 1.26E-01 0. 4.95E-01 1.95E-01 5.80E-05 CM248 1.72E+01 6.61E+00 1.04E+00 0. 4.08E+00 1.61 E+00 9.35E-04 CF252 3.92E+00 0. 9.33E-02 0. 0. 6.62E-01 1.84E-04

Proc No ODCM Attachment 6 Revision 24 Page 9 of 16 INHALATION DOSE COMMITMENT FACTORS TEEN INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3* 0. 1.59E-07 1.59E-07 1.59E-07 1.59E-07 1.59E-07 1.59E-07 BE10 2.78E-04 4.33E-05 7.09E-06 0. 0. 3.84E-04 1.77E-05 C14 3.25E-06 6.09E-07 6.09E-07 6.09E-07 6.09E-07 6.09E-07 6.09E-07 N13 8.65E-09 8.65E-09 8.65E-09 8.65E-09 8.65E-09 8.65E-09 8.65E-09 F18 6.52E-07 0. 7.10E-08 0. 0. 0. 3.89E-08 NA22 1.76E-05 1.76E-05 1.76E-05 1.76E-05 1.76E-05 1.76E-05 1.76E-05 NA24 1.72E-06 1.72E-06 1.72E-06 1.72E-06 1.72E-06 1.72E-06 1.72E-06 P32 2.36E-04 1.37E-05 8.95E-06 0. 0. 0. 1.16E-05 AR39 0. 0. 0. 0. 0. 4.OOE-09 0.

AR41 0. 0. 0. 0. 0. 1.44E-08 0.

CA41 4.05E-05 0. 4.38E-06 0. 0. 1.01E-01 3.03E-07 SC46 7.24E-05 1.41E-04 4.18E-05 0. 1.35E-04 0. 2.98E-05 CR51 0. 0. 1.69E-08 9.37E-09 3.84E-09 2.62E-06 3.75E-07 MN54 0. 6.39E-06 1.05E-06 0. 1.59E-06 2.48E-04 8.35E-06 MN56 0. 2.12E-10 3.15E-11 0. 2.24F-10 1.90E-06 7.18E-06 FE55 4.18E-06 2.98E-06 6.93E-07 0. 0. 1.55E-05 7.99E-07 FE59 1.99E-06 4.62E-06 1.79E-06 0. 0. 1.91E-04 2.23E-05 C057 0. 1.18E-07 1.15E-07 0. 0. 7.33E-05 3.93E-06 C058 0. 2.59E-07 3.47E-07 0. 0. 1.68E-04 1.19E-05 C060 0. 1.89E-06 2.48E-06 0. 0. 1.09E-03 3.24E-05 N159 5.44E-06 2.02E-06 9.24E-07 0. 0. 1.41 E-05 6.48E-07 N163 7.25E-05 5.43E-06 2.47E-06 0. 0. 3.84E-05 1.77E-06 N165 2.73E-10 3.66E-11 1.59E-11 0. 0. 1.17E-06 4.59E-06 CU64 0. 2.54E-10 1.06E-10 0. 8.01E-10 1.39E-06 7.68E-06 ZN65 4.82E-06 1.67E-05 7.80E-06 0. 1.08E-05 1.55E-04 5.83E-06 ZN69M+D 1.44E-09 3.39E-09 3.11E-10 0. 2.06E-09 3.92E-06 2.14E-05 ZN69 6.04E-12 1.15E-11 8.07E-13 0. 7.53E-12 1.98E-07 3.56E-08 SE79 0. 5.43E-07 8.71E-08 0. 8.13E-07 7.71E-05 3.53E-06 BR82 0. 0. 2.28E-06 0. 0. 0. 0.

BR83+D 0. 0. 4.30E-08 0. 0. 0. 0.

BR84 0. 0. 5.41 E-08 0. 0. 0. 0.

BR85 0. 0. 2.29E-09 0. 0. 0. 0.

KR83M 0. 0. 0. 0. 0. 9.97E-10 0.

KR85M 0. 0. 0. 0. 0. 5.46E-09 0.

KR85 0. 0. 0. 0. 0. 4.63E-09 0.

KR87 0. 0. 0. 0. 0. 2.82E-08 0.

KR88+D 0. 0. 0. 0. 0. 5.81E-08 0.

KR89 0. 0. 0. 0. 0. 3.85E-08 0.

RB86 0. 2.38E-05 1.05E-05 0. 0. 0. 2.21 E-06 RB87 0. 1.40E-05 4.58E-06 0. 0. 0. 3.05E-07 RB88 0. 6.82E-08 3.40E-08 0. 0. 0. 3.65E-15 RB89+D 0. 4.40E-08 2.91E-08 0. 0. 0. 4.22E-17 SR89+ID 5.43E-05 0. 1.56E-06 0. 0. 3.02E-04 4.64E-05 SR90+D 1.35E-02 0. 8.35E-04 0. 0. 2.06E-03 9.56E-05 SR91+D 1.1OE-08 0. 4.39E-10 0. 0. 7.59E-06 3.24E-05 SR92+D 1.19E-09 0. 5.08E-11 0. 0. 3.43E-06 1.49E-05

Includes a 50% increase to account for percutaneous transpiration.

Proc No ODCM Attachment 6 Revision 24 Page 10 of 16 INHALATION DOSE COMMITMENT FACTORS TEEN INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 3.73E-07 0. 1.OOE-08 0. 0. 3.66E-05 6.99E-05 Y91M+D 4.63E-1 1 0. 1.77E-12 0. 0. 4.OOE-07 3.77E-09 Y91 8.26E-05 0. 2.21 E-06 0. 0. 3.67E-04 5.11 E-05 Y92 1.84E-09 0. 5.36E-11 0. 0. 3.35E-06 2.06E-05 Y93 1.69E-08 0. 4.65E-10 0. 0. 1.04E-05 7.24E-05 ZR93+D 6.83E-05 3.38E-05 1.84E-05 0. 1.16E-04 3.67E-04 1.60E-05 ZR95+D 1.82E-05 5.73E-06 3.94E-06 0. 8.42E-06 3.36E-04 1.86E-05 ZR97+D 1.72E-08 3.40E-09 1.57E-09 0. 5.15E-09 1.62E-05 7.88E-05 NB93M 4.14E-05 1.36E-05 3.41 E-06 0. 1.59E-05 5.36E-05 2.52E-06 NB95 2.32E-06 1.29E-06 7.08E-07 0. 1.25E-06 9.39E-05 1.21 E-05 NB97 3.92E-11 9.72E- 12 3.55E-12 0. 1.14E-1 1 4.91 E-07 2.71E-07 M093 0. 1.66E-06 4.52E-08 0. 5.06E-07 8.81 E-05 3.99E-06 M099+D 0. 2.11E-08 4.03E-09 0. 5.14E-08 1.92E-05 3.36E-05 TC99M 1.73E-13 4.83E-13 6.24E-12 0. 7.20E-12 1.44E-07 7.66E-07 TC99 4.48E-08 6.58E-08 1.79E-08 0. 8.35E-07 1.74E-04 7.99E-06 TC101 7.40E-1 5 1.05E-14 1.03E-13 0. 1.90E-13 8.34E-08 1.09E-16 RU103+D 2.63E-07 0. 1.12E-07 0. 9.29E-07 9.79E-05 1.36E-05 RU105+D 1.40E-10 0. 5.42E- 11 0. 1.76E-10 2.27E-06 1.13E-05 RU106+D 1.23E-05 0. 1.55E-06 0. 2.38E-05 2.01 E-03 1.20E-04 RHi105 1.32E-09 9.48E-1 0 6.24E-10 0. 4.04E-09 4.09E-06 1.23E-05 PD107 0. 1.17E-07 8.39E-09 0. 9.39E-07 1.63E-05 7.49E-07 PD109 0. 6.56E-10 1.66E-10 0. 3.36E-09 3.19E-06 1.96E-05 AG110M+D 1.73E-06 1.64E-06 9.99E-07 0. 3.13E-06 8.44E-04 3.41 E-05 AG111 6.07E-08 2.52E-08 1.26E-08 0. 8.17E-08 4.OOE-05 3.OOE-05 CD113M 0. 2.17E-04 7.1 OE-06 0. 2.43E-04 3.59E-04 1.68E-05 CD115M 0. 3.48E-05 1.14E-06 0. 2.82E-05 3.03E-04 5.1 OE-05 SN123 4.31 E-05 9.44E-07 1.40E-06 7.55E-07 0. 4.96E-04 4.16E-05 SN125+D 1.66E-06 4.42E-08 9.99E-08 3.45E-08 0. 1.26E-04 7.29E-05 SN126+D 2.18E-04 5.39E-06 8.24E-06 1.42E-06 0. 1.72E-03 1.68E-05 SB124 5.38E-06 9.92E-08 2.1OE-06 1.22E-08 0. 4.81 E-04 4.98E-05 SB125+D 9.23E-06 1.01E-07 2.15E-06 8.80E-09 0. 3.42E-04 1.24E-05 SB126 6.19E-07 1.27E-08 2.23E-07 3.50E-09 0. 1.55E-04 6.01 E-05 SB127 4.64E-08 9.92E-10 1.75E-08 5.21E-10 0. 3.31 E-05 3.94E-05 TE125M 6.1 OE-07 2.80E-07 8.34E-08 1.75E-07 0. 6.70E-05 9.38E-06 TE127M+D 2.25E-06 1.02E-06 2.73E-07 5.48E-07 8.17E-06 2.07E-04 1.99E-05 TE127 2.51E-10 1.14E-10 5.52E- 11 1.77E-10 9.10E-10 11.40E-06 1.01E-05 TE129M+D 1.74E-06 8.23E-07 2.81 E-07 5.72E-07 6.49E-06 2.47E-04 5.06E-05 TE129 8.87E-12 4.22E-12 2.20E-12 6.48E-12 3.32E-1 1 4.12E-07 2.02E-07 TE131M+D 1.23E-08 7.51 E-09 5.03E-09 9.06E-09 5.49E-08 2.97E-05 7.76E-05 TE131+D 1.97E-12 1.04E-12 6.30E-13 1.55E-12 7.72E- 12 2.92E-07 1.89E-09 TE132+D 4.50E-08 3.63E-08 2.74E-08 3.07E-08 2.44E-07 5.61 E-05 5.79E-05 TE133M+D 1.01E-11 7.33E-1 2 5.71E-12 8.18E-12 5.07E-11 8.71 E-07 1.23E-07 TE134+D 5.31E-12 4.35E-12 3.64E- 12 4.46E-12 2.91 E-11 6.75E-07 1.37E-09 1129 3.53E-06 2.94E-06 4.90E-06 3.66E-03 5.26E-06 0. 2.29E-07 1130 7.80E-07 2.24E-06 8.96E-07 1.86E-04 3.44E-06 0. 1.14E-06 1131+D 4.43E-06 6.14E-06 3.30E-06 1.83E-03 1.05E-05 0. 8.11E-07

Proc No ODCM Attachment 6 Revision 24 Page 11 of 16 INHALATION DOSE COMMITMENT FACTORS TEEN INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 1.99E-07 5.47E-07 1.97E-07 1.89E-05 8.65E-07 0. 1.59E-07 1133+D 1.52E-06 2.56E-06 7.78E-07 3.65E-04 4.49E-06 0. 1.29E-06 1134 1.11E-07 2.90E-07 1.05E-07 4.94E-06 4.58E-07 0. 2.55E-09 1135+D 4.62E-07 1.18E-06 4.36E-07 7.76E-05 1.86E-06 0. 8.69E-07 XE131M 0. 0. 0. 0. 0. 2.70E-09 0.

XE133M 0. 0. 0. 0. 0. 3.59E-09 0.

XE133 0. 0. 0. 0. 0. 2.99E-09 0.

XE135M 0. 0. 0. 0. 0. 3.88E-09 0.

XE135 0. 0. 0. 0. 0. 7.55E-09 0.

XE137 0. 0. 0. 0. 0. 3.33E-08 0.

XE138+D 0. 0. 0. 0. 0. 4.38E-08 0.

CS134M+D 2.20E-08 4.35E-08 2.35E-08 0. 2.54E-08 4.56E-09 2.02E-08 CS134 6.28E-05 1.41 E-04 6.86E-05 0. 4.69E-05 1.83E-05 1.22E-06 CS135 2.08E-05 1.82E-05 4.47E-06 0. 7.30E-06 2.70E-06 2.23E-07 CS136 6.44E-06 2.42E-05 1.71 E-05 0. 1.38E-05 2.22E-06 1.36E-06 CS137+D 8.38E-05 1.06E-04 3.89E-05 0. 3.80E-05 1.51 E-05 1.06E-06 CS138 5.82E-08 1.07E-07 5.58E-08 0. 8.28E-08 9.84E-09 3.38E-1 1 CS139+D 3.65E-08 5.12E-08 1.97E-08 0. 4.34E-08 4.86E-09 1.66E-23 BA139 1.67E-10 1.18E-13 4.87E-12 0. 1.11E-13 8.08E-07 8.06E-07 BA140+D 6.84E-06 8.38E-09 4.40E-07 0. 2.85E-09 2.54E-04 2.86E-05 BA141+D 1.78E- 11 1.32E-14 5.93E-13 0. 1.23E-14 4.11 E-07 9.33E-14 BA142+D 4.62E-12 4.63E-15 2.84E-13 0. 3.92E-15 2.39E-07 5.99E-20 LA140 5.99E-08 2.95E-08 7.82E-09 0. 0. 2.68E-05 6.09E-05 LA141 7.63E-10 2.35E-10 3.87E-1 1 0. 0. 2.31 E-06 1.54E-05 LA142 1.20E-10 5.31 E-1 1 1.32E-11 0. 0. 1.27E-06 1.50E-06 CE141 3.55E-06 2.37E-06 2.71 E-07 0. 1.11E-06 7.67E-05 1.58E-05 CE143+D 3.32E-08 2.42E-08 2.70E-09 0. 1.08E-08 1.63E-05 3.19E-05 CE144+D 6.11 E-04 2.53E-04 3.28E-05 0. 1.51E-04 1.67E-03 1.08E-04 PR143 1.67E-06 6.64E-07 8.28E-08 0. 3.86E-07 6.04E-05 2.67E-05 PR144 5.37E-12 2.20E-12 2.72E-13 0. 1.26E-12 2.19E-07 2.94E-14 ND147+D 9.83E-07 1.07E-06 6.41 E-08 0. 6.28E-07 4.65E-05 2.28E-05 PM147 1.15E-04 1.10E-05 4.50E-06 0. 2.10E-05 1.14E-04 5.87E-06 PM148M+D 1.32E-05 3.35E-06 2.62E-06 0. 5.07E-06 3.20E-04 4.10E-05 PM148 5.44E-07 8.88E-08 4.48E-08 0. 1.60E-07 6.52E-05 6.14E-05 PM149 4.91 E-08 6.89E-09 2.84E-09 0. 1.31 E-08 1.24E-05 2.79E-05 PM151 1.20E-08 1.99E-09 1.01 E-09 0. 3.57E-09 6.56E-06 2.27E-05 SM151 1.07E-04 2.1 OE-05 4.86E-06 0. 2.27E-05 7.68E-05 3.53E-06 SM 153 2.43E-08 2.01 E-08 1.47E-09 0. 6.56E-09 7.11E-06 1.77E-05 EU152 2.96E-04 7.19E-05 6.30E-05 0. 3.34E-04 5.01 E-04 1.35E-05 EU154 9.43E-04 1.23E-04 8.60E-05 0. 5.44E-04 9.12E-04 3.34E-05 EU155 2.OOE-04 1.96E-05 1.21 E-05 0. 7.65E-05 1.51 E-03 5.97E-05 EU156 2.70E-06 2.03E-06 3.30E-07 0. 1.36E-06 1.37E-04 4.56E-05 TB160 3.04E-05 0. 3.79E-06 0. 1.20E-05 2.97E-04 2.60E-05 H0166M 4.40E-04 1.36E-04 9.87E-05 0. 2.OOE-04 6.24E-04 1.68E-05 Wi 81 8.90E-09 2.88E-09 3.01E-10 0. 0. 2.95E-06 2.69E-07 WI 85 2.78E-07 9.17E-08 9.73E-09 0. 0. 9.60E-05 1.14E-05 W187 1.50E-09 1.22E-09 4.29E-1 0 0. 0. 5.92E-06 2.21 E-05

Proc No ODCM Attachment 6 Revision 24 Page 12 of 16 INHALATION DOSE COMMITMENT FACTORS TEEN INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI PB210+D 3.09E-02 8.28E-03 1.07E-03 0. 2.95E-02 4.52E-02 3.87E-05 B1210+D 0. 2.26E-06 1.89E-07 0. 2.74E-05 1.91E-03 3.19E-05 P0210 5.68E-04 1.22E-03 1.37E-04 0. 4.21E-03 5.41E-02 4.45E-05 RN222+D 0. 0. 0. 0. 0. 3.94E-06 0.

RA223+D 2.57E-04 3.93E-07 5.14E-05 0. 1.12E-05 4.39E-02 3.04E-04 RA224+D 2.83E-05 6.77E-08 5.65E-06 0. 1.93E-06 1.51 E-02 3.29E-04 RA225+D 4.28E-04 5.04E-07 8.56E-05 0. 1.44E-05 5.04E-02 2.89E-04 RA226+D 1.33E-01 3.38E-06 9.87E-02 0. 9.67E-05 2.02E-01 3.11E-04 RA228+D 5.34E-02 1.74E-06 5.88E-02 0. 4.97E-05 2.78E-01 5.30E-05 AC225 6.04E-04 8.25E-04 4.06E-05 0. 9.47E-05 3.81 E-02 2.70E-04 AC227+D 2.49E+00 3.69E-01 1.48E-01 0. 1.07E-01 4.16E-01 5.38E-05 TH227+D 3.09E-04 5.56E-06 8.93E-06 0. 3.18E-05 6.50E-02 3.57E-04 TH228+D 2.60E-01 4.37E-03 8.78E-03 0. 2.45E-02 1.69E+00 3.70E-04 TH229 9.06E+00 1.36E-01 4.45E-01 0. 6.67E-01 5.05E+00 3.36E-04 TH230 2.34E+00 1.34E-01 6.49E-02 0. 6.55E-01 8.98E-01 3.95E-05 TH232+D 2.61E+00 1.14E-01 9.21E-02 0. 5.60E-01 8.60E-01 3.36E-05 TH234 2.32E-06 1.35E-07 6.71 E-08 0.: 7.73E-07 3.26E-04 7.49E-05 PA231+D 5.32E+00 2.OOE-01 2.07E-01 0. 1.12E+00 9.91E-02 4.71E-05 PA233 1.68E-06 3.24E-07 2.89E-07 0. 1.22E-06 5.39E-05 1.O0E-05 U232+D 7.31 E-02 0. 5.23E-03 0. 7.94E-03 3.84E-01 4.46E-05 U233+D 1.55E-02 0. 9.42E-04 0. 3.63E-03 9.18E-02 4.12E-05 U234 1.48E-02 0. 9.23E-04 0. 3.55E-03 8.99E-02 4.04E-05 U235+D 1.42E-02 0. 8.67E-04 0. 3.34E-03 8.44E-02 5.13E-05 U236 1.42E-02 0. 8.86E-04 0. 3.41 E-03 8.62E-02 3.79E-05 U237 5.25E-08 0. 1.40E-08 0. 2.16E-07 1.76E-05 1.29E-05 U238+D 1.36E-02 0. 8.10E-04 0. 3.12E-03 7.89E-02 3.62E-05 NP237+D 1.77E+00 1.54E-01 7.21E-02 0. 5.35E-01 8.99E-02 5.22E-05 NP238 4.23E-07 1.13E-08 6.59E-09 0. 3.88E-08 1.75E-05 2.38E-05 NP239 4.23E-08 3.99E-09 2.21E-09 0. 1.25E-08 8.11E-06 1.65E-05 PU238 2.86E+00 4.06E-01 7.22E-02 0. 3.10E-01 3.12E-01 4.79E-05 PU239 3.31E+00 4.50E-01 8.05E-02 0. 3.44E-01 2.93E-01 4.37E-05 PU240 3.31E+00 4.49E-01 8.04E-02 0. 3.43E-01 2.93E-01 4.46E-05 PU241+D 6.97E-02 3.57E-03 1.40E-03 0. 6.47E-03 2.60E-04 9.17E-07 PU242 3.07E+00 4.33E-01 7.75E-02 0. 3.31 E-01 2.82E-01 4.29E-05 PU244 3.59E+00 4.96E-01 8.88E-02 0. 3.79E-01 3.23E-01 6.39E-05 AM241 1.06E+00 4.07E-01 7.1OE-02 0. 5.32E-01 1.05E-01 4.88E-05 AM242M 1.07E+00 3.93E-01 7.15E-02 0. 5.30E-01 4.21E-02 6.14E-05 AM243 1.06E+00 3.92E-01 6.95E-02 0. 5.21E-01 9.91E-02 5.72E-05 CM242 2.12E-02 2.14E-02 1.41E-03 0. 6.40E-03 6.76E-02 5.21E-05 CM243 8.45E-01 3.50E-01 5.OOE-02 0. 2.34E-01 1.09E-01 5.13E-05 CM244 6.46E-01 .3.03E-01 3.88E-02 0. 1.81 E-01 1.05E-01 4.96E-05 CM245 1.32E+00 4.11E-01 7.53E-02 0. 3.52E-01 1.01E-01 4.63E-05 CM246 1.31E+00 4.11E-01 7.52E-02 0. 3.51E-01 1.03E-01 4.54E-05 CM247+D 1.28E+00 4.04E-01 7.41E-02 0. 3.46E-01 1.01 E-01 5.97E-05 CM248 1.06E+01 3.33E+00 6.11E-01 0. 2.85E+00 8.32E-01 9.63E-04 CF252 1.29E+00 0. 3.07E-02 0. 0. 3.43E-01 1.89E-04

Proc No ODCM Attachment 6 Revision 24 Page 13 of 16 INHALATION DOSE COMMITMENT FACTORS ADULT INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3* 0. 1.58E-07 1.58E-07 1.58E-07 1.58E-07 1.58E-07 1.58E-07 BE10 1.98E-04 3.06E-05 4.96E-06 0. 0. 2.22E-04 1.67E-05 C14 2.27E-06 4.26E-07 4.26E-07 4.26E-07 4.26E-07 4.26E-07 4.26E-07 N13 6.27E-09 6.27E-09 6.27E-09 6.27E-09 6.27E-09 6.27E-09 6.27E-09 F18 4.71E-07 0. 5.19E-08 0. 0. 0. 9.24E-09 NA22 1.30E-05 1.30E-05 1.30E-05 1.30E-05 1.30E-05 1.30E-05 1.30E-05 NA24 1.28E-06 1.28E-06 1.28E-06 1.28E-06 1.28E-06 1.28E-06 1.28E-06 P32 1.65E-04 9.64E-06 6.26E-06 0. 0. 0. 1.08E-05 AR39 0. 0. 0. 0. 0. 2.08E-09 0.

AR41 0. 0. 0. 0. 0. 8.06E-09 0.

CA41 3.83E-05 0. 4.13E-06 0., 0. 3.83E-06 2.86E-07 SC46 5.51E-05 1.07E-04 3.11E-05 0. 9.99E-05 0. 3.23E-05 CR51 0. 0. 1.25E-08 7.44E-09 2.85E-09 1.80E-06 4.15E-07 MN54 0. 4.95E-06 7.87E-07 0. 1.23E-06 1.75E-04 9.67E-06 MN56 0. 1.55E-10 2.29E-11 0. 1.63E-10 1.18E-06 2.53E-06 FE55 3.07E-06 2.12E-06 4.93E-07 0. 0. 9.01E-06 7.54E-07 FE59 1.47E-06 3.47E-06 1.32E-06 0. 0. 1.27E-04 2.35E-05 C057 0. 8.65E-08 8.39E-08 0. 0. 4.62E-05 3.93E-06 C058 0. 1.98E-07 2.59E-07 0. 0. 1.16E-04 1.33E-05 C060 0. 1.44E-06 1.85E-06 0. 0. 7.46E-04 3.56E-05 N159 4.06E-06 1.46E-06 6.77E-07 0. 0. 8.20E-06 6.11E-07 N163 5.40E-05 3.93E-06 1.81 E-06 0. 0. 2.23E-05 1.67E-06 N165 1.92E-10 2.62E-11 1.14E-11 0. 0. 7.OOE-07 1.54E-06 CU64 0. 1.83E-10 7.69E-11 0. 5.78E-10 8.48E-07 6.12E-06 ZN65 4.05E-06 1.29E-05 5.82E-06 0. 8.62E-06 1.08E-04 6.68E-06 ZN69M+D 1.02E-09 2.45E-09 2.24E-10 0. 1.48E-09 2.38E-06 1.71E-05 ZN69 4.23E-12 8.14E-12 5.65E-13 0. 5.27E-12 1.15E-07 2.04E-09 SE79 0. 3.83E-07 6.09E-08 0. 5.69E-07 4.47E-05 3.33E-06 BR82 0. 0. 1.69E-06 0. 0. 0. 1.30E-06 BR83+D 0. 0. 3.01 E-08 0. 0. 0. 2.90E-08 BR84 0. 0. 3.91E-08 0. 0. 0. 2.05E-13 BR85 0. 0. 1.60E-09 0. 0. 0. 0.

KR83M 10. 0. 0. 0. 0. 5.19E-10 0.

KR85M 0. 0. 0. 0. 0. 2.91 E-09 0.

KR85 0. 0. 0. 0. 0. 2.41 E-09 0.

KR87 0. 0. 0. 0. 0. 1.53E-08 0.

KR88+D 0. 0. 0. 0. 0. 3.13E-08 0.

KR89 0. 0. 0. 0. 0. 2.13E-08 0.

RB86 0. 1.69E-05 7.37E-06 0. 0. 0. 2.08E-06 RB87 0. 9.86E-06 3.21 E-06 0. 0. 0. 2.88E-07 RB88 0. 4.84E-08 2.41E-08 0. 0. 0. 4.18E-19 RB89+D 0. 3.20E-08 2.12E-08 0. 0. 0. 1.16E-21 SR89+D 3.80E-05 0. 1.09E-06 0. 0. 1.75E-04 4.37E-05 SR90+D 1.24E-02 0. 7.62E-04 0. 0. 1.20E-03 9.02E-05 SR91+D 7.74E-09 0. 3.13E-10 0. 0. 4.56E-06 2.39E-05 SR92+D 8.43E-10 0. 3.64E-11 0. 0. 2.06E-06 5.38E-06

Includes a 50% increase to account for percutaneous transpiration.

Proc No ODCM Attachment 6 Revision 24 Page 14 of 16 INHALATION DOSE COMMITMENT FACTORS ADULT INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 2.61 E-07 0. 7.01 E-09 0. 0. 2.12E-05 6.32E-05 Y91M+D 3.26E-1 1 0. 1.27E-12 0. 0. 2.40E-07 1.66E-1 0 Y91 5.78E-05 0. 1.55E-06 0. 0. 2.13E-04 4.81 E-05 Y92 1.29E-09 0. 3.77E-1 1 0. 0. 1.96E-06 9.19E-06 Y93 1.18E-08 0. 3.26E-10 0. 0. 6.06E-06 5.27E-05 ZR93+D 5.22E-05 2.92E-06 1.37E-06 0. 1.11E-05 2.13E-05 1.51 E-06 ZR95+D 1.34E-05 4.30E-06 2.91 E-06 0. 6.77E-06 2.21 E-04 1.88E-05 ZR97+D 1.21 E-08 2.45E-09 1.13E-09 0. 3.71 E-09 9.84E-06 6.54E-05 NB93M 3.10E-05 1.01E-05 2.49E-06 0. 1.16E-05 3.11 E-05 2.38E-06 NB95 1.76E-06 9.77E-07 5.26E-07 0. 9.67E-07 6.31 E-05 1.30E-05 NB97 2.78E-11 7.03E-12 2.56E-12 0. 8.18E-12 3.OOE-07 3.02E-08 M093 0. 1.17E-06 3.17E-08 0. 3.55E-07 5.11E-05 3.79E-06 M099+D 0. 1.51 E-08 2.87E-09 0. 3.64E-08 1.14E-05 3.1OE-05 TC99M 1.29E-13 3.64E-13 4.63E-12 0. 5.52E-12 9.55E-08 5.20E-07 TC99 3.13E-08 4.64E-08 1.25E-08 0. 5.85E-07 1.01 E-04 7.54E-06 TC101 5.22E-15 7.52E-1 5 7.38E-14 0. 1.35E-13 4.99E-08 1.36E-21 RU103+D 1.91E-07 0. 8.23E-08 0. 7.29E-07 6.31 E-05 1.38E-05 RU105+D 9.88E-1 1 0. 3.89E-1 1 0. 1.27E-10 1.37E-06 6.02E-06 RU106+D 8.64E-06 0. 1.09E-06 0. 1.67E-05 1.17E-03 1.14E-04 RH105 9.24E-10 6.73E-10 4.43E-1 0 0. 2.86E-09 2.41 E-06 1.09E-05 PD107 0. 8.27E-08 5.87E-09 0. 6.57E-07 9.47E-06 7.06E-07 PD109 0. 4.63E-10 1.16E-10 0. 2.35E-09 1.85E-06 1.52E-05 AG110M+D 1.35E-06 1.25E-06 7.43E-07 0. 2.46E-06 5.79E-04 3.78E-05 AG111 4.25E-08 1.78E-08 8.87E-09 0. 5.74E-08 2.33E-05 2.79E-05 CDI13M 0. 1.54E-04 4.97E-06 0. 1.71 E-04 2.08E-04 1.59E-05 CD115M 0. 2.46E-05 7.95E-07 0. 1.98E-05 1.76E-04 4.80E-05 SN123 3.02E-05 6.67E-07 9.82E-07 5.67E-07 0. 2.88E-04 3.92E-05 SN125+D 1.16E-06 3.12E-08 7.03E-08 2.59E-08 0. 7.37E-05 6.81 E-05 SN126+D 1.58E-04 4.18E-06 6.OOE-06 1.23E-06 0. 1.17E-03 1.59E-05 SB124 3.90E-06 7.36E-08 1.55E-06 9.44E-09 0. 3.10E-04 5.08E-05 SB125+D 6.67E-06 7.44E-08 1.58E-06 6.75E-09 0. 2.18E-04 1.26E-05 SB126 4.50E-07 9.13E-09 1.62E-07 2.75E-09 0. 9.57E-05 6.01 E-05 SB127 3.30E-08 7.22E-10 1.27E-08 3.97E-10 0. 2.05E-05 3.77E-05 TE125M 4.27E-07 1.98E-07 5.84E-08 1.31 E-07 1.55E-06 3.92E-05 8.83E-06 TE127M+D 1.58E-06 7.21 E-07 1.96E-07 4.11E-07 5.72E-06 1.20E-04 1.87E-05 TE127 1.75E-10 8.03E-1 1 3.87E-1 1 1.32E-10 6.37E-10 8.14E-07 7.17E-06 TE129M+D 1.22E-06 5.84E-07 1.98E-07 4.30E-07 4.57E-06 1.45E-04 4.79E-05 TE129 6.22E-12 2.99E-12 1.55E-12 4.87E-12 2.34E-1 1 2.42E-07 1.96E-08 TE131M+D 8.74E-09 5.45E-09 3.63E-09 6.88E-09 3.86E-08 1.82E-05 6.95E-05 TE131+D 1.39E-12 7.44E-13 4.49E-13 1.17E-12 5.46E-12 1.74E-07 2.30E-09 TE132+D 3.25E-08 2.69E-08 2.02E-08 2.37E-08 1.82E-07 3.60E-05 6.37E-05 TE133M+D 7.24E-12 5.40E-12 4.17E-12 6.27E-12 3.74E-11 5.51 E-07 5.49E-08 TE134+D 3.84E-12 3.22E-12 1.57E-12 3.44E-12 2.18E-11 4.343-07 2.97E-11 1129 2.48E-06 2.11E-06 6.91 E-06 5.54E-03 4.53E-06 0. 2.22E-07 1130 5.72E-07 1.68E-06 6.60E-07 1.42E-04 2.61 E-06 0. 9.61 E-07 1131+D 3.15E-06 4.47E-06 2.56E-06 1.49E-03 7.66E-06 0. 7.85E-07

Proc No ODCM Attachment 6 Revision 24 Page 15 of 16 INHALATION DOSE COMMITMENT FACTORS ADULT INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 1.45E-07 4.07E-07 1.45E-07 1.43E-05 6.48E-07 0. 5.08E-08 1133+D 1.08E-06 1.85E-06 5.65E-07 2.69E-04 3.23E-06 0. 1.11E-06 1134 8.05E-08 2.16E-07 7.69E-08 3.73E-06 3.44E-07 0. 1.26E-10 1135+D 3.35E-07 8.73E-07 3.21 E-07 5.60E-05 1.39E-06 0. 6.56E-07 XE131M 0. 0. 0. 0. 0. 1.40E-09 0.

XE133M 0. 0. 0. 0. 0. 1.89E-09 0.

XE133 0. 0. 0. 0. 0. 1.57E-09 0.

XE135M 0. 0. 0. 0. 0. 2.22E-09 0.

XE135 0. 0. 0. 0. 0. 4.05E-09 0.

XE137 0. 0. 0. 0. 0. 1.74E-08 0.

XE138+D 0. 0. 0. 0. 0. 2.44E-08 0.

CS134M+D 1.59E-08 3.20E-08 1.72E-08 0. 1.83E-08 2.93E-09 7.92E-09 CS134 4.66E-05 1.06E-04 9.10E-05 0. 3.59E-05 1.22E-05 1.30E-06 CS135 1.46E-05 1.29E-05 5.99E-06 0. 5.11 E-06 1.57E-06 2.11E-07 CS136 4.88E-06 1.83E-05 1.38E-05 0. 1.07E-05 1.50E-06 1.46E-06 CS137+D 5.98E-05 7.76E-05 5.35E-05 0. 2.78E-05 9.40E-06 1.05E-06 CS138 4.14E-08 7.76E-08 4.05E-08 0. 6.OOE-08 6.07E-09 2.33E-13 CS139+D 2.56E-08 3.63E-08 1.39E-08 0. 3.05E-08 2.84E-09 5.49E-31 BA139 1.17E-10 8.32E-14 3.42E-12 0. 7.78E-14 4.70E-07 1.12E-07 BA140+D 4.88E-06 6.13E-09 3.21 E-07 0. 2.09E-09 1.59E-04 2.73E-05 BA141+D 1.25E-11 9.41 E-1 5 4.20E-13 0. 8.75E-15 2.42E-07 1.45E-17 BA142+D 3.29E-12 3.38E-15 2.07E-'l13 0. 2.86E-15 1.49E-07 1.96E-26 LA140 4.30E-08 2.17E-08 5.73E-09 0. 0. 1.70E-05 5.73E-05 LA141' 5.34E-10 1.66E-10 2.71 E-11 0. 0. 1.35E-06 7.31 E-06 LA142 8.54E-1 1 3.88E-1 1 9.65E-12 0. 0. 7.91 E-07 2.64E-07 CE141 2.49E-06 1.69E-06 1.91 E-07 0. 7.83E-07 4.52E-05 1.50E-05 CE143+D 2.33E-08 1.72E-08 1.91 E-09 0. 7.60E-09 9.97E-06 2.83E-05 CE144+D 4.29E-04 1.79E-04 2.30E-05 0. 1.06E-04 9.72E-04 1.02E-04 PR143 1.17E-06 4.69E-07 5.80E-08 0. 2.70E-07 3.51 E-05 2.50E-05 PR144 3.76E-12 1.56E-12 1.91 E-1 3 0. 8.81 E-1 3 1.27E-07 2.69E-18 ND147+D 6.59E-07 7.62E-07 4.56E-08 0. 4.45E-07 2.76E-05 2.16E-05 PM147 8.37E-05 7.87E-06 3.19E-06 0. 1.49E-05 6.60E-05 5.54E-06 PM148M+D 9.82E-06 2.54E-06 1.94E-06 0. 3.85E-06 2.14E-04 4.18E-05 PM148 3.84E-07 6.37E-08 3.20E-08 0. 1.20E-07 3.91 E-05 5.80E-05 PM149 3.44E-08 4.87E-09 1.99E-09 0. 9.19E-09 7.21 E-06 2.50E-05 PM151 8.50E-09 1.42E-09 7.21 E-10 0. 2.55E-09 3.94E-06 2.OOE-05 SM151 8.59E-05 1.48E-05 3.55E-06 0. 1.66E-05 4.45E-05 3.25E-06 SM153 1.70E-08 1.42E-08 1.04E-09 0. 4.59E-09 4.14E-06 1.58E-05 EU152 2.38E-04 5.41 E-05 4.76E-05 0. 3.35E-04 3.43E-04 1.59E-05 EU154 7.40E-04 9.1 OE-05 6.48E-05 0. 4.36E-04 5.84E-04 3.40E-05 EU155 1.01E-04 1.43E-05 9.21 E-06 0. 6.59E-05 9.46E-05 5.95E-06 EU 156 1.93E-06 1.48E-06 2.40E-07 0. 9.95E-07 8.56E-05 4.50E-05 TB160 2.21 E-05 0. 2.75E-06 0. 9.1 OE-06 1.92E-04 2.68E-05 H0166M 3.37E-04 1.05E-04 8.OOE-05 0. 1.57E-04 3.94E-04 1.59E-05 Wi 81 6.23E-09 2.03E-09 2.17E-10 0. 0. 1.71 E-06 2.53E-07 W185 1.95E-07 6.47E-08 6.81 E-09 0. 0. 5.57E-05 1.07E-05 Wi 87 1.06E-09 8.85E-10 3.10E-10 0. 0. 3.63E-06 1.94E-05

Proc No ODCM Attachment 6 Revision 24 Page 16 of 16 INHALATION DOSE COMMITMENT FACTORS ADULT INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI PB210+D 2.64E-02 6.73E-03 8.37E-04 0. 2.12E-02 2.62E-02 3.65E-05 B1210+D 0. 1.59E-06 1.32E-07 0. 1.92E-05 1.11E-03 2.95E-05 P0210 3.97E-04 8.60E-04 9.58E-05 0. 2.95E-03 3.14E-02 4.19E-05 RN222+D 0. 0. 0. 0. 0. 2.05E-06 0.

RA223+D 1.80E-04 2.77E-07 3.60E-05 0. 7.85E-06 2.55E-02 2.84E-04 RA224+D 1.98E-05 4.78E-08 3.96E-06 0. 1.35E-06 8.77E-03 3.01 E-04 RA225+D 3.OOE-04 3.56E-07 5.99E-05 0. 1.01 E-05 2.92E-02 2.71 E-04 RA226+D 1.25E-01 2.39E-06 9.14E-02 0. 6.77E-05 1.17E-01 2.94E-04 RA228+D 4.41E-02 1.23E-06 4.78E-02 0. 3.48E-05 1.61E-01 5.OOE-05 AC225 4.23E-04 5.82E-04 2.84E-05 0. 6.63E-05 2.21 E-02 2.52E-04 AC227+D 2.30E+00 3.05E-01 1.36E-01 0. 9.82E-02 2.41E-01 5.08E-05 TH227+D 2.17E-04 3.92E-06 6.25E-06 0. 2.22E-05 3.77E-02 3.34E-04 TH226+D 2.OOE-01 3.39E-03 6.77E-03 0. 1.89E-02 1.01 E+00 3.49E-04 TH229 8.88E+00 1.33E-01 4.36E-01 0. 6.52E-01 3.49E+00 3.17E-04 TH230 2.29E+00 1.31E-01 6.36E-02 0. 6.40E-01 6.21E-01 3.73E-05 TH232+D 2.56E+00 1.12E-01 9.04E-02 0. 5.47E-01 5.96E-01 3.17E-05 TH234 1.63E-06 9.56E-08 4.70E-08 0. 5.41 E-07 1.89E-04 7.03E-05 PA231 +D 5.08E+00 1.91 E-01 1.98E-01 0. 1.07E+00 5.75E-02 4.44E-05 PA233 1.21 E-06 2.42E-07 2.09E-07 0. 9.15E-07 3.52E-05 1.02E-05 U232+D 5.14E-02 0. 3.66E-03 0. 5.56E-03 2.22E-01 4.21E-05 U233+D 1.09E-02 0. 6.60E-04 0. 2.54E-03 5.32E-02 3.89E-05 U234 1.04E-02 0. 6.46E-04 0. 2.49E-03 5.22E-02 3.81 E-05 U235+D 1.OOE-02 0. 6.07E-04 0. 2.34E-03 4.90E-02 4.84E-05 U236 1.OOE-02 0. 6.20E-04 0. 2.39E-03 5.OOE-02 3.57E-05 U237 3.67E-08 0. 9.77E-09 0. 1.51 E-07 1.02E-05 1.20E-05 U238+D 9.58E-03 0. 5.67E-04 0. 2.18E-03 4.58E-02 3.41E-05 NP237+D 1.69E+00 1.47E-01 6.87E-02 0. 5.10E-01 5.22E-02 4.92E-05 NP238 2.96E-07 8.OOE-09 4.61E-09 0. 2.72E-08 1.02E-05 2.13E-05 NP239 2.87E-08 2.82E-09 1.55E-09 0. 8.75E-09 4.70E-06 1.49E-05 PU238 2.74E+00 3.87E-01 6.90E-02 0. 2.96E-01 1.82E-01 4.52E-05 PU239 3.19E+00 4.31E-01 7.75E-02 0. 3.30E-01 1.72E-01 4.13E-05 PU240 3.18E+00 4.30E-01 7.73E-02 0. 3.29E-01 1.72E-01 4.21E-05 PU241+D 6.41E-02 3.28E-03 1.29E-03 0. 5.93E-03 1.52E-04 8.65E-07 PU242 2.95E+00 4.15E-01 7.46E-02 0. 3.17E-01 1.65E-01 4.05E-05 PU244 3.45E+00 4.76E-01 8.54E-02 0. 3.64E-01 1.89E-01 6.03E-05 AM241 1.01 E+00 3.59E-01 6.71 E-02 0. 5.04E-01 6.06E-02 4.60E-05 AM242M 1.02E+00 3.46E-01 6.73E-02 0. 5.01 E-01 2.44E-02 5.79E-05 AM243 1.01 E+00 3.47E-01 6.57E-02 0. 4.95E-01 5.75E-02 5.40E-05 CM242 1.48E-02 1.51 E-02 9.84E-04 0. 4.48E-03 3.92E-02 4.91 E-05 CM243 7.86E-01 2.97E-01 4.61E-02 0. 2.15E-01 6.31E-02 4.84E-05 CM244 5.90E-01 2.54E-01 3.51E-02 0. 1.64E-01 6.06E-02 4.68E-05 CM245 1.26E+00 3.59E-01 7.14E-02 0. 3.33E-01 5.85E-02 4.36E-05 CM246 1.25E+00 3.59E-01 7.13E-02 0. 3.33E-01 5.96E-02 4.29E-05 CM247+D 1.22E+00 3.53E-01 7.03E-02 0. 3.28E-01 5.85E-02 5.63E-05 CM248 1.01 E+01 2.91 E+00 5.79E-01 0. 2.70E+00 4.82E-01 9.09E-04 CF252 9.78E-01 0. 2.33E-02 0. 0. 1.99E-01 1.78E-04

Proc No ODCM Attachment 7 Revision 24 Page 1 of 2 EXTERNAL DOSE FACTORS FOR STANDING ON CONTAMINATED GROUND (DFG!)

(mrem/hr per pCi/m 2)

ELEMENT TOTAL BODY SKIN H-3 0.0 0.0 C-14 0.0 0.0 Na-24 2.50E-08 2.90E-08 P-32 0.0 0.0 Cr-51 2.20E-10 2.60E-10 Mn-54 5.80E-09 6.80E-09 Mn-56 1.10E-08 1.30E-08 Fe-55 0.0 0.0 Fe-59 8.OOE-09 9.40E-09 Co-58 7.OOE-09 8.20E-09 Co-60 1.70E-08 2.OOE-08 Ni-63 0.0 0.0 Ni-65 3.70E-09 4.30E-09 Cu-64 1.50E-09 1.70E-09 Zn-65 4.OOE-09 4.60E-09 Zn-69 0.0 0.0 Br-83 6.40E-11 9.30E- 11 Br-84 1.20E-08 1.40E-08 Br-85 0.0 0.0 Rb-86 6.30E-10 7.20E-10 Rb-88 3.50E-09 4.OOE-09 Rb-89 1.50E-08 1.80E-08 Sr-89 5.60E-13 6.50E- 13 Sr-91 7.10E-09 8.30E-09 Sr-92 9.OOE-09 1.OOE-08 Y-90 2.20E-12 2.60E-12 Y-91 m 3.80E-09 4.40E-09 Y-91 2.40E-11 2.70E- 11 Y-92 1.60E-09 1.90E-09 Y-93 5.70E-10 7.80E-10 Zr-95 5.OOE-09 5.80E-09 Zr-97 5.50E-09 6.40E-09 Nb-95 5.10E-09 6.OOE-09 Mo-99 1.90E-09 2.20E-09 Tc-99m 9.60E-10 1.10E-09 Tc-101 2.70E-09 3.OOE-09

Proc No ODCM Attachment 7 Revision 24 Page 2 of 2 EXTERNAL DOSE FACTORS FOR STANDING ON CONTAMINATED GROUND (DFG!)

(mrem/hr per pCi/m2 )

ELEMENT TOTAL BODY SKIN Ru-103 3.60E-09 4.20E-09 Ru-105 4.50E-09 5.10E-09 Ru-106 1.50E-09 1.80E-09 Ag-110m 1.80E-08 2.1OE-08 Te-125m 3.50E-11 4.80E-11 Te-127m 1.10E-12 1.30E-12 Te-127 1.OOE-11 1.10E-11 Te-129m 7.70E-10 9.OOE-10 Te-129 7.10E-10 8.40E-10 Te-131 m 8.40E-09 9.90E-09 Te-131 2.20E-09 2.60E-06 Te-132 1.70E-09 2.OOE-09 1-130 1.40E-08 1.70E-08 1-131 2.80E-09 3.40E-09 1-132 1.70E-08 2.OOE-08 1-133 3.70E-09 4.50E-09 1-134 1.60E-08 1.90E-08 1-135 1.20E-08 1.40E-08 Cs-134 1.20E-08 1.40E-08 Cs-136 1.50E-08 1.70E-08 Cs-1 37 4.20E-09 4.90E-09 Cs-138 2.1OE-08 2.40E-08 Ba-139 2.40E-09 2.70E-09 Ba-140 2.1OE-09 2.40E-09 Ba-141 4.30E-09 4.90E-09 Ba-142 7.90E-09 9.OOE-09 La-140 1.50E-08 1.70E-08 La-142 1.50E-08 1.80E-08 Ce-141 5.50E-10 6.20E-1 0 Ce-143 2.20E-09 2.50E-09 Ce-144 3.20E-10 3.70E-10 Pr-143 0.0 0.0 Pr-144 2.OOE-10 2.30E-10 Nd-147 1.00E-09 1.20E-09 W-187 3.10E-09 3.60E-09 Np-239 9.50E-10 1.10E-09

Proc No ODCM Attachment 8 Revision 24 Page 1 of I BIOACCUMULATION FACTORS utCi/qm per ttCi/ml FRESHWATER ELEMENT FISH H 9.OE-01 C 4.6E 03 NA 1.0E 02 P 1.0E 05 CR 2.0E 02 MN 4.OE 02 FE 1.0E 02 Co 5.OE 01 NI 1.OE 02 CU 5.0E 01 ZN 2.OE 03 BR 4.2E 02 RB 2.0E 03 SR 3.0E 01 Y 2.5E 01 ZR 3.3E 00 NB 3.ME 04 MO 1.OE 01 TC 1.5E 01 RU 1.OE 01 RH 1.OE 01 TE 4.OE 02 I 1.5E 01 CS 2.OE 03 BA 4.OE 00 LA 2.5E 01 CE 1.0E 00 PR 2.5E 01 ND 2.5E 01 W 1.2E 03 NP 1.OE 01

Proc No ODCM Attachment 9 Revision 24 Page 1 of 16 INGESTION DOSE COMMITMENT FACTORS INFANT INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3 0. 3.08E-07 3.08E-07 3.08E-07 3.08E-07 3.08E-07 3.083-07 BE10 1.71E-05 2.49E-06 5.16E-07 0. 1.64E-06 0. 2.78E-05 C14 2.37E-05 5.06E-06 5.06E-06 5.06E-06 5.06E-06 5.06E-06 5.06E-06 N13 5.85E-08 5.85E-08 5.85E-08 5.835E-08 5.85E-08 5.85E-08 5.85E-08 F18 5.19E-06 0. 4.43E.07 0. 0. 0. 1.22E-06 NA22 9.83E-05 9.83E-05 9.83E-05 9.83E-05 9.83E-05 9.83E-05 9.83E-05 NA24 1.01E-05 1.01E-05 1.01E-05 1.01E-05 1.01E-05 1.01E-05 1.01E-05 P32 1.70E-03 1.OOE-04 6.59E-05 0. 0. 0. 2.30E-05 AR39 0. 0. 0. 0. 0. 0. 0.

AR41 0. 0. 0. 0. 0. 0. 0.

CA41 3.74E-04 0. 4.08E-05 0. 0. 0. 1.91 E-07 SC46 3.75E-08 5.41 E-08 1.69E-08 0. 3.56E-08 0. 3.53E-05 CR51 0. 0. 1.41 E-08 9.20E-09 2.01E-09 1.79E-08 4.11E-07 MN54 0. 1.99E-05 4.51 E-06 0. 4.41 E-06 0. 7.31 E-06 MN56 0. 8.18E-07 1.41E-07 0. 7.03E-07 0. 7.43E-05 FE55 1.39E-05 8.98E-06 2.40E-06 0. 0. 4.39E-06 1.14E-06 FE59 3.08E-05 5.38E-05 2.12E-05 0. 0. 1.59E-05 2.57E-05 C057 0. 1.15E-06 1.87E-06 0. 0. 0. 3.92E-06 C058 0. 3.60E-06 8.98E-06 0. 0. 0. 8.97E-06 C060 0. 1.08E-05 2.55E-05 0. 0. 0. 2.57E-05 N159 4.78E-05 1.45E-05 8.17E-06 0. .0. 0. 7.16E-07 N163 6.34E-04 3.92E-05 2.20E-05 0. 0. 0. 1.95E-06 N165 4.70E-06 5.32E-07 2.42E-07 0. 0. 0. 4.05E-05 CU64 0. 6.09E-07 2.82E-07 0. 1.03E-06 0. 1.25E-05 ZN65 1.84E-05 6.31 E-05 2.91 E-05 0. 3.06E-05 0. 5.33E-05 ZN69M+D 1.50E-06 3.06E-06 2.79E-07 0. 1.24E-06 0. 4.24E-05 ZN69 9.33E-08 1.68E-07 1.25E-08 0. 6.98E-08 0. 1.37E-05 SE79 0. 2.1OE-05 3.90E-06 0. 2.43E-05 0. 5.58E-07 BR82 0. 0. 1.27E-05 0. 0. 0. 0.

BR83+D 0. 0. 3.63E-07 0. 0. 0. 0.

BR84 0. 0. 3.82E-07 0. 0. 0. 0.

BR85 0. 0. 1.94E-08 0. 0. 0. 0.

KR83M 0. 0. 0. 0. 0. 0. 0.

KR85M 0. 0. 0. 0. 0. 0. 0.

KR85 0. 0. 0. 0. 0. 0. 0.

KR87 0. 0. 0. 0. 0. 0. 0.

KR88+D 0. 0. 0. 0. 0. 0. 0.

KR89 0. 0. 0. 0. 0. 0. 0.

RB86 0. 1.70E-04 8.40E-05 0. 0. 0. 4.35E-06 RB87 0. 8.88E-05 3.52E-05 0. 0. 0. 5.98E-07 RB88 0. 4.98E-07 2.73E-07 0. 0. 0. 4.85E-07 RB89+D 0. 2.86E-07 1.97E-07 0. 0. 0. 9.74E-08 SR89+D 2.51E-03 0. 7.20E-05 0. 0. 0. 5.16E-05 SR90+D 1.85E-02 0. 4.71 E-03 0. 0. 0. 2.31 E-04 SR91+D 5.OOE-05 0. 1.81E-06 0. 0. 0. 5.92E-05 SR92+D 1.92E-05 0. 7.13E-07 0. 0. 0. 2.07E-04

Proc No ODCM Attachment 9 Revision 24 Page 2 of 16 INGESTION DOSE COMMITMENT FACTORS INFANT INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 8.69E-08 0. 2.33E-09 0. 0. 0. 1.20E-04 Y91M+D 8.10E-10 0. 2.76E-1 1 0. 0. 0. 2.70E-06 Y91 1.13E-06 0. 3.01 E-08 0. 0. 0. 8.1 OE-05 Y92 7.65E-09 0. 2.15E-10 0. 0. 0. 1.46E-04 Y93 2.43E-08 0. 6.62E-1 0 0. 0. 0. 1.92E-04 ZR93+D 1.93E-07 9.18E-08 5.54E-08 0. 2.71E-07 0. 2.39E-05 ZR95+D 2.06E-07 5.02E-08 3.56E-08 0. 5.41 E-08 0. 2.50E-05 ZR97+D 1.48E-08 2.54E-09 1.16E-09 0. 2.56E-09 0. 1.62E-04 NB93M 1.23E-07 3.33E-08 1.04E-08 0. 3.25E-08 0. 3.98E-06 NB95 4.20E-08 1.73E-08 1.OOE-08 0. 1.24E-08 0. 1.46E-05 NB97 4.59E-10 9.79E-11 3.53E-11 0. 7.65E-11 0. 3.09E-05 M093 0. 5.65E-05 1.82E-06 0. 1.13E-05 0. 1.21 E-06 M099+D 0. 3.40E-05 6.63E-06 0. 5.08E-05 0. 1.12E-05 TC99M 1.92E-09 3.96E-09 5.10E-08 0. 4.26E-08 2.07E-09 1.15E-06 TC99 1.08E-06 1.46E-06 4.55E-07 0. 1.23E-05 1.42E-07 6.31 E-06 TC101 2.27E-09 2.86E-09 2.83E-08 0. 3.40E-08 1.56E-09 4.86E-07 RU103+D 1.48E-06 0. 4.95E-07 0. 3.08E-06 0. 1.80E-05 RU105+D 1.36E-07 0. 4.58E-08 0. 1.OOE-06 0. 5.41 E-05 RU 106+0 2.41E-05 0. 3.01E-06 0. 2.85E-05 0. 1.83E-04 RH 105 1.09E-06 7.13E-07 4.79E-07 0. 1.98E-06 0. 1.77E-05 PD107 0. 1.19E-06 8.45E-08 0. 6.79E-06 0. 9.46E-07 PD109 0. 1.50E-06 3.62E-07 0. 5.51 E-06 0. 3.68E-05 AG110M+D 9.96E-07 7.27E-07 4.81 E-07 0. 1.04E-06 0. 3.77E-05 AG111 5.20E-07 2.02E-07 1.07E-07 0. 4.22E-07 0. 4.82E-05 CD113M 0. 1.77E-05 6.52E-07 0. 1.34E-05 0. 2.66E-05 CD115M 0. 1.42E-05 4.93E-07 0. 7.41 E-06 0. 8.09E-05 SN123 2.49E-04 3.89E-06 6.50E-06 3.91 E-06 0. 0. 6.58E-05 SN125+D 7.41 E-05 1.38E-06 3.29E-06 1.36E-06 0. 0. 1.11 E-04 SN126+D 5.53E-04 7.26E-06 1.80E-05 1.91 E-06 0. 0. 2.52E-05 SB124 2.14E-05 3.15E-07 6.63E-06 5.68E-08 0. 1.34E-05 6.60E-05 SB125+D 1.23E-05 1.19E-07 2.53E-06 1.54E-08 0. 7.72E-06 1.64E-05 SB126 8.06E-06 1.58E-07 2.91 E-06 6.19E-08 0. 5.07E-06 8.35E-05 SB127 2.23E-06 3.98E-08 6.90E-07 2.84E-08 0. 1.15E-06 5.91 E-05 TE125M 2.33E-05 7.79E-06 3.15E-06 7.84E-06 0. 0. 1.11E-05 TE127M+D 5.85E-05 1.94E-05 7.08E-06 1.69E-05 1.44E-04 0. 2.36E-05 TE127 1.OOE-06 3.35E-07 2.15E-07 8.14E-07 2.44E-06 0. 2.10E-05 TE129M+D 1.OOE-04 3.43E-05 1.54E-05 3.84E-05 2.50E-04 0. 5.97E-05 TE129 2.84E-07 9.79E-08 6.63E-08 2.38E-07 7.07E-07 0. 2.27E-05 TE131M+D 1.52E-05 6.12E-06 5.05E-06 1.24E-05 4.21 E-05 0. 1.03E-04 TE131+D 1.76E-07 6.50E-08 4.94E-08 1.57E-07 4.50E-07 0. 7.11E-06 TE132+D 2.08E-05 1.03E-05 9.61 E-06 1.52E-05 6.44E-05 0. 3.81 E-05 TE133M+D 3.91 E-07 1.79E-07 1.71 E-07 3.45E-07 1.22E-06 0. 1.93E-05 TE 134+D 2.67E-07 1.34E-07 1.38E-07 2.39E-07 9.03E-07 0. 3.06E-06 1129 2.86E-05 2.12E-05 1.55E-05 1.36E-02 2.51 E-05 0. 4.24E-07 1130 6.OOE-06 1.32E-05 5.30E-06 1.48E-03 1.45E-05 0. 2.83E-06 1131+D 3.59E-05 4.23E-05 1.86E-05 1.39E-02 4.94E-05 0. 1.51E-06

Proc No ODCM Attachment 9 Revision 24 Page 3 of 16 INGESTION DOSE COMMITMENT FACTORS INFANT INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 1.66E-06 3.37E-06 1.20E-06 1.58E-04 3.76E-06 0. 2.73E.06 1133+D 1.25E-05 1.82E-05 5.33E-06 3.31 E-03 2.14E-05 0. 3.08E-06 1134 8.69E-07 1.78E-06 6.33E-07 4.15E-05 1.99E-06 0. 1.84E-06 1135+D 3.64E-06 7.24E-06 2.64E-06 6.49E-04 8.07E-06 0. 2.62E-06 XE131M 0. 0. 0. 0. 0. 0. 0.

XE133M 0. 0. 0. 0. 0. 0. 0.

XE133 0. 0. 0. 0. 0. 0. 0.

XE135M 0. 0. 0. 0. 0. 0. 0.

XE135 0. 0. 0. 0. 0. 0. 0.

XE137 0. 0. 0. 0. 0. 0. 0.

XE138+D 0. 0. 0. 0. 0. 0. 0.

CS134M+D 1.76E-07 2.93E-07 1.48E-07 0. 1.13E-07 2.60E-08 2.32E-07 CS134 3.77E-04 7.03E-04 7.10E-05 0. 1.81 E-04 7.42E-05 1.91 E-06 CS135 1.33E-04 1.21 E-04 6.30E-06 0. 3.44E-05 1.31 E-05 4.37E-07 CS136 4.59E-05 1.35E-04 5.04E-05 0. 5.38E-05 1.10E-05 2.05E-06 CS137+D 5.22E-04 6.11E-04 4.33E-05 0. 1.64E-04 6.64E-05 1.91 E-06 CS138 4.81 E-07 7.82E-07 3.79E-07 0. 3.90E-07 6.09E-08 1.25E-06 CS139+D 3.1 0E-07 4.24E-07 1.62E-07 0. 2.19E-07 3.30E-08 2.66E-08 BA139 8.81 E-07 5.84E-10 2.55E-08 0. 3.51E-10 3.54E-10 5.58E-05 BA140+D 1.71 E-04 1.71 E-07 8.81 E-06 0. 4.06E-08 1.05E-07 4.20E-05 BA141+D 4.25E-07 2.91 E-1 0 1.34E-08 0. 1.75E-10 1.77E-10 5.19E-06 BA142+D 1.84E-07 1.53E-10 9.06E-09 0. 8.81 E-11 9.26E-1 1 7.59E-07 LA140 2.11 E-08 8.32E-09 2.14E-09 0. 0. 0. 9.77E-05 LA141 2.89E-09 8.38E-10 1.46E-10 0. 0. 0. 9.61 E-05 LA142 1.10E-09 4.04E-10 9.67E-1 1 0. 0. 0. 6.86E-05 CE141 7.87E-08 4.80E-08 5.65E-09 0. 1.48E-08 0. 2.48E-05 CE143+D 1.48E-08 9.82E-06 1.12E-09 0. 2.86E-09 0. 5.73E-05 CE144+D 2.98E-06 1.22E-06 1.67E-07 0. 4.93E-07 0. 1.71E-04 PR143 8.18E-08 3.04E-08 4.03E-09 0. 1.13E-08 0. 4.29E-05 PR144 2.74E-10 1.06E-10 1.38E-1 1 0. 3.84E-11 0. 4.93E-06 ND147+D 5.53E-08 5.68E-08 3.48E-09 0. 2.19E-08 0. 3.60E-05 PM147 3.88E-07 3.27E-08 1.59E-08 0. 4.88E-08 0. 9.27E-06 PM148M+D 1.65E-07 4.18E-08 3.28E-08 0. 4.80E-08 0. 5.443-05 PM148 6.32E-08 9.13E-09 4.60E-09 0. 1.09E-08 0. 9.74E-05 PM149 1.38E-08 1.81E-09 7.90E-10 0. 2.20E-09 0. 4.86E-05 PM151 6.18E-09 9.01E-10 4.56E-10 0. 1.07E-09 0. 4.17E-05 SM151 2.90E-07 6.67E-08 1.44E-08 0. 4.53E-08 0. 5.58E-06 SM153 7.72E-09 5.97E-09 4.58E-10 0. 1.25E-09 0. 3.12E-05 EU152 6.74E-07 1.79E-07 1.51 E-07 0. 5.02E-07 0. 1.59E-05 EU154 2.64E-06 3.67E-07 2.20E-07 0. 9.95E-07 0. 4.58E-05 EU 155 5.42E-07 6.25E-08 3.23E-08 0. 1.40E-07 0. 8.37E-05 EU156 1.14E-07 7.06E-08 1.12E-08 0. 3.26E-08 0. 6.67E-05 TB160 2.59E-07 0. 3.24E-08 0. 7.37E-08 0. 3.45E-05 H0166M 1.25E-06 2.69E-07 2.13E-07 0. 3.57E-07 0. 0.

W181 8.85E-08 2.72E-08 3.04E-09 0. 0. 0. 3.82E-07 W1 85 3.62E-06 1.13E-06 1.29E-07 0. 0. 0. 1.62E-05 Wi 87 9.03E-07 6.28E-07 2.17E-07 0. 0. 0. 3.69E-05

Proc No ODCM Attachment 9 Revision 24 Page 4 of 16 INGESTION DOSE COMMITMENT FACTORS INFANT INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI PB210+D 5.28E-02 1.42E-02 2.38E-03 0. 4.33E-02 0. 5.62E-05 B1210+D 4.16E-06 2.68E-05 3.58E-07 0. 2.08E-04 0. 5.27E-05 P0210 3.10E-03 5.93E-03 7.41E-04 0. 1.26E-02 0. 6.61E-05 RN222+D 0. 0. 0. 0. 0. 0. 0.

RA223+D 4.41E-02 6.42E-05 8.82E-03 0. 1.17E-03 0. 3.43E-04 RA224+LD 1.46E-02 3.29E-05 2.91 E-03 0. 6.00E-04 0. 3.86E-04 RA225+D 5.78E-02 6.42E-05 1.15E-02 0. 1.19E-03 0. 3.24E-04 RA226+1D 6.20E-01 4.76E-05 5.14E-01 0. 8.71E-04 0. 3.44E-04 RA228+D 4.32E-01 2.58E-05 4.86E-01 0. 4.73E-04 0. 5.86E-05 AC225 3.92E-05 5.03E-05 2.63E-06 0. 3.69E-06 0. 4.36E-04 AC227+D 4.49E-03 7.67E-04 2.79E-04 0. 1.56E-04 0. 8.50E-05 TH227+D 1.20E-04 2.01 E-06 3.45E-06 0. 7.41 E-06 0. 5.70E-04 TH228+1D 2.47E-03 3.38E-05 8.36E-05 0. 1.58E-04 0. 5.84E-04 TH229 1.48E-02 1.94E-04 7.29E-04 0. 9.29E-04 0. 5.31E-04 TH230 3.80E-03 1.90E-04 1.06E-04 0. 9.12E-04 0. 6.24E-05 TH232+D 4.24E-03 1.63E-04 1.65E-04 0. 7.79E-04 0. 5.31E-05 TH234 6.92E-07 3.77E-08 2.OOE-08 0. 1.39E-07 0. 1.19E-04 PA231 +1) 7.57E-03 2.50E-04 3.02E-04 0. 1.34E-03 0. 7.44E-05 PA233 3.11E-08 6.09E-09 5.43E-09 0. 1.67E-08 0. 1.46E-05 U232+D 2.42E-02 0. 2.16E-03 0. 2.37E-03 0. 7.04E-05 U233+D 5.08E-03 0. 3.87E-04 0. 1.08E-03 0. 6.51 E-05 U234 4.88E-03 0. 3.80E-04 0. 1.06E-03 0. 6.37E-05 U235+D 4.67E-03 0. 3.56E-04 0. 9.93E-04 0. 8.10E-05 U236 4.67E-03 0. 3.64E-04 0. 1.01 E-03 0. 5.98E-05 U237 4.95E-07 0. 1.32E-07 0. 1.23E-06 0. 2.11E-05 U238+D 4.47E-03 0. 3.33E-04 0. 9.28E-04 0. 5.71E-05 NP237+D 2.53E-03 1.93E-04 1.05E-04 0. 6.34E-04 0. 8.23E-05 NP238 1.24E-07 3.12E-09 1.92E-09 0. 6.81E-09 0. 4.17E-05 NP239 1.11E-08 9.93E-10 5.61E-10 0. 1.98E-09 0. 2.87E-05 PU238 1.34E-03 1.69E-04 3.40E-05 0. 1.21 E-04 0. 7.57E-05 PU239 1.45E-03 1.77E-04 3.54E-05 0. 1.28E-04 0. 6.91E-05 PU240 1.45E-03 1.77E-04 3.54E-05 0. 1.28E-04 0. 7.04E-05 PU241+D 4.38E-05 1.90E-06 8.82E-07 0. 3.17E-06 0. 1.45E-06 PU242 1.35E-03 1.70E-04 3.41E-05 0. 1.23E-04 0. 6.77E-05 PU244 1.57E-03 1.95E-04 3.91E-05 0. 1.41E-04 0. 1.01E-04 AM241 1.53E-03 7.18E-04 1.09E-04 0. 6.55E-04 0. 7.70E-05 AM242M 1.58E-03 7.02E-04 1.13E-04 0. 6.64E-04 0. 9.69E-05 AM243 1.51 E-03 6.88E-04 1.06E-04 0. 6.36E-04 0. 9.03E-05 CM242 1.37E-04 1.24E-04 9.10E-06 0. 2.62E-05 0. 8-23E-05 CM243 1.45E-03 6.88E-04 8.98E-05 0. 3.27E-04 0. 8.1OE-05 CM244 1.22E-03 6.16E-04 7.59E-05 0. 2.71E-04 0. 7.84E-05 CM245 1.88E-03 7.49E-04 1.13E-04 0. 4.32E-04 0. 7.30E-05 CM246 1.87E-03 7.49E-04 1.13E-04 0. 4.31E-04 0. 7.17E-05 CM247+D 1.82E-03 7.36E-04 1.11E-04 0. 4.24E-04 0. 9.43E-05 CM248 1.51E-02 6.07E-03 9.16E-04 0. 3.50E-03 0. 1.52E-03 CF252 1.24E-03 0. 2.95E-05 0 0. 0. 2.99E-04

Proc No ODCM Attachment 9 Revision 24 Page 5 of 16 INGESTION DOSE COMMITMENT FACTORS CHILD INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3 0. 2.03E-07 2.03E-07 2.03E-07 2.03E-07 2.03E-07 2.03E-07 BE10 1.35E-05 1.57E-06 3.39E-07 0. 1.11E-06 0. 2.75E-05 C14 1.21 E-05 2.42E-06 2.42E-06 2.42E-06 2.42E-06 2.42E-06 2.42E-06 N13 3.10E-08 3.10E-08 3.10E-08 3.1OE-08 3.1OE-08 3.10E-08 3.1OE-08 F18 2.49E-06 0. 2.47E-07 0. 0. 0. 6.74E-07 NA22 5.88E-05 5.88E-05 5.88E-05 5.88E-05 5.88E-05 5.88E-05 5.88E-05 NA24 5.80E-06 5.80E-06 5.80E-06 5.80E-06 5.80E-06 5.80E-06 5.80E-06 P32 8.25E-04 3.86E-05 3.18E-05 0. 0. 0. 2.28E-05 AR39 0. 0. 0. 0. 0. 0. 0.

AR41 0. 0. 0. 0. 0. 0. 0.

CA41 3.47E-04 0. 3.79E-05 0. 0. 0. 1.90E-07 SC46 1.97E-08 2.70E-08 1.04E-08 0. 2.30E-08 0. 3.95E-05 CR51 0. 0. 8.90E-09 4.94E-09 1.35E-09 9.02E-09 4.72E-07 MN54 0. 1.07E-05 2.85E-06 0. 3.OOE-06 0. 8.98E-06 MN56 0. 3.34E-07 7.54E-08 0. 4.04E-07 0. 4.84E-05 FE55 1.15E-05 6.10E-06 1.89E-06 0. 0. 3.45E-06 1.13E-06 FE59 1.65E-05 2.67E-05 1.33E-05 0. 0. 7.74E-06 2.78E-05 C057 0. 4.93E-07 9.98E-07 0. 0. 0. 4.04E-06 C058 0. 1.80E-06 5.51E-06 0. 0. 0. 1.05E-05 C060 0. 5.29E-06 1.56E-05 0. 0. 0. 2.93E-05 N159 4.02E-05 1.07E-05 6.82E-06 0. 0. 0. 7.10E-07 N163 5.38E-04 2.88E-05 1.83E-05 0. 0. 0. 1.94E-06 N165 2.22E-06 2.09E-07 1.22E-07 0. 0. 0. 2.56E-05 CU64 0. 2.45E-07 1.48E-07 0. 5.92E-07 0. 1.15E-05 ZN65 1.37E-05 3.65E-05 2.27E-05 0. 2.30E-05 0. 6.41 E-06 ZN69M+D 7.1OE-07 1.21E-06 1.43E-07 0. 7.03E-07 0. 3.94E-05 ZN69 4.38E-08 6.33E-08 5.85E-09 0. 3.84E-08 0.' 3.99E-06 SE79 0. 8.43E-06 1.87E-06 0. 1.37E-05 0. 5.53E-07 BR82 0. 0. 7.55E-06 0. 0. 0. 0.

BR83+D 0. 0. 1.71 E-07 0. 0. 0. 0.

BR84 0. 0. 1.98E-07 0. 0. 0. 0.

BR85 0 0. 9.12E-09 0. 0. 0. 0.

KR83M 0. 0. 0. 0. 0. 0. 0.

KR85M 0. 0. 0. 0. 0. 0. 0.

KR85 0. 0. 0. 0. 0. 0. 0.

KR87 0. 0. 0. 0. 0. 0. 0.

KR88+D 0. 0. 0. 0. 0. 0. 0.

KR89 0. 0. 0. 0. 0. 0. 0.

RB86 0. 6.70E-05 4.12E-05 0. 0. 0. 4.31E-06 RB87 0. 3.95E-05 1.83E-05 0. 0. 0. 5.92E-07 RB88 0. 1.90E-07 1.32E-07 0. 0. 0. 9.32E-09 RB89+D 0. 1.17E-07 1.04E-07 0. 0. 0. 1.02E-09 SR89+D 1.32E-03 0. 3.77E-05 0. 0. 0. 5.11E-05 SR90+D 1.70E-02 0. 4.31 E-03 0. 0. 0. 2.29E-04 SR91+D 2.40E-05 0. 9.06E-07 0. 0. 0. 5.30E-05 SR92+D 9.03E-06 0. 3.62E-07 0. 0. 0. 1.71E-04

Proc No ODCM Affachment 9 Revision 24 Page 6 of 16 INGESTION DOSE COMMITMENT FACTORS CHILD INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 4.11 E-08 0. 1.10E-09 0. 0. 0. 1.17E-04 Y91M+D 3.82E-10 0. 1.39E-11 0. 0. 0. 7.48E-07 Y91 6.02E-07 0. 1.61 E-08 0. 0. 0. 8.02E-05 Y92 3.60E-09 0. 1.03E-10 0. 0. 0. 1.04E-04 Y93 1.14E-08 0. 3.13E-10 0. 0. 0. 1.70E-04 ZR93+D 1.67E-07 6.25E-08 4.45E-08 0. 2.42E-07 0. 2.37E-05 ZR95+D 1.16E-07 2.55E-08 2.27E-08 0. 3.65E-08 0. 2.66E-05 ZR97+D 6.99E-09 1.01 E-09 5.96E-10 0. 1.45E-09 0. 1.53E-04 NB93M 1.05E-07 2.62E-08 8.61 E-09 0. 12.83E-08 0. 3.95E-06 NB95 2.25E-08 8.76E-09 6.26E-09 0. 8.23E-09 0. 1.62E-05 NB97 2.17E-10 3.92E-1 1 1.83E-11 0. 4.35E-11 0. 1.21 E-05 M093 0. 2.41 E-05 8.65E-07 0. 6.35E-06 0. 1.22E-06 M099+D 0. 1.33E-05 3.29E-06 0. 2.84E-05 0. 1.10E-05 TC99M 9.23E-10 1.81 E-09 3.OOE-08 0. 2.63E-08 9.19E-10 1.03E-06 TC99 5.35E-07 5.96E-07 2.14E-07 0. 7.02E-06 5.27E-08 6.25E-06 TC101 1.07E-09 1.12E-09 1.42E-08 0. 1.91 E-08 5.92E-10 3.56E-09 RU 103+D 7.31E-07 0. 2.81 E-07 0. 1.84E-06 0. 1.89E-05 RU105+D 6.45E-08 0. 2.34E-08 0. 5.67E-07 0. 4.21 E-05 RU106+D 1.17E-05 0. 1.46E-06 0. 1.58E-05 0. 1.82E-04 RH 105 5.14E-07 2.76E-07 2.36E-07 0. 1.10E-06 0. 1.71 E-05 PD107 0. 4.72E-07 4.01 E-08 0. 3.95E-06 0. 9.37E-07 PD109 0. 5.67E-07 1.70E-07 0. 3.04E-06 0. 3.35E-05 AG110M+D 5.39E-07 3.64E-07 2.91 E-07 0. 6.78E-07 0. 4.33E-05 AG111 2.48E-07 7.76E-08 5.12E-08 0. 2.34E-07 0. 4.75E-05 CD113M 0. 1.02E-05 4.34E-07 0. 1.05E-05 0. 2.63E-05 CD115M 0. 5.89E-06 2.51 E-07 0. 4.38E-06 0. 8.01 E-05 SN123 1.33E-04 1.65E-06 3.24E-06 1.75E-06 0. 0. 6.52E-05 SN125+D 3.55E-05 5.35E-07 1.59E-06 5.55E-07 0. 0. 1.1OE-04 SN126+D 3.33E-04 4.15E-06 9.46E-06 1.14E-06 0. 0. 2.50E-05 SB124 1.11E-05 1.44E-07 3.89E-06 2.45E-08 0. 6.16E-06 6.94E-05 SB125+D 7.16E-06 5.52E-08 1.50E-06 6.63E-09 0. 3.99E-06 1.71 E-05 SB126 4.40E-06 6.73E-08 1.58E-06 2.58E-08 0. 2.10 E-06 8.87E-05 SB127 1.06E-06 1.64E-08 3.68E-07 1.18E-08 0. 4.60E-07 5.97E-05 TE125M 1.14E-05 3.09E-06 1.52E-06 3.20E-06 0. 0. 1.10E-05 TE127M+D 2.89E-05 7.78E-06 3.43E-06 6.91 E-06 8.24E-05 0. 2.34E-05 TE127 4.71 E-07 1.27E-07 1.01E-07 3.26E-07 1.34E-06 0. 1.84E-05 TE129M+D 4.87E-05 1.36E-05 7.56E-06 1.57E-05 1.43E-04 0. 5.94E-05 TE129 1.34E-07 3.74E-08 3.18E-08 9.56E-08 3.92E-07 0. 8.34E-06 TE131M+D 7.20E-06 2.49E-06 2.65E-06 5.12E-06 2.41 E-05 0. 1.01 E-04 TE131+D 8.30E-08 2.53E-08 2.47E-08 6.35E-08 2.51 E-07 0. 4.36E-07 TE132+D 1.01E-05 4.47E-06 5.40E-06 6.51 E-06 4.15E-05 0. 4.50E-05 TE133M+D 1.87E-07 7.56E-08 9.37E-08 1.45E-07 7.18E-07 0. 5.77E-06 TE134+D 1.29E-07 5.80E-08 7.74E-08 1.02E-07 5.37E-07 0. 5.89E-07 1129 1.39E-05 8.53E-06 7.62E-06 5.58E-03 1.44E-05 0. 4.29E-07 1130 2.92E-06 5.90E-06 3.04E-06 6.50E-04 8.82E-06 0. 2.76E-06 1131+D 1.72E-05 1.73E-05 9.83E-06 5.72E-03 2.84E-05 0. 1.54E-06

Proc No ODCM Attachment 9 Revision 24 Page 7 of 16 INGESTION DOSE COMMITMENT FACTORS CHILD INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 8.OOE-07 1.47E-06 6.76E-07 6.82E-05 2.25E-06 0. 1.73E-06 1133+D 5.92E-06 7.32E-06 2.77E-06 1.36E-03 1.22E-05 0. 2.95E-06 1134 4.19E-07 7.78E-07 3.58E-07 1.79E-05 1.19E-06 0. 5.16E-07 1135+D 1.75E-06 3.15E-06 1.49E-06 2.79E-04 4.83E-06 0. 2.40E-06 XE131M 0. 0. 0. 0. 0. 0. 0.

XE133M 0. 0. 0. 0. 0. 0. 0.

XE133 0. 0. 0. 0. 0. 0. 0.

XE135M 0. 0. 0. 0. 0. 0. 0.

XE135 0. 0. 0. 0. 0. 0. 0.

XE137 0. 0. 0. 0. 0. 0. 0.

XE138+D 0. 0. 0. 0. 0. 0. 0.

CS134M+D 8.44E-08 1.25E-07 8.16E-08 0. 6.59E-08 1.09E-08 1.58E-07 CS134 2.34E-04 3.84E-04 8.1 OE-05 0. 1.19E-04 4.27E-05 2.07E-06 CS135 8.30E-05 5.78E-05 5.93E-06 0. 2.04E-05 6.81 E-06 4.33E-07 CS136 2.35E-05 6.46E-05 4.18E-05 0. 3.44E-05 5.13E-06 2.27E-06 CS137+D 3.27E-04 3.13E-04 4.62E-05 0. 1.02E-04 3.67E-05 1.96E-06 CS138 2.28E-07 3.17E-07 2.01 E-07 0. 2.23E-07 2.40E-08 1.46E-07 CS139+D 1.45E-07 1.61 E-07 7.74E-08 0. 1.21 E-07 1.22E-08 1.45E-11 BA139 4.14E-07 2.21,E-10 1.20E-08 0. 1.93E-10 1.30E-10 2.39E-05 BA140+D 8.31 E-05 7.28E-08 4.85E-06 0. 2.37E-08 4.34E-08 4.21 E-05 BA141+D 2.OOE-07 1.12E-10 6.51 E-09 0. 9.69E-1 1 6.58E-10 1.14E-07 BA142+D 8.74E-08 6.29E-1 1 4.88E-09 0. 5.09E-1 1 3.70E-1 1 1.14E-09 LA140 1.01E-08 3.53E-09 1 .19E-09 0. 0. 0. 9.84E-05 LA141 1.35E-09 3.17E-10 6.88E-1 1 0. 0. 0. 7.05E-05 LA142 5.24E-10 1.67E-10 5.23E-1 1 0. 0. 0. 3.31 E-05 CE141 3.97E-08 1.98E-08 2.94E-09 0. 8.68E-09 0. 2.47E-05 CE143+D 6.99E-09 3.79E-06 5.49E-10 0. 1.59E-09 0. 5.55E-05 CE144+D 2.08E-06 6.52E-07 1.11E-07 0. 3.61 E-07 0. 1.70E-04 PR143 3.93E-08 1.18E-08 1.95E-09 0. 6.39E-09 0. 4.24E-05 PR144 1.29E-10 3.99E-1 1 6.49E-12 0. 2.11E-11 0. 8.59E-08 ND147+D 2.79E-08 2.26E-08 1.75E-09 0. 1.24E-08 0. 3.58E-05 PM147 3.18E-07 2.27E-08 1.22E-08 0. 4.01E-08 0. 9.19E-06 PM148M+D 1.03E-07 2.05E-08 2.05E-08 0. 3.04E-08 0. 5.78E-05 PM148 3.02E-08 3.63E-09 2.35E-09 0. 6.17E-09 0. 9.70E-05 PM149 6.49E-09 6.90E-10 3.74E-10 0. 1.22E-09 0. 4.71 E-05 PM151 2.92E-09 3.55E-10 2.31E-10 0. 6.02E-10 0. 4.03E-05 SM151 2.56E-07 3.81 E-08 1.20E-08 0. 3.94E-08 0. 5.53E-06 SM153 3.65E-09 2.27E-09 2.19E-10 0. 6.91E-10 0. 3.02E-05 EU152 6.15E-07 1.12E-07 1.33E-07 0. 4.73E-07 0. 1.84E-05 EU154 2.30E-06 2.07E-07 1.89E-07 0. 9.09E-07 0. 4.81 E-05 EU155 4.82E-07 3.47E-08 2.72E-08 0. 1.30E-07 0. 8.69E-05 EU156 5.62E-08 3.01 E-08 6.23E-09 0. 1.94E-08 0. 6.83E-05 TB160 1.66E-07 0. 2.06E-08 0. 4.94E-08 0. 3.68E-05 H0166M 1.08E-06 2.26E-07 1.91 E-07 0. 3.22E-07 0. 0.

WI 81 4.23E-06 1.04E-08 1.43E-09 0. 0. 0. 3.79E-07 Wi 85 1.73E-06 4.32E-07 6.05E-08 0. 0. 0. 1.61 E-05 WI 87 4.29E-07 2.54E-07 1.14E-07 0. 0. 0. 3.57E-05

Proc No ODCM Affachment 9 Revision 24 Page 8 of 16 INGESTION DOSE COMMITMENT FACTORS CHILD INGESTION DOSE COMMITMENT FACTORS (MREMI50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI PB210+D 4.75E-02 1.22E-02 2.09E-03 0. 3.67E-02 0. 5.57E-05 B1210+D 1.97E-06 1.02E-05 1.69E-07 0. 1.15E-04 0. 5.17E-05 P0210 1.52E-03 2.43E-03 3.67E-04 0. 7.56E-03 0. 6.55E-05 RN222+D 0. 0. 0. 0. 0. 0. 0.

RA223+D 2.12E-02 2.45E-05 4.24E-03 0. 6.50E-04 0. 3.38E-04 RA224+D 6.89E-03 1.25E-05 1.38E-03 0. 3.31E-04 0. 3.78E-04 RA225+D 2.80E-02 2.50E-05 5.59E-03 0. 6.62E-04 0. 3.21E-04 RA226+D 5.75E-01 1.84E-05 4.72E-01 0. 4.88E-04 0. 3.41 E-04 RA228+D 3.85E-01 9.99E-06 4.32E-01 0. 2.65E-04 0. 5.81 E-05 AC225 1.88E-05 1.94E-05 1.26E-06 0. 2.07E-06 0. 4.31 E-04 AC227+D 4.12E-03 6.63E-04 2.55E-04 0. 1.46E-04 0. 8.43E-05 TH227+D 5.85E-05 7.96E-07 1.69E-06 0. 4.22E-06 0. 5.63E-04 TH228+D 2.07E-03 2.65E-05 7.OOE-05 0. 1.38E-04 0. 5.79E-04 TH229 1.38E-02 1.81 E-04 6.80E-04 0. 8.84E-04 0. 5.27E-04 TH230 3.55E-03 1.78E-04 9.91E-05 0. 8.67E-04 0. 6.19E-05 TH232+D 3.96E-03 1.52E-04 3.01 E-04 0. 7.41 E-04 0. 5.27E-05 TH234 3.42E-07 1.51E-08 9.88E-09 0. 8.01E-08 0. 1.18E-04 PA231 +D 7.07E-03 2.34E-04 2.81E-04 0. 1.28E-03 0. 7.37E-05 PA233 1.81 E-08 2.82E-09 3.16E-09 0. 1.04E-08 0. 1.44E-05 U232+D 1.76E-02 0. 1.26E-03 0. 1.34E-03 0. 6.98E-05 U233+D 3.72E-03 0. 2.25E-04 0. 6.1OE-04 0. 6.45E-05 U234 3.57E-03 0. 2.21E-04 0. 5.98E-04 0. 6.32E-05 U235+D 3.42E-03 0. 2.07E-04 0. 5.61 E-04 0. 8.03E-05 U236 3.42E-03 0. 2.12E-04 0. 5.73E-04 0. 5.92E-05 U237 2.36E-07 0. 6.27E-08 0. 6.81 E-07 0. 2.08E-05 U238+D 3.27E-03 0. 1.94E-04 0. 5.24E-04 0. 5.66E-05 NP237+D 2.36E-03 1.81 E-04 9.79E-05 0. 6.05E-04 0. 8.16E-05 NP238 5.83E-08 1.18E-09 9.08E-10 0. 3.76E-09 0. 4.04E-05 NP239 5.25E-09 3.77E-10 2.65E-10 0. 1.09E-09 0. 2.79E-05 PU238 1.25E-03 1.56E-04 3.16E-05 0. 1.15E-04 0. 7.50E-05 PU239 1.36E-03 1.65E-04 3.31E-05 0. 1.22E-04 0. 6.85E-05 PU240 1.36E-03 1.65E-04 3.31E-05 0. 1.22E-04 0. 6.98E-05 PU241+D 4.OOE-05 1.72E-06 8.04E-07 0. 2.96E-06 0. 1.44E-06 PU242 1.26E-03 1.59E-04 3.19E-05 0. 1.17E-04 0. 6.71E-05 PU244 1.47E-03 1.82E-04 3.65E-05 0. 1.35E-04 0. 1.OOE-04 AM241 1.43E-03 6.40E-04 1.02E-04 0. 6.23E-04 0. 7.64E-05 AM242M 1.47E-03 6.25E-04 1.04E-04 0. 6.30E-04 0. 9.61 E-05 AM243 1.41E-03 6.14E-04 9.83E-05 0. 6.06E-04 0. 8.95E-05 CM242 8.80E-05 6.73E-05 5.84E-06 0. 1.87E-05 0. 8.16E-05 CM243 1.33E-03 6.03E-04 8.24E-05 0. 3.08E-04 0. 8.03E-05 CM244 1.11E-03 5.36E-04 6.93E-05 0. 2.54E-04 0. 7.77E-05 CM245 1.76E-03 6.64E-04 1.05E-04 0. 4.11E-04 0. 7.24E-05 CM246 1.74E-03 6.64E-04 1.05E-04 0. 4.1OE-04 0. 7.11E-05 CM247+D 1.70E-03 6.53E-04 1.03E-04 0. 4.04E-04 0. 9.35E-05 CM248 1.41E-02 5.38E-03 8.52E-04 0. 3.33E-03 0. 1.51E-03 CF252 1.07E-03 0. 2.54E-05 0. 0. 0. 2.96E-04

Proc No ODCM Attachment 9 Revision 24 Page 9 of 16 INGESTION DOSE COMMITMENT FACTORS TEEN INGESTION DOSE COMMITMENT FACTORS (MREMI50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3 0. 1.06E-07 1.06E-07 1.06E-07 1.06E-07 1.06E-07 1.06E-07 BE10 4.48E-06 6.94E-07 1.13E-07 0. 5.30E-07 0. 2.84E-05 C14 4.06E-06 8.12E-07 8.12E-07 8.12E-07 8.12E-07 8.12E-07 8.12E-07 N13 1.15E-08 1.15E-08 1.15E-08 1.15E-08 1.15E-08 1.15E-08 1.15E-08 F18 8.64E-07 0. 9.47E-08 0. 0. 0. 7.78E-08 NA22 2.34E-05 2.34E-05 2.34E-05 2.34E-05 2.34E-05 2.34E-05 2.34E-05 NA24 2.30E-06 2.30E-06 2.30E-06 2.30E-06 2.30E-06 2.30E-06 2.30E-06 P32 2.76E-04 1.71 E-05 1.07E-05 0. 0. 0. 2.32E-05 AR39 0. 0. 0. 0. 0. 0. 0.

AR41 0. 0. 0. 0. 0. 0. 0.

CA41 1.97E-04 0. 2.13E-05 0. 0. 0. 1.95E-07 SC46 7.24E-09 1.41 E-08 4.18E-09 0. 1.35E-08 0. 4.80E-05 CR51 0. 0. 3.60E-09 2.OOE-09 7.89E-10 5.14E-09 6.05E-07 MN54 0. 5.90E-06 1.17E-06 0. 1.76E-06 0. 1.21 E-05 MN56 0. 1.58E-07 2.81E-08 0. 2.OOE-07 0. 1.04E-05 FE55 3.78E-06 2.68E-06 6.25E-07 0. 0. 1.70E-06 1.16E-06 FE59 5.87E-06 1.37E-05 5.29E-06 0. 0. 4.32E-06 3.24E-05 C057 0. 2.38E-07 3.99E-07 0. 0. 0. 4.44E-06 C058 02 9.72E-07 2.24E-06 0. 0. 0. 1.34E-05 C060 0 2.81 E-06 6.33E-06 0. 0. 0. 3.66E-05 N159 1.32E-05 4.66E-06 2.24E-06 0. 0. 0. 7.31E-07 N163 1.77E-04 1.25E-05 6.00E-06 0. 0. 0. 1.99E-06 N165 7.49E-07 9.57E-08 4.36E-08 0. 0. 0. 5.193-06 CU64 0. 1.15E-07 5.41E-08 0. 2.91E-07 0. 8.92E-06 ZN65 5.76E-06 2.OOE-05 9.33E-06 0. 1.28E-05 0. 8.47E-06 ZN69M+D 2.40E-07 5.66E-07 5.19E-08 0. 3.44E-07 0. 3.11E-05 ZN69 1.47E-08 2.80E-08 1.96E-09 0. 1.83E-08 0. 5.16E-08 SE79 0. 3.73E-06 6.27E-07 0. 6.50E-06 0. 5.70E-07 BR82 0. 0. 3.04E-06 0. 0. 0. 0.

BR83+D 0. 0. 5.74E-08 0. 0. 0. 0.

BR84 0. 0. 7.22E-08 0. 0. 0. 0.

BR85 0. 0. 3.05E-09 0. 0. 0. 0.

KR83M 0. 0. 0. 0. 0. 0. 0.

KR85M 0. 0. 0. 0. 0. 0. 0.

KR85 0. 0. 0. 0. 0. 0. 0.

KR87 0. 0. 0. 0. 0. 0. 0.

KR88+D 0. 0. 0. 0. 0. 0. 0.

KR89 0. 0. 0. 0. 0. 0. 0.

RB86 0. 2.98E-05 1.40E-05 0. 0. 0. 4.41E-06 RB87 0. 1.75E-05 6.11E-06 0. 0. 0. 6.11E-07 RB88 0. 8.52E-08 4.54E-08 0. 0. 0. 7.30E-15 RB89+D 0. 5.50E-08 3.89E-08 0. 0. 0. 8.43E-17 SR89+D 4.40E-04 0. 1.26E-05 0. 0. 0. 5.24E-05 SR90+D 8.30E-03 0. 2.05E-03 0. 0. 0. 2.33E-04 SR91+D 8.07E-06 0. 3.21E-07 0. 0. 0. 3.66E-05 SR92+D 3.05E-06 0. 1.30E-07 0. 0. 0. 7.77E-05

Proc No ODCM Attachment 9 Revision 24 Page 10 of 16 INGESTION DOSE COMMITMENT FACTORS TEEN INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 1.37E-08 0. 3.69E-10 0. 0. 0. 1.13E-04 Y91M+D 1.29E-10 0. 4.93E-12 0. 0. 0. 6.09E-09 Y91 2.01 E-07 0. 5.39E-09 0. 0. 0. 8.24E-05 Y92 1.21 E-09 0. 3.50E-11 0. 0. 0. 3.32E-05 Y93 3.83E-09 0. 1.05E-10 0. 0. 0. 1.17E-04 ZR93+D 5.53E-08 2.73E-08 1.49E-08 0. 9.65E-08 0. 2.58E-05 ZR95+D 4.12E-08 1.30E-08 8.94E-09 0. 1.91E-08 0. 3.OOE-05 ZR97+D 2.37E-09 4.69E-10 2.16E-10 0. 7.11E-10 0. 1.27E-04 NB93M 3.44E-08 1.13E-08 2.83E-09 0. 1.32E-08 0. 4.07E-06 NB95 8.22E-09 4.56E-09 2.51 E-09 0. 4.42E-09 0. 1.95E-05 NB97 7.37E-1 I 1.83E-11 6.68E-12 0. 2.14E-1 1 0. 4.37E-07 M093 0. 1.06E-05 2.90E-07 0. 3.04E-06 0. 1.29E-06 M099+D 0. 6.03E-06 1.15E-06 0. 1.38E-05 0. 1.08E-05 TC99M 3.32E-1 0 9.26E-10 1.20E-08 0. 1.38E-08 5.14E-10 6.08E-07 TC99 1.79E-07 2.63E-07 7.17E-08 0. 3.34E-06 2.72E-08 6.44E-06 TC101 3.60E-10 5.12E-10 5.03E-09 0. 9.26E-09 3.12E-10 8.75E-17 RU103+D 2.55E-07 0. 1.09E-07 0. 8.99E-07 0. 2.13E-05 RU105+D 2.18E-08 0. 8.46E-09 0. 2.75E-07 0. 1.76E-05 RU 106+D 3.92E-06 0. 4.94E-07 0. 7.56E-06 0. 1.88E-04 RH 105 1.73E-07 1.25E-07 8.20E-08 0. 5.31 E-07 0. 1.59E-05 PD107 0. 2.08E-07 1.34E-08 0. 1.88E-06 0. 9.66E-07 PD109 0. 2.51 E-07 5.70E-08 0. 1.45E-06 0. 2.53E-05 AG'110M+D 2.05E-07 1.94E-07 1.18E-07 0. 3.70E-07 0. 5.45E-05 AG111 8.29E-08 3.44E-08 1.73E-08 0. 1.12E-07 0. 4.80E-05 CD113M 0. 4.51 E-06 1.45E-07 0. 4.99E-06 0. 2.71 E-05 CD115M 0. 2.60E-06 8.39E-08 0. 2.08E-06 0. 8.23E-05 SN123 4.44E-05 7.29E-07 1.08E-06 5.84E-07 0. 0. 6.71 E-05 SN125+D 1.19E-05 2.37E-07 5.37E-07 1.86E-07 0. 0. 1.12E-04 SN126+D 1.16E-04 2.16E-06 3.30E-06 5.69E-07 0. 0. 2.58E-05 SB124 3.87E-06 7.13E-08 1.51 E-06 8.78E-09 0. 3.38E-06 7.80E-05 SB125+D 2.48E-06 2.71 E-08 5.80E-07 2.37E-09 0. 2.18E-06 1.93E-05 SB126 1.59E-06 3.25E-08 5.71 E-07 8.99E-09 0. 1.14E-06 9.41 E-05 SB127 3.63E-07 7.76E-09 1.37E-07 4.08E-09 0. 2.47E-07 6.16E-05 TE125M 3.83E-06 1.38E-06 5.12E-07 1.07E-06 0. 0. 1.13E-05 TE127M+D 9.67E-06 3.43E-06 1.15E-06 2.30E-06 3.92E-05 0. 2.41 E-05 TE127 1.58E-07 5.60E-08 3.40E-08 1.09E-07 6.40E-07 0. 1.22E-05 TE129M+D 1.63E-05 6.05E-06 2.58E-06 5.26E-06 6.82E-05 0. 6.12E-05 TE129 4.48E-08 1.67E-08 1.09E-08 3.20E-08 1.88E-07 0. 2.45E-07 TE131M+D 2.44E-06 1.17E-06 9.76E-07 1.76E-06 1.22E-05 0. 9.39E-05 TE131+D 2.79E-08 1.15E-08 8.72E-09 2.15E-08 1.22E-07 0. 2.29E-09 TE132+D 3.49E-06 2.21 E-06 2.08E-06 2.33E-06 2.12E-05 0. 7.OOE-05 TE133M+D 6.44E-08 3.66E-08 3.56E-08 5.11E-08 3.62E-07 0. 1.48E-07 TE134+D 4.47E-08 2.87E-08 3.OOE-08 3.67E-08 2.74E-07 0. 1.66E-09 1129 4.66E-06 3.92E-06 6.54E-06 4.77E-03 7.01 E-06 0. 4.57E-07 1130 1.03E-06 2.98E-06 1.19E-06 2.43E-04 4.59E-06 0. 2.29E-06 1131+D 5.85E-06 8.19E-06 4.40E-06 2.39E-03 1.41 E-05 0. 1.62E-06

Proc No ODCM Attachment 9 Revision 24 Page 11 of 16 INGESTION DOSE COMMITMENT FACTORS TEEN INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 2.79E-07 7.30E-07 2.62E-07 2.46E-05 1.15E-06 0. 3.18E-07 1133+D 2.01 E-06 3.41 E-06 1.04E-06 4.76E-04 5.98E-06 0. 2.58E-06 1134 1.46E-07 3.87E-07 1.39E-07 6.45E-06 6.10E-07 0. 5.10E-09 1135+D 6.1 OE-07 1.57E-06 5.82E-07 1.01E-04 2.48E-06 0. 1.74E-06 XE131M 0. 0. 0. 0. 0. 0. 0.

XE133M 0. 0. 0. 0. 0. 0. 0.

XE133 0. 0. 0. 0. 0. 0. 0.

XE135M 0. 0. 0. 0. 0. 0. 0.

XE135 0. 0. 0. 0. 0. 0. 0.

XE137 0. 0. 0. 0. 0. 0. 0.

XE138+D 0. 0. 0. 0. 0. 0. 0.

CS134M+D 2.94E-08 6.09E-08 3.13E-08 0. 3.39E-08 5.95E-09 4.05E-08 CS134 8.37E-05 1.97E-04 9.14E-05 0. 6.26E-05 2.39E-05 2.45E-06 CS135 2.78E-05 2.55E-05 5.96E-06 0. 9.73E-06 3.52E-06 4.46E-07 CS136 8.59E-06 3.38E-05 2.27E-05 0. 1.84E-05 2.90E-06 2.72E-06 CS137+D 1.12E-04 1.49E-04 5.19E-05 0. 5.07E-05 1.97E-05 2.12E-06 CS138 7.76E-08 1.49E-07 7.45E-08 0. 1.10E-07 1.28E-08 6.76E-1 1 CS139+D 4.87E-08 7.17E-08 2.63E-08 0. 5.79E-08 6.34E-09 3.33E-23 BA139 1.39E-07 9.78E-1 1 4.05E-09 0. 9.22E-1 1 6.74E-11 1.24E-06 BA140+D 2.84E-05 3.48E-08 1.83E-06 0. 1.18E-08 2.34E-08 4.38E-05 BA141+D 6.71 E-08 5.01 E-11 2.24E-09 0. 4.65E-1 1 3.43E-1 1 1.43E-13 BAl 42+D 2.99E-08 2.99E-11 1.84E-09 0. 2.53E-1 1 1.99E-11 9.18E-20 LA140 3.48E-09 1.71 E-09 4.55E-10 0. 0. 0. 9.82E-05 LA141 4.55E-10 1.40E-10 2.31 E-11 0. 0. 0. 2.48E-05 LA142 1.79E-10 7.95E-1 1 1.98E- 11 0. 0. 0. 2.42E-06 CE141 1.33E-08 8.88E-09 1.02E-09 0. 4.18E-09 0. 2.54E-05 CE143+D 2.35E-09 1.71 E-06 1.91E-10 0. 7.67E-10 0. 5.14E-05 CE144+D 6.96E-07 2.88E-07 3.74E-08 0. 1.72E-07 0. 1.75E-04 PR143 1.31 E-08 5.23E-09 6.52E-10 0. 3.04E-09 0. 4.31 E-05 PR144 4.30E-1 1 1.76E-11 2.18E-12 0. 1.01 E-11 0. 4.74E-14 ND147+D 9.38E-09 1.02E-08 6.11E-10 0. 5.99E-09 0. 3.68E-05 PM147 1.05E-07 9.96E-09 4.06E-09 0. 1.90E-08 0. 9.47E-06 PM148M+D 4.14E-08 1.05E-08 8.21 E-09 0. 1.59E-08 0. 6.61 E-05 PM148 1.02E-08 1.66E-09 8.36E-10 0. 3.OOE-09 0. 9.90E-05 PM149 2.17E-09 3.05E-10 1.25E-10 0. 5.81 E-10 0. 4.49E-05 PM151 9.87E-10 1.63E-10 8.25E-1 1 0. 2.93E-1 0 0. 3.66E-05 SM151 8.73E-08 1.68E-08 3.94E-09 0. 1.84E-08 0. 5.70E-06 SM153 1.22E-09 1.01 E-09 7.43E- 11 0. 3.30E-10 0. 2.85E-05 EU152 2.45E-07 5.90E-08 5.20E-08 0. 2.74E-07 0. 2.17E-05 EU154 7.91 E-07 1.02E-07 7.19E-08 0. 4.56E-07 0. 5.39E-05 EU155 1.74E-07 1.68E-08 1.04E-08 0. 6.57E-08 0. 9.63E-05 EU156 1.92E-08 1.44E-08 2.35E-09 0. 9.69E-09 0. 7.36E-05 TB160 6.47E-08 0. 8.07E-09 0. 2.56E-08 0. 4.19E-05 H0166M 3.57E-07 1.1OE-07 7.96E-08 0. 1.61 E-07 0. 0.

W181 1.42E-08 4.58E-09 4.79E-10 0. 0. 0. 3.90E-07 W185 5.79E-07 1.91 E-07 2.02E-08 0. 0. 0. 1.65E-05 WI 87 1.46E-07 1.19E-07 4.17E-08 0. 0. 0. 3.22E-05

Proc No ODCM Attachment 9 Revision 24 Page 12 of 16 INGESTION DOSE COMMITMENT FACTORS TEEN INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI PB210+D 1.81E-02 5.44E-03 7.01E-04 0. 1.72E-02 0. 5.74E-05 B1210+D 6.59E-07 4.51E-06 5.66E-08 0. 5.48E-05 0. 5.15E-05 P0210 6.09E-04 1.07E-03 1.23E-04 0. 3.60E-03 0. 6.75E-05 RN222+D 0. 0. 0. 0. 0. 0. 0.

RA223+D 7.11E-03 1.08E-05 1.42E-03 0. 3.10E-04 0. 3.43E-04 RA224+D 2.31E-03 5.52E-06 4.61E-04 0. 1.58E-04 0. 3.71E-04 RA225+D 9.37E-03 1.10E-05 1.87E-03 0. 3.15E-04 0. 3.27E-04 RA226+D 3.22E-01 8.13E-06 2.39E-01 0. 2.32E-04 0. 3.51E-04 RA228+D 1.37E-01 4.41 E-06 1.51 E-01 0. 1.26E-04 0. 5.98E-05 AC225 6.29E-06 8.59E-06 4.22E-07 0. 9.85E-07 0. 4.36E-04 AC227+13 2.05E-03 3.03E-04 1.22E-04 0. 8.81E-05 0. 8.68E-05 TH227+D 1.96E-05 3.52E-07 5.65E-07 0. 2.01E-06 0. 5.75E-04 TH228+D 6.80E-04 1.14E-05 2.30E-05 0. 6.41 E-05 0. 5.97E-04 TH229 8.39E-03 1.26E-04 4.11E-04 0. 6.1OE-04 0. 5.43E-04 TH230 2.16E-03 1.23E-04 6.OOE-05 0. 5.99E-04 0. 6.38E-05 TH232+D 2.42E-03 1.05E-04 1.63E-04 0. 5.11E-04 0. 5.43E-05 TH234 1.14E-07 6.68E-09 3.31E-09 0. 3.81E-08 0. 1.21 E-04 PA231+D 4.31E-03 1.62E-04 1.68E-04. 0. 9.1OE-04 0. 7.60E-05 PA233 7.33E-09 1.41 E-09 1.26E-09 0. 5.32E-09 0. 1.61 E-05 U232+D 5.89E-03 0. 4.21E-04 0. 6.38E-04 0. 7.19E-05 U233+D 1.24E-03 0. 7.543-05 0. 2.90E-04 0. 6.65E-05 U234 1.19E-03 0. 7.39E-05 0. 2.85E-04 0. 6.51E-05 U235+D 1.14E-03 0. 6.94E-05 0. 2.67E-04 0. 8.28E-05 U236 1.14E-03 0. 7.09E-05 0. 2.73E-04 0. 6.11E-05 U237 7.89E-08 0. 2.1OE-08 0. 3.24E-07 0. 2.09E-05 U238+D 1.09E-03 0. 6.49E-05 0. 2.50E-04 0. 5.83E-05 NP237+13 1.44E-03 1.25E-04 5.85E-05 0. 4.33E-04 0. 8.41 E-05 NP238 1.95E-08 5.22E-10 3.04E-10 0. 1.79E-09 0. 3.83E-05 NP239 1.76E-09 1.66E-10 9.22E-11 0. 5.21E-10 0. 2.67E-05 PU238 7.21E-04 1.02E-04 1.82E-05 0. 7.80E-05 0. 7.73E-05 PU239 8.27E-04 1.12E-04 2.01E-05 0. 8.57E-05 0. 7.06E-05 PU240 8.26E-04 1.12E-04 2.01E-05 0. 8.56E-05 0. 7.19E-05 PU241+D 1.84E-05 9.42E-07 3.69E-07 0. 1.71E-06 0. 1.48E-06 PU242 7.66E-04 1.08E-04 1.94E-05 0. 8.25E-05 0. 6.92E-05 PU244 8.95E-04 1.23E-04 2.22E-05 0. 9.45E-05 0. 1.03E-04 AM241 8.62E-04 3.29E-04 5.75E-05 0. 4.31 E-04 0. 7.87E-05 AM242M 8.70E-04 3.19E-04 5.80E-05 0. 4.30E-04 0. 9.90E-05 AM243 8.60E-04 3.17E-04 5.62E-05 0. 4.22E-04 0. 9.23E-05 CM242 2.94E-05 2.97E-05 1.95E-06 0. 8.89E-06 0. 8.40E-05 CM243 6.91E-04 2.86E-04 4.09E-05 0. 1.91E-04 0. 8.28E-05 CM244 5.32E-04 2.49E-04 3.19E-05 0. 1.49E-04 0. 8.OOE-05 CM245 1.07E-03 3.33E-04 6.1OE-05 0. 2.85E-04 0. 7.46E-05 CM246 1.06E-03 3.32E-04 6.09E-05 0. 2.84E-04 0. 7.33E-05 CM247+D 1.03E-03 3.27E-04 6.OOE-05 0. 2.80E-04 0. 9.63E-05 CM248 8.60E-03 2.69E-03 4.95E-04 0. 2.31E-03 0. 1.55E-03 CR252 3.51 E-04 0. 8.37E-06 0. 0. 0. 3.05E-04

Proc No ODCM Attachment 9 Revision 24 Page 13 of 16 INGESTION DOSE COMMITMENT FACTORS ADULT INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3 0. 1.05E-07 1.05E-07 1.05E-07 1.05E-07 1.05E-07 1.05E-07 BE10 3.18E-06 4.91E-07 7.94E-08 0. 3.71E-07 0. 2.68E-05 C14 2.84E-06 5.68E-07 5.68E-07 5.68E-07 5.68E-07 5.68E-07 5.68E-07 N13 8.36E-09 8.36E-09 8.36E-09 8.36E-09 8.36E-09 8.36E-09 8.36E-09 F18 6.24E-07 0. 6.92E-08 0. 0. 0. 1.85E-08 NA22 1.74E-05 1.74E-05 1.74E-05 1.74E-05 1.74E-05 1.74E-05 1.74E-05 NA24 1.70E-06 1.70E-06 1.70E-06 1.70E-06 1.70E-06 1.70E-06 1.70E-06 P32 1.93E-04 1.20E-05 7.46E-06 0. 0. 0. 2.17E-05 AR39 0. 0. 0. 0. 0. 0. 0.

AR41 0. 0. 0. 0. 0. 0. 0.

CA41 1.83E-05 0. 2.OOE-05 0. 0. 0. 1.84E-07 SC46 5.51E-09 1.07E-08 3.11E-09 0. 9.99E-09 0. 5.21E-05 CR51 0. 0. 2.66E-09 1.59E-09 5.86E-10 3.53E-09 6.69E-07 MN54 0. 4.57E-06 8.72E-07 0. 1.36E-06 0. 1.40E-05 MN56 0. 1.15E-07 2.04E-08 0. 1.46E-07 0. 3.67E-06 FE55 2.75E-06 1.90E-06 4.43E-07 0. 0. 1.06E-06 1.09E-06 FE59 4.34E-06 1.02E-05 3.91E-06 0. 0. 2.85E-06 3.40E-05 C057 0. 1.75E-07 2.91 E-07 0. 0. 0. 4.44E-06 C058 0. 7.45E-07 1.67E-06 0. 0. 0. 1.51 E-05 C060 0. 2.14E-06 4.72E-06 0. 0. 0. 4.02E-05 N159 9.76E-06 3.35E-06 1.63E-06 0. 0. 0. 6.90E-07 N163 1.30E-04 9.01E-06 4.36E-06 0. 0. 0. 1.88E-06 N165 5.28E-07 6.86E-08 3.13E-08 0. 0. 0. 1.74E-06 CU64 0. 8.33E-08 3.91E-08 0. 2.1OE-07 0. 7.10E-06 ZN65 4.84E-06 1.54E-05 6.96E-06 0. 1.03E-05 0. 9.70E-06 ZN69M+D 1.70E-07 4.08E-07 3.73E-08 0. 2.47E-07 0. 2.49E-05 ZN69 1.03E-08 1.97E-08 1.37E-09 0. 1.28E-08 0. 2.96E-09 SE79 0. 2.63E-06 4.39E-07 0. 4.55E-06 0. 5.38E-07 BR82 0. 0. 2.26E-06 0. 0. 0. 2.59E-06 BR83+D 0. 0. 4.02E-08 0. 0. 0. 5.79E-08 BR84 0. 0. 5.21E-08 0. 0. 0. 4.09E-13 BR85 0. 0. 2.14E-09 0. 0. 0. 0.

KR83M 0. 0. 0. 0. 0. 0. 0.

KR85M 0. 0. 0. 0. 0. 0. 0.

KR85 0. 0. 0. 0. 0. 0. 0.

KR87 0. 0. 0. 0. 0. 0. 0.

KR88+D 0. 0. 0. 0. 0. 0. 0.

KR89 0. 0. 0. 0. 0. 0. 0.

RB86 0. 2.11E-05 9.83E-06 0. 0. 0. 4.16E-06 RB87 0. 1.23E-05 4.28E-06 0. 0. 0. 5.76E-07 RB88 0. 6.05E-08 3.21E-08 0. 0. 0. 8.36E-19 RB89+D 0. 4.01 E-08 2.82E-08 0. 0. 0. 2.33E-21 SR89+D 3.08E-04 0. 8.84E-06 0. 0. 0. 4.94E-05 SR90+D 7.58E-03 0. 1.86E-03 0. 0. 0. 2.19E-04 SR91+D 5.67E-06 0. 2.29E-07 0. 0. 0. 2.70E-05 SR92+D 2.15E-06 0. 9.30E-08 0. 0. 0. 4.26E-05

Proc No ODCM Attachment 9 Revision 24 Page 14 of 16 INGESTION DOSE COMMITMENT FACTORS ADULT INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 9.62E-09 0. 2.58E-10 0. 0. 0. 1.02E-04 Y91M+D 9.09E-1 1 0. 3.52E- 12 0. 0. 0. 2.67E-10 Y91 1.41 E-07 0. 3.77E-09 0. 0. 0. 7.76E-05 Y92 8.45E- 10 0. 2.47E-1 1 0. 0. 0. 1.48E-05 Y93 2.68E-09 0. 7.40E-1 I 0. 0. 0. 8.50E-05 ZR93+D 4.18E-08 2.34E-09 1.09E-09 0. 8.87E-09 0. 2.43E-06 ZR95+D 3.04E-08 9.75E-09 6.60E-09 0. 1.53E-08 0. 3.09E-05 ZR97+D 1.68E-09 3.39E-10 1.55E-10 0. 5.12E-10 0. 1.05E-04 NB93M 2.55E-08 8.32E-09 2.05E-09 0. 9.57E-09 0. 3.84E-06 NB95 6.22E-09 3.46E-09 1.86E-09 0. 3.42E-09 0. 2.1OE-05 NB97 5.22E-11 1.32E-11 4.82E- 12 0. 1.54E- 11 0. 4.87E-08 M093 0. 7.51 E-06 2.03E-07 0. 2.13E-06 0. 1.22E-06 M099+D 0. 4.31 E-06 8.20E-07 0. 9.76E-06 0. 9.99E-06 TC99M 2.47E-1 0 6.98E-10 8.89E-09 0. 1.06E-08 3.42E-10 4.13E-07 TC99 1.25E-07 1.86E-07 5.02E-08 0. 2.34E-06 1.58E-08 6.08E-06 TC101 2.54E- 10 3.66E-10 3.59E-09 0. 6.59E-09 1.87E-10 1.10 E-21 RU103+D 1.85E-07 0. 7.97E-08 0. 7.06E-07 0. 2.16E-05 RU105+D 1.54E-08 0. 6.08E-09 0. 1.99E-07 0. 9.42E-06 RU106+D 2.75E-06 0. 3.48E-07 0. 5.31 E-06 0. 1.78E-04 RH105 1.21 E-07 8.85E-08 5.83E-08 0. 3.76E-07 0. 1.41 E-05 PD107 0. 1.47E-07 9.40E-09 0. 1.32E-06 0. 9.11E-07 PD109 0. 1.77E-07 3.99E-08 0. 1.01 E-06 0. 1.96E-05 AG110M+D 1.60E-07 1.48E-07 8.79E-08 0. 2.91 E-07 0. 6.04E-05 AG111 5.81 E-08 2.43E-08 1.21 E-08 0. 7.84E-08 0. 4.46E-05 CD113M 0. 3.18E-06 1.02E-07 0. 3.50E-06 0. 2.56E-05 CD115M 0. 1.84E-06 5.87E-08 0. 1.46E-06 0. 7.74E-05 SN123 3.11 E-05 5.15E-07 7.59E-07 4.38E-07 0. 0. 6.33E-05 SN125+D 8.33E-06 1.68E-07 3.78E-07 1.39E-07 0. 0. 1.04E-04 SN126+D 8.45E-05 1.67E-06 2.40E-06 4.92E-07 0. 0. 2.43E-05 SB124 2.80E-06 5.29E-08 1.11E-06 6.79E-09 0. 2.18E-06 7.95E-05 SB125+D 1.79E-06 2.OOE-08 4.26E-07 1.82E-09 0. 1.38E-06 1.97E-05 SB126 1.15E-06 2.34E-08 4.15E-07 7.04E-09 0. 7.05E-07 9.40E-05 SB127 2.58E-07 5.65E-09 9.90E-08 3.1 OE-09 0. 1.53E-07 5.90E-05 TE125M 2.68E-06 9.71 E-07 3.59E-07 8.06E-07 1.09E-05 0. 1.07E-05 TE125M+D 6.77E-06 2.42E-06 8.25E-07 1.73E-06 2.75E-05 0. 2.27E-05 TE127 1.1OE-07 3.95E-08 2.38E-08 8.15E-08 4.48E-07 0. 8.68E-06 TE129M+D 1.15E-05 4.29E-06 1.82E-06 3.95E-06 4.80E-05 0. 5.79E-05 TE129 3.14E-08 1.18E-08 7.65E-09 2.41 E-08 1.32E-07 0. 2.37E-08 TE131M+D 1.73E-06 8.46E-07 7.05E-07 1.34E-06 8.57E-06 0. 8.40E-05 TE131+D 1.97E-08 8.23E-09 6.22E-09 1.62E-08 8.63E-08 0. 2.79E-09 TE132+D 2.52E-06 1.63E-06 1.53E-06 1.80E-06 1.57E-05 0. 7.71 E-05 TE133M+D 4.62E-08 2.70E-08 2.60E-08 3.91 E-08 2.67E-07 0. 6.64E-08 TE134+D 3.24E-08 2.12E-08 1.30E-08 2.83E-08 2.05E-07 0. 3.59E-11 1129 3.27E-06 2.81 E-06 9.21 E-06 7.23E-03 6.04E-06 0. 4.44E-07 1130 7.56E-07 2.23E-06 8.80E-07 1.89E-04 3.48E-06 0. 1.92E-06 1131+D 4.16E-06 5.95E-06 3.41 E-06 1.95E-03 1;02E-05 0. 1.57E-06

Proc No ODCM Attachment 9 Revision 24 Page 15 of 16 INGESTION DOSE COMMITMENT FACTORS ADULT INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 2.03E-07 5.43E-07 1.90E-07 1.90E-05 8.65E-07 0. 1.02E-07 1133+D 1.42E-06 2.47E-06 7.53E-07 3.63E-04 4.31E-06 0. 2.22E-06 1134 1.06E-07 2.88E-07 1.03E-07 4.99E-06 4.58E-07 0. 2.51E-10 1135+D 4.43E-07 1.16E-06 4.28E-07 7.65E-05 1.86E-06 0. 1.31E-06 XE131M 0. 0. 0. 0. 0. 0. 0.

XE133M 0. 0. 0. 0. 0. 0. 0.

XE133 0. 0. 0. 0. 0. 0. 0.

XE135M 0. 0. 0. 0., 0. 0. 0.

XE135 0. 0. 0. 0. 0. 0. 0.

XE137 0. 0. 0. 0. 0. 0. 0.

XE138+D 0. 0. 0. 0. 0. 0. 0.

CS134M+D 2.13E-08 4.48E-08 2.29E-08 0. 2.43E-08 3.83E-09 1.58E-08 CS134 6.22E-05 1.48E-04 1.21 E-04 0. 4.79E-05 1.59E-05 2.59E-06 CS135 1.95E-05 1.80E-05 7.99E-06 0. 6.81 E-06 2.04E-06 4.21 E-07 CS136 6.51 E-06 2.57E-05 1.85E-05 0. 1.43E-05 1.96E-06 2.92E-06 CS137+D 7.97E-05 1.09E-04 7.14E-05 0. 3.70E-05 1.23E-05 2.11E-06 CS138 6.52E-08 1.09E-07 5.40E-08 0. 8.01E-08 7.91 E-09 4.65E-1 3 CS139+D 3.41 E-08 5.08E-08 1.85E-08 0. 4.07E-08 3.70E-09 1.1OE-30 BA139 9.70E-08 6.91 E-11 2.84E-09 0. 6.46E-11 3.92E-11 1.72E-07 BA140+D 2.03E-05 2.55E-08 1.33E-06 0. 8.67E-09 1.46E-08 4.18E-05 BA141+D 4.71 E-08 3.56E-11 1.59E-09 0. 3.31 E-11 2.02E-11 2.22E-17 BA142+D 2.13E-08 2.19E-11 1.34E-09 0. 1.85E-11 1.24E-11 3.OOE-26 LA140 2.50E-09 1.26E-09 3.33E-10 0. 0. 0. 9.25E-05 LA141 3.19E- 10 9.90E-1 1 1.62E- 11 0. 0. 0. 1.18E-05 LA142 1.28E-10 5.82E-11 1.45E-11 0. 0. 0. 4.25E-07 CE141 9.36E-09 6.33E-09 7.18E-10 0. 2.94E-09 0. 2.42E-05 CE143+D 1.65E-09 1.22E-06 1.35E-10 .0. 5.37E-10 0. 4.56E-05 CE144+D 4.88E-07 2.04E-07 2.62E-08 0. 1.21E-07 0. 1.65E-04 PR143 9.20E-09 3.69E-09 4.56E-10 0. 2.13E-09 0. 4.03E-05 PR144 3.01E-11 1.25E-1 1 1.53E-12 0. 7.05E-12 0. 4.33E-1 8 ND147+0 6.29E-09 7.27E-09 4.35E-10 0. 4.25E-09 0. 3.49E-05 PM147 7.54E-08 7.09E-09 2.87E-09 0. 1.34E-08 0. 8.93E-06 PM148M+D 3.07E-08 7.95E-09 6.08E-09 0. 1.20E-08 0. 6.74E-05 PM148 7.17E-09 1.19E-09 5.99E-10 0. 2.25E-09 0. 9.35E-05 PM149 1.52E-09 2.15E-10 8.78E-11 0. 4.06E-10 0. 4.03E-05 PM151 6.97E-10 1.17E-10 5.91 E-11 0. 2.09E-10 0. 3.22E-05 SM151 6.90E-08 1.19E-08 2.85E-09 0. 1.33E-08 0. 5.25E-06 SM153 8.57E-10 7.15E-10 5.22E-11 0. 2.31 E-10 0. 2.55E-05 EU 152 1.95E-07 4.44E-08 3.90E-08 0. 2.75E-07 0. 2.56E-05 EU 154 6.15E-07 7.56E-08 5.38E-08 0. 3.62E-07 0. 5.48E-05 EU155 8.60E-08 1.22E-08 7.87E-09 0. 5.63E-08 0. 9.60E-06 EU156 1.37E-08 1.06E-08 1.71E-09 0. 7.08E-09 0. 7.26E-05 TB160 4.70E-08 0. 5.86E-09 0. 1.94E-08 0. 4.33E-05 H0166M 2.70E-07 8.43E-08 6.40E-08 0. 1.26E-07 0. 0.

WI 81 9.91 E-09 3.23E-09 3.46E-10 0. 0. 0. 3.68E-07 WI 85 4.05E-07 1.35E-07 1.42E-08 0. 0. 0. 1.56E-05 W187 1.03E-07 8.61 E-08 3.01E-08 0. 0. 0. 2.82E-05

Proc No ODCM Attachment 9 Revision 24 Page 16 of 16 INGESTION DOSE COMMITMENT FACTORS ADULT INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)

ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI PB210+D 1.53E-02 4.37E-03 5.44E-04 0. 1.23E-02 5.42E-05 B121 0+D 4.61 E-07 3.18E-06 3.96E-08 0. 3.83E-05 4.75E-05 P0210 3.56E-04 7.56E-04 8.59E-05 0. 2.52E-03 6.36E-05 RN222+D 0. 0. 0. 0. 0. 0.

RA223+D 4.97E-03 7.65E-06 9.94E-04 0. 2.17E-04 3.21 E-04 RA224+D 1.61 E-03 3.90E-06 3.23E-04 0. 1.1OE-04 3.40E-04 RA225+D 6.56E-03 7.78E-06 1.31E-03 0. 2.21E-04 3.06E-04 RA226+D 3.02E-01 5.74E-06 2.20E-01 0. 1.63E-04 3.32E-04 RA228+D 1.12E-01 3.12E-06 1.21 E-01 0. 8.83E-05 5.64E-05 AC225 4.40E-06 6.06E-06 2.96E-07 0. 6.90E-07 4.07E-04 AC227+D 1.87E-03 2.48E-04 1.11 E-04 0. 8.OOE-05 8.19E-05 TH227+D 1.37E-05 2.48E-07 3.95E-07 0. 1.41 E-06 5.40E-04 TH228+D 4.96E-04 8.40E-06 1.68E-05 0. 4.67E-05 5.63E-04 TH229 7.98E-03 1.19E-04 3.91 E-04 0. 5.75E-04 5.12E-04 TH230 2.06E-03 1.17E-04 5.70E-05 0. 5.65E-04 6.02E-05 TH232+D 2.30E-03 1.OOE-04 1.50E-04 0. 4.82E-04 5.12E-05 TH234 8.01 E-08 4.71 E-09 2.31 E-09 0. 2.67E-08 1.13E-04 PA231 +D 4.1OE-03 1.54E-04 1.59E-04 0. 8.64E-04 7.17E-05 PA233 5.26E-09 1.06E-09 9.12E-10 0. 3.99E-09 1.64E-05 U232+D 4.13E-03 0. 2.95E-04 0. 4.47E-04 6.78E-05 U233+D 8.71 E-04 0. 5.28E-05 0. 2.03E-04 6.27E-05 U234 8.36E-04 0. 5.17E-05 0. 1.99E-04 6.14E-05 U235+D 8.01 E-04 0. 4.86E-05 0. 1.87E-04 7.81 E-05 U236 8.01 E-04 0. 4.96E-05 0. 1.91 E-04 5.76E-05 U237 5.52E-8 0. 1.47E-08 0. 2.27E-07 1.94E-05 U238+D 7.67E-04 0. 4.54E-05 0. .1.75E-04 5.50E-05 NP237+D 1.37E-03 1.1 9E-04 5.54E-05 0. 4.12E-04 7.94E-05 NP238 1.37E-08 3.69E-10 2.13E-10 0. 1.25E-09 3.43E-05 NP239 1.19E-09 1.17E-10 6.45E-1 1 0. 3.65E-10 2.40E-05 PU238 6.80E-04 9.58E-05 1.71E-05 0. 7.32E-05 7.30E-05 PU239 7.87E-04 1.06E-04 1.91 E-05 0. 8.11E-05 6.66E-05 PU240 7.85E-04 1.06E-04 1.91 E-05 0. 8.10E-05 6.78E-05 PU241 +D 1.65E-05 8.44E-07 3.32E-07 0. 1.53E-06 1.40E-06 PU242 7.29E-04 1.02E-04 1.84E-05 0. 7.81 E-05 6.53E-05 PU244 8.52E-04 1.17E-04 2.11E-05 0. 8.95E-05 9.73E-05 AM241 8.19E-04 2.88E-04 5.41 E-05 0. 4.07E-04 7.42E-05 AM242M 8.24E-04 2.78E-04 5.43E-05 0. 4.05E-04 9.34E-05 AM243 8.18E-04 2.78E-04 5.30E-05 0. 3.99E-04 8.70E-05 CM242 2.06E-05 2.10E-05 1.37E-06 0. 6.22E-06 7.92E-05 CM243 6.39E-04 2.41 E-04 3.75E-05 0. 1.75E-04 7.81 E-05 CM244 4.83E-04 2.07E-04 2.87E-05 0. 1.34E-04 7.55E-05 CM245 1.02E-03 2.87E-04 5.76E-05 0. 2.69E-04 7.04E-05 CM246 1.01E-03 2.87E-04 5.75E-05 0. 2.68E-04 6.91 E-05 CM247+D 9.84E-04 2.83E-04 5.67E-05 0. 2.64E-04 9.09E-05 CM248 8.18E-03 2.33E-03 4.67E-04 0. 2.18E-03 1.47E-03 CF252 2.64E-04 0. 6.29E-06 0. 0. 2.88E-04

ATTACHMENT 2 BIG ROCK POINT INDEPENDENT SPENT FUEL STORAGE INSTALLATION 2010 RADIOACTIVE EFFLUENT RELEASE REPORT This report provides information relating to radioactive effluent releases and solid radioactive waste disposal at Big Rock Point (BRP) for the year 2010. The report format is detailed in the BRP Offsite Dose Calculation Manual (ODCM). Effluent releases from BRP are controlled by the Defueled Technical Specifications and the ODCM requirements. The ODCM was not revised in 2010.

2010 Operating History On January 8, 2007, the Nuclear Regulatory Commission (NRC) approved release of the former BRP Nuclear Plant property for unrestricted use in accordance with the BRP License Termination Plan 1 . On April 11, 2007, the license for BRP, DPR-6, was transferred to Entergy Nuclear Operations, Inc.

During 2010, normal independent spent fuel installation (ISFSI) operations continued.

There were no operational activities that generated any solid radioactive waste.

Liquid and gaseous effluent monitoring is no longer conducted as the former BRP nuclear plant property has been released from the license. Short-lived radionuclides, including iodines and noble gas, are neither expected nor reported.

1. Supplemental Information A. Batch Releases There were no batch releases of gaseous or liquid effluents during 2010. All batch releases of radioactive liquids as described in the ODCM ceased in 2004.

B. Abnormal Releases There were no abnormal releases from BRP during 2010.

C. Radioactive Effluent Monitoring Instrumentation BRP ODCM currently specifies required actions when less than the minimum number of radioactive effluent monitoring instrument channels are operable. The ODCM also specifies these actions be taken when installed effluent monitoring systems are removed from service for decommissioning.

All plant-installed liquid and gaseous radioactive effluent monitoring instrument channels have been permanently removed and dismantled.

Letter from the USNRC dated January 8, 2007, "Release of Land from Part 50 License for Unrestricted Use" Page 1 of 8

2. Gaseous Effluents Although there were no gaseous effluents released during 2010, Table 2 provides a summary of all gaseous radioactive effluent monitoring conducted during the reporting period as required by the ODCM.

3. Liquid Effluents There were no liquid effluent batch releases during 2010. Table 3 lists and summarizes liquid effluent releases in accordance with the ODCM.

4. Solid Waste There was no solid radioactive waste generated or shipped during 2010.

5. Summary of Radioloqical Impact on Man The ODCM specifies that the annual effluent release report provide potential dose calculations based on measured effluent to liquid and gaseous pathways, if estimates of dose exceed one millirem to an organ or total body of any individual or more than one person-rem to the population within 50 miles. During 2010, there were no releases. Therefore, no calculations were required.

6. Offsite Dose Calculation Manual The ODCM describes the radiological release requirements for the BRP site.

There were no revisions to the ODCM in 2010.

7. Process Control Program (PCP)

The Process Control Program (PCP) describes solid waste processing and disposal methods utilized at the BRP site. The PCP was not revised during 2010.

Page 2 of 8

TABLE 1 Big Rock Point Batch Releases January 1,2010 to December 31, 2010 A. GASEOUS B. LIQUID Units 1ST QTR 2ND QTR 3RD QTR 4TH QTR Number of Releases N/A N/A N/A N/A Total Release Time Minutes N/A N/A N/A N/A Maximum Release Time- Minutes N/A N/A N/A N/A Average Release Time Minutes N/A N/A N/A N/A Minimum Release Time Minutes N/A N/A N/A N/A Page 3 of 8

TABLE 2 Big Rock Point Gaseous Effluent Releases January 1,2010 to December 31, 2010 1ST 2ND 3RD 4TH Est Total A. FISSION AND ACTIVATION GASES Units QTR QTR QTR QTR Error %

1. Total release Ci N/A N/A N/A N/A

2. Average release rate for period pCi/sec N/A N/A N/A N/A N/A

3. Percent of annual avg EC % N/A N/A N/A N/A B. IODINES

1. Total iodine Ci N/A N/A N/A N/A

2. Average release rate for period tjCi/sec N/A N/A N/A N/A N/A

3. Percent of annual avg EC % N/A N/A N/A N/A C. PARTICULATES

1. Particulates with half-life >8 day Ci N/A N/A N/A N/A

2. Average release rate for period laCi/sec N/A N/A N/A N/A N/A

3. Percent of annual avg EC % N/A N/A N/A N/A

4. Gross alpha radioactivity Ci N/A N/A N/A N/A D. TRITIUM

1. Total Release Ci N/A N/A N/A N/A

2. Average release rate for period pCi/sec N/A N/A N/A N/A

3. Percent of annual avg EC % N/A N/A N/A N/A E. WHOLE BODY DOSE

1. Beta Air dose at Site Boundary due to Noble Gases (ODCM Section 1, 1.3.2 a (1) (2)) mrads N/A N/A N/A N/A

2. Percent limit % N/A N/A N/A N/A 3, Gamma Air dose at Site Boundary due to Noble Gas (ODCM Section 1, 1.3.2 a (1) (2)) mrads N/A N/A N/A N/A

4. Percent limit % N/A N/A N/A N/A F. ORGAN DOSE (ODCM Section 1, 1.3.2b (1) (2))

1. Maximum organ dose to pubic based on Critical Receptors (child bone) mrem N/A N/A N/A N/A

2. Percent of limit (7.5 mrem/quarter) % N/A N/A N/A N/A Page 4 of 8

TABLE 2 Big Rock Point Gaseous Effluent Releases January 1,2010 to December 31, 2010

1. FISSION GASES Units 1ST QTR 2ND QTR 3RD QTR 4TH QTR Krypton-85m Ci N/A N/A N/A N/A Krypton-87 Ci N/A N/A N/A N/A Krypton-88 Ci N/A N/A N/A N/A Xenon-133 Ci N/A N/A N/A N/A Xenon-133m Ci N/A N/A N/A N/A Xenon-135 Ci N/A N/A N/A N/A Xenon-135m Ci N/A N/A N/A N/A Xenon-138 Ci N/A N/A N/A N/A Total for Period Ci N/A N/A N/A N/A

2. IODINES Iodine-131 Ci N/A NYA N/A N/A Iodine-132 Ci N/A N/A N/A N/A Iodine-133 Ci N/A N/A N/A N/A Iodine-134 Ci N/A N/A N/A N/A Iodine-135 Ci N/A N/A N/A N/A Total for Period Ci N/A N/A N/A N/A Page 5 of 8

TABLE 2 Big Rock Point Gaseous Effluent Releases January 1,2010 to December 31, 2010

3. PARTICULATES* Units 1ST QTR 2ND QTR 3RD QTR 4TH QTR Chromium-51 Ci N/A N/A N/A N/A Manganese-54 Ci N/A N/A N/A N/A Cobalt-58 Ci N/A N/A N/A N/A Iron-59 Ci N/A N/A N/A N/A Cobalt-60 Ci N/A N/A N/A N/A Zinc-65 Ci N/A N/A N/A N/A Silver-11Om Ci N/A N/A N/A N/A Cesium-134 Ci N/A N/A N/A N/A Cesium-137 Ci N/A N/A N/A N/A Barium-140 Ci N/A N/A N/A N/A Europium-152 Ci N/A N/A N/A N/A Strontium-89 Ci N/A N/A N/A N/A Strontium-90 Ci N/A N/A N/A N/A Net unidentified beta Ci N/A N/A N/A N/A Total Ci N/A N/A N/A N/A

Particulates with half-life >8 days Page 6 of 8

TABLE 3 Big Rock Point Liquid Effluent Releases January 1, 2010 to December 31, 2010 Est Total A. FISSION AND ACTIVATION PRODUCTS Units 1STQTR I 2NDQTR I3RD QTR I4TH QTR Error %

1. Total release (not including tritium, gases, alpha) Ci N/A N/A N/A N/A N/A

2. Average diluted concentration during period pCi/m l N/A N/A N/A N/A

3. Percent of EC % N/A N/A N/A N/A B. TRITIUM

1. Total release Ci N/A N/A N/A N/A N/A

2. Average diluted concentration during period ICi/mfl N/A N/A N/A N/A

3. Percent of EC % N/A N/A N/A N/A C. DISSOLVED AND ENTRAINED GASES

1. Total release Ci N/A N/A N/A N/A N/A

2. Average diluted concentration during period pCi/ml N/A N/A N/A N/A

3. Percent of EC % N/A N/A N/A N/A D. GROSS ALPHA RADIOACTIVITY Ci N/A N/A ] N/A N/A E. VOLUME OF WASTE RELEASED (Prior to dilution)J 1 Liters N/A N/A N/A N/A F. VOLUME OF DILUTION WATER USED DURING PERIOD T _

Liters N/A N/A] N/A N/A G. MAXIMUM DOSE COMMITMENT WHOLEBODY mrem N/A N/A N/A N/A Percent of ODCM Section 1, 2.3.2 a (1.5 mrem) % N/A N/A N/A N/A H. MAXIMUM DOSE COMMITMENT- ORGAN Mrem N/A N/A N/A N/A Percent of ODCM Section 1, 2.3.2 b (3.0 mrem) % N/A N/A N/A N/A Page 7 of 8

TABLE 3 Big Rock Point Liquid Effluent Releases January 1,2010 to December 31, 2010

1. NUCLIDES RELEASED Units 1ST OTR 2ND QTR 3RD QTR 4TH QTR Chromium-51 Ci ........

Manganese 54 Ci ....

Cobalt-58 Ci ....

Iron-59 Ci ........

Cobalt-60 Ci ........

Zinc-65 Ci ........

Strontium-89 Ci ........

Strontium-90 Ci ....

Molybdenum-99 Ci ....

Silver-11Orn Ci Iodine-131 Ci --

Cesium-134 Ci ........

Cesium-137 Ci ........

Antimony-125 Ci ........

Tin-113 Ci ........

Net Unidentified Beta Ci ........

Fission &Activation Product Total Ci ........

Xenon-133 Ci ........

Tritium Ci ........

Grand Total Ci ........

Page 8 of 8

ML11129A079

Text

Conclusion:

Navigation menu

Search